

chain nodes :

7 42 49 51 52 53 72 73 80 81 89 90 91 92 105 108

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27  
 28 29 30 31 43 44 45 46 47 48 54 55 56 57 58 59 60 61 62 63 64 65 66 67  
 68 69 70 71 74 75 76 93 94 95 96 97 98 99 100 101

chain bonds :

6-7 7-42 45-89 48-49 51-52 51-53 55-90 59-72 60-91 65-73 68-92 80-81 94-105

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19 15-16 15-26  
 16-17 16-28 17-18 18-19 20-21 20-25 21-22 21-29 22-23 22-31 23-24 24-25 26-27  
 27-28 29-30 30-31 43-44 43-48 44-45 45-46 46-47 47-48 54-55 54-59 55-56 56-57  
 57-58 58-59 60-61 60-65 61-62 62-63 63-64 64-65 66-67 66-71 66-76 67-68 68-69  
 69-70 70-71 71-74 74-75 75-76 93-94 93-98 93-101 94-95 95-96 96-97 97-98 98-99  
 99-100 100-101

exact/norm bonds :

6-7 7-42 15-16 15-26 16-17 16-28 21-22 21-29 22-23 22-31 26-27 27-28 29-30 30-31  
 43-44 43-48 44-45 45-46 45-89 46-47 47-48 48-49 51-52 51-53 54-55 54-59 55-56  
 55-90 56-57 57-58 58-59 59-72 60-61 60-65 60-91 61-62 62-63 63-64 64-65 65-73  
 66-71 66-76 68-92 71-74 74-75 75-76 80-81 93-98 93-101 94-105 98-99 99-100 100-101

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19 17-18 18-19  
 20-21 20-25 23-24 24-25 66-67 67-68 68-69 69-70 70-71 93-94 94-95 95-96 96-97  
 97-98

isolated ring systems :

containing 1 : 8 : 14 : 20 : 66 : 93 :

G2:[\*1],[\*2],[\*3]

G3:C,N

G4:[\*4],[\*5]

G5:[\*6],[\*7],[\*8],[\*9],[\*10]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom  
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom  
42:CLASS 43:Atom 44:Atom 45:Atom 46:Atom 47:Atom 48:Atom 49:CLASS 51:CLASS 52:CLASS  
53:CLASS 54:Atom 55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom  
63:Atom 64:Atom 65:Atom 66:Atom 67:Atom 68:Atom 69:Atom 70:Atom 71:Atom 72:CLASS  
73:CLASS 74:Atom 75:Atom 76:Atom 80:CLASS 81:CLASS 89:CLASS 90:CLASS 91:CLASS 92:CLASS  
93:Atom 94:Atom 95:Atom 96:Atom 97:Atom 98:Atom 99:Atom 100:Atom 101:Atom 105:CLASS  
108:CLASS 109:Atom

10/507,060 (amended)

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840


L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10507060 (amd).str



chain nodes :

7 42 49 51 52 53 72 73 80 81 89 90 91 92 105 108



```

ring nodes :
1  2  3  4  5  6  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24
25  26  27  28  29  30  31  43  44  45  46  47  48  54  55  56  57  58  59  60  61
62  63  64  65  66  67  68  69  70  71  74  75  76  93  94  95  96  97  98  99  100
101
chain bonds :
6-7  7-42  45-89  48-49  51-52  51-53  55-90  59-72  60-91  65-73  68-92  80-81
94-105
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-13  9-10  10-11  11-12  12-13  14-15  14-19
15-16  15-26  16-17  16-28  17-18  18-19  20-21  20-25  21-22  21-29  22-23  22-31
23-24  24-25  26-27  27-28  29-30  30-31  43-44  43-48  44-45  45-46  46-47  47-48
54-55  54-59  55-56  56-57  57-58  58-59  60-61  60-65  61-62  62-63  63-64  64-65
66-67  66-71  66-76  67-68  68-69  69-70  70-71  71-74  74-75  75-76  93-94  93-98
93-101  94-95  95-96  96-97  97-98  98-99  99-100  100-101
exact/norm bonds :
6-7  7-42  15-16  15-26  16-17  16-28  21-22  21-29  22-23  22-31  26-27  27-28
29-30  30-31  43-44  43-48  44-45  45-46  45-89  46-47  47-48  48-49  51-52  51-53
54-55  54-59  55-56  55-90  56-57  57-58  58-59  59-72  60-61  60-65  60-91  61-62
62-63  63-64  64-65  65-73  66-71  66-76  68-92  71-74  74-75  75-76  80-81  93-98
93-101  94-105  98-99  99-100  100-101
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-13  9-10  10-11  11-12  12-13  14-15  14-19
17-18  18-19  20-21  20-25  23-24  24-25  66-67  67-68  68-69  69-70  70-71  93-94
94-95  95-96  96-97  97-98
isolated ring systems :
containing 1 : 8 : 14 : 20 : 66 : 93 :

```

G2:[\*1],[\*2],[\*3]

G3:C,N

G4:[\*4],[\*5]

G5:[\*6],[\*7],[\*8],[\*9],[\*10]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 42:CLASS 43:Atom 44:Atom 45:Atom 46:Atom 47:Atom
48:Atom 49:CLASS 51:CLASS 52:CLASS 53:CLASS 54:Atom 55:Atom 56:Atom 57:Atom
58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom 64:Atom 65:Atom 66:Atom
67:Atom 68:Atom 69:Atom 70:Atom 71:Atom 72:CLASS 73:CLASS 74:Atom 75:Atom
76:Atom 80:CLASS 81:CLASS 89:CLASS 90:CLASS 91:CLASS 92:CLASS 93:Atom
94:Atom 95:Atom 96:Atom 97:Atom 98:Atom 99:Atom 100:Atom 101:Atom 105:CLASS
108:CLASS 109:Atom

```

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

10/507,060 (amended)

=> d 14

L4 HAS NO ANSWERS

L1 SCR 1840

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s 14 sss sam

SAMPLE SEARCH INITIATED 10:29:28 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7570 TO ITERATE

26.4% PROCESSED 2000 ITERATIONS

22 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 146184 TO 156616

PROJECTED ANSWERS: 1118 TO 2212

L5 22 SEA SSS SAM L3 AND L1 NOT L2

=> => s 14 sss ful

FULL SEARCH INITIATED 10:40:14 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 154273 TO ITERATE

100.0% PROCESSED 154273 ITERATIONS

1530 ANSWERS

SEARCH TIME: 00.00.04

L6 1530 SEA SSS FUL L3 AND L1 NOT L2

=> => s 16

L7 72 L6

=> d 17 1-72 bib,ab,hitstr

L7 ANSWER 1 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:1360637 CAPLUS  
 DN 149:553338  
 TI Genetic polymorphisms associated with an increased risk of  
 neurodegenerative disease and their detection and diagnostic and  
 prophylactic use  
 IN Grupe, Andrew; Li, Yonghong  
 PA Applera Corporation, USA  
 SO PCT Int. Appl., 137pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008137110	A1	20081113	WO 2008-US5734	20080501
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20080286796	A1	20081120	US 2008-151163	20080501
PRAI	US 2007-927864P	P	20070503		

AB The present invention is based on the discovery of genetic polymorphisms that are associated with neurodegenerative disease, particularly Alzheimer's disease and Parkinson's disease. In particular, the present invention relates to nucleic acid mols. containing the polymorphisms, variant proteins encoded by such nucleic acid mols., reagents for detecting the polymorphic nucleic acid mols. and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. An anal. of genetic polymorphisms surrounding the NEDD9 gene is reported. Expression of the NEDD9 gene is lower in the hippocampus of Alzheimer's disease patients than in controls. A number of polymorphisms around the gene were shown to be associated with an increased risk of Alzheimer's disease.

IT 761437-28-9, NVP-TAE-226  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in treatment of Alzheimer's disease; genetic polymorphisms associated with increased risk of neurodegenerative disease and their detection and diagnostic and prophylactic use)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:1293678 CAPLUS  
 DN 149:493697  
 TI Preparation of 2-aminopyrimidine-4-carbamates as inhibitors of Lck kinase enzyme  
 IN Buchanan, John L.; Elbaum, Daniel; Martin, Matthew W.; McGowan, David C.; Novak, Perry M.; Nunes, Joseph J.  
 PA Amgen Inc., USA  
 SO U.S., 93pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7442698	B2	20081028	US 2004-891636	20040713
	US 20050026914	A1	20050203		
	AU 2004259737	A1	20050203	AU 2004-259737	20040715
	CA 2532980	A1	20050203	CA 2004-2532980	20040715
	WO 2005009978	A1	20050203	WO 2004-US23233	20040715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1654238	A1	20060510	EP 2004-778640	20040715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007516212	T	20070621	JP 2006-521176	20040715
	MX 2006PA00829	A	20060407	MX 2006-PA829	20060120
PRAI	US 2003-490220P	P	20030724		
	US 2004-891636	A	20040713		
	WO 2004-US23233	W	20040715		

AB Title compds. represented by the formula I [wherein one of X and Y is N and the other of X and Y is CH; R1, R2, R3 = independently (un)substituted unsatd. monocycle, (un)saturated bicycle, (un)saturated heterocycle, etc.; and pharmaceutically acceptable salts thereof] were prepared as inhibitors of Lck kinase enzyme. For example, II was provided in a multi-step synthesis starting from the reaction of 2,4-dichloropyrimidine with benzylamine. I exhibited an average IC50 value of 1 uM or less in the human LCK HTFR assay for the inhibition of the Lck kinase enzyme. Thus, I and their pharmaceutical compns. are useful for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, or osteoarthritis in a mammal comprising administering to the mammal a therapeutically-effective amount of a compound

IT 835649-17-7P, 2,6-Dimethylphenyl  
 N-[2-[[[3,4-bis(methyloxy)-5-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[[1-methylpropyl]amino]carbonyl]phenyl]carbamate 835649-18-8P,  
 2,6-Dimethylphenyl N-[2-[[[3-fluoro-4-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[[1-

methylpropyl)amino]carbonyl]phenyl]carbamate 835649-19-9P,  
 2,6-Dimethylphenyl N-[2-[[3-fluoro-4-[[3-(1-  
 piperidinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-  
 methylpropyl)amino]carbonyl]phenyl]carbamate 835649-20-2P,  
 2,6-Dimethylphenyl N-[2-[[3-fluoro-4-[[2-[4-(1-methylethyl)-1-  
 piperazinyl]ethyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-  
 methylpropyl)amino]carbonyl]phenyl]carbamate


RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)

(drug candidate; preparation of 2-aminopyrimidine-4-carbamates as inhibitors  
 of Lck kinase enzyme)


RN 835649-17-7 CAPLUS

CN Carbamic acid, [2-[[3,4-dimethoxy-5-[3-(4-methyl-1-  
 piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-  
 methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA  
 INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 835649-18-8 CAPLUS

CN Carbamic acid, [2-[[3-fluoro-4-[3-(4-methyl-1-  
 piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-  
 methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA  
 INDEX NAME)




RN 835649-19-9 CAPLUS

CN Carbamic acid, [2-[[3-fluoro-4-[3-(1-piperidiny1)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 835649-20-2 CAPLUS

CN Carbamic acid, [2-[[3-fluoro-4-[2-[4-(1-methylethyl)-1-piperazinyl]ethoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 3 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:1280153 CAPLUS  
 DN 149:556640  
 TI Preparation of pyrimidine derivatives as inhibitors of kinase insert  
 domain receptors for treatment of angiogenesis related diseases  
 IN Su, Weiguo; Jia, Hong; Zhang, Weihai; Cui, Yumin; Yan, Xiaoqiang; Ren,  
 Yongxin; Duan, Jifeng; Sai, Yang  
 PA Hutchison Medipharma Limited, Peop. Rep. China  
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 37pp.  
 CODEN: CNXXEV  
 DT Patent  
 LA Chinese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 101289444	A	20081022	CN 2007-10039509	20070416
PRAI	CN 2007-10039509		20070416		


AB The title pyrimidine derivs. I [wherein X and Y = independently O, S, or  
 NR; R = H, (cyclo)alkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl,  
 etc.; R1 and R2 = independently H, halo, NO<sub>2</sub>, NH<sub>2</sub>, CN, OH, alkyl, alkenyl,  
 alkynyl, aryl, etc.; R5 = H, (cyclo)alkyl, heterocyclyl, (hetero)aryl,  
 etc.; Ar = (un)substituted (hetero)aryl] were prepared as inhibitors of  
 kinase insert domain receptors (KDR) for treatment of angiogenesis related  
 diseases, such as neoplasm and age-related macular degeneration. For  
 example, 2,4-dichloropyrimidine was reacted with  
 5-amino-2-methyl-1H-indole, followed by coupling with aniline to give II  
 in high yield. The compds. showed inhibitory activity with IC<sub>50</sub> of  
 0.001-10  $\mu$ M against KDR.

IT 1071105-11-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of pyrimidine derivs. for treatment of  
angiogenesis related diseases)

RN 1071105-11-7 CAPLUS

CN Benzamide, 2-[[5-cyano-2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-  
 (CA INDEX NAME)



L7 ANSWER 4 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:1251387 CAPLUS  
 DN 149:471496  
 TI Preparation of pyrimidine derivatives for treating angiogenesis-related disorders  
 IN Su, Wei-Guo; Jia, Hong; Zhang, Wei-han; Cui, Yumin; Yan, Xiaoqiang; Ren, Yongxin; Duan, Jifeng; Sai, Yang  
 PA Hutchison Medipharma Enterprises Limited, Bahamas  
 SO U.S. Pat. Appl. Publ., 75pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080255172	A1	20081016	US 2008-103876	20080416
	WO 2008128231	A1	20081023	WO 2008-US60366	20080415
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2007-911921P P 20070416

OS MARPAT 149:471496

AB The title compds. I [X, Y = O, S or NR (wherein R = H, alkyl, aryl, etc.); Z = CR' or N (wherein R' = H, halo, NO<sub>2</sub>, etc.); V, U, and T together = NHC(R<sub>7</sub>):CR<sub>6</sub>, N:CR<sub>6</sub>O, NHCR<sub>6</sub>:N, NHN:CR<sub>6</sub>; R<sub>1</sub>-R<sub>4</sub>, R<sub>6</sub> = H, halo, NO<sub>2</sub>, etc.; R<sub>5</sub> = alkyl, (hetero)cycloalkyl, (hetero)aryl; R<sub>7</sub> = alkyl], useful for treating an angiogenesis-related disorder, e.g., cancer or age-related macular degeneration, were prepared. Thus, reacting 2,4-dichloropyrimidine with 5-amino-2-methylindole followed by reaction of N-(2-chloropyrimidin-4-yl)-2-methyl-1H-indol-5-amine with aniline afforded II. All of the tested compds. I inhibited the activity of KDR with IC<sub>50</sub> values from 0.001 to 10  $\mu$ M.


IT 1071105-11-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. for treating angiogenesis-related disorders)

RN 1071105-11-7 CAPLUS

CN Benzamide, 2-[[[5-cyano-2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



L7 ANSWER 5 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:1186991 CAPLUS  
 DN 149:425967  
 TI Pyrimidinediamine derivatives as JAK kinase inhibitors and their  
 preparation, pharmaceutical compositions and use in the treatment of  
 diseases  
 IN Li, Hui; Taylor, Vanessa; Bhamidipati, Somasekhar; Ramphal, John; Tso,  
 Kin; Sran, Arvinder; Keim, Holger; Markovtsov, Vadim; Carroll, David;  
 Thota, Sambaiah; Argade, Ankush; Clough, Jeffrey Wayne; Singh, Rajinder  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 240pp., which  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008118822	A1	20081002	WO 2008-US57930	20080321
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080279867	A1	20081113	US 2008-53382	20080321
PRAI US 2007-896823P	P	20070323		
US 2007-910749P	P	20070409		

OS MARPAT 149:425967  
 AB The invention encompasses compds. of formula I and the compns. and methods using these compds. in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful. Compds. of formula I wherein A and B are independently (hetero)aryl; when A is monocyclic, then p and q are independently 0-3; when A is multiple ring, then p and q are independently 0-5; X is (un)substituted alkyl, OH, (un)substituted alkoxy, (un)substituted amino, carboxyl, etc.; W is SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, -alk-SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub> and NR<sub>4</sub>SO<sub>2</sub>R<sub>5</sub>; alk is (un)substituted (un)branched C<sub>1</sub>-6 alkylene; R<sub>1</sub> is H and C<sub>1</sub>-3 alkyl; each R<sub>2</sub> is independently (un)substituted alkyl, (un)substituted alkoxy, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkenyl, etc.; R<sub>4</sub> or R<sub>5</sub> and one of R<sub>2</sub> taken together with the intervening atoms attached to form (un)substituted heterocyclic fused to ring A; each R<sub>3</sub> is independently (un)substituted alkyl, (un)substituted alkoxy, (un)substituted alkenyl, (un)substituted alkynyl, alkynyloxy, etc.; R<sub>4</sub> is H, (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl, etc.; R<sub>5</sub> is H, (un)substituted alkyl, (un)substituted amino, (un)substituted cycloalkyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl, etc.; R<sub>4</sub>R<sub>5</sub> taken together with the intervening atoms attached to form (un)substituted heterocyclyl; provided that when W is SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, then W is not attached to an atom adjacent to the atom of ring A that is bound to N<sub>4</sub> of pyrimidine, A is not chromanyl; and their solvates,

prodrugs and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multi-step procedure (procedure given). All the invention compds. were evaluated for their JAK kinase inhibitory activity. From the assay, it was determined that II exhibited an IC<sub>50</sub> value of 0.08797  $\mu$ M.


IT 936091-14-4P 1065078-71-8P 1065078-73-0P  
 1065078-75-2P 1065078-77-4P 1065078-78-5P  
 1065078-79-6P 1065078-80-9P 1065078-85-4P  
 1065078-88-7P 1065078-91-2P 1065078-93-4P  
 1065078-97-8P 1065078-98-9P 1065079-00-6P  
 1065079-02-8P 1065079-05-1P 1065079-07-3P  
 1065086-41-0P 1065086-60-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinediamine derivs. as JAK kinase inhibitors useful in the treatment of diseases)


RN 936091-14-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1065078-71-8 CAPLUS

CN Benzenesulfonamide, 3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 1065078-73-0 CAPLUS

CN Benzenesulfonamide, 2-methyl-5-[[5-methyl-2-[[4-(2-propyn-1-yloxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1065078-75-2 CAPLUS

CN Benzenesulfonamide, 2-methyl-5-[[2-[[4-(2-propyn-1-yloxy)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1065078-77-4 CAPLUS

CN Benzenesulfonamide, 3-[[5-fluoro-2-[(4-methoxy-3,5-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 1065078-78-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-fluoro-2-[(4-methoxy-3,5-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 1065078-79-6 CAPLUS

CN Acetamide, 2-[3-[[5-amino-4-[[4-(aminosulfonyl)phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 1065078-80-9 CAPLUS

CN Acetamide, 2-[3-[[5-amino-4-[[3-(aminosulfonyl)phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 1065078-85-4 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(2-pyridinylmethoxy)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1065078-88-7 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[[2-[[4-(3-pyridinylmethoxy)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1065078-91-2 CAPLUS

CN Benzenesulfonamide, 3-[[5-chloro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1065078-93-4 CAPLUS


CN Benzenesulfonamide, 3-[[5-chloro-2-[(4-methoxy-3,5-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1065078-97-8 CAPLUS


CN Benzenesulfonamide, 3-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)






RN 1065078-98-9 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1065079-00-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1065079-02-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1065079-05-1 CAPLUS


CN Benzenesulfonamide, 3-[[5-chloro-2-[[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1065079-07-3 CAPLUS


CN Benzenesulfonamide, 3-[[5-chloro-2-[[3-methyl-4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1065086-41-0 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 1065086-60-3 CAPLUS

CN Benzenesulfonamide, 3-[[5-amino-2-(1H-indazol-6-ylamino)-4-[[4-aminosulfonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)-

pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:1157565 CAPLUS  
 DN 149:402383  
 TI Preparation of dianilinopyrimidines as antitumor agents  
 IN Reid, Paul; Drewry, David Harold; Deanda, Felix, Jr.  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 66pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008115742	A1	20080925	WO 2008-US56622	20080312
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2007-895899P P 20070320

OS CASREACT 149:402383; MARPAT 149:402383

AB The title compds. I [A = H, (un)substituted aryl, heteroaryl; J = NR(CH<sub>2</sub>)<sub>n</sub>Ph or NR(CH<sub>2</sub>)<sub>n</sub>(4-morpholinyl) (wherein Ph can be optionally substituted; n = 0-2; R = H or alkyl); D = substituted anilino], useful in the treatment of diseases associated with inappropriate Wee-1 kinase activity, were prepared E.g., a 3-step synthesis of II, starting from 5-bromo-2,4-dichloropyrimidine and 2-methoxyaniline, was given. All of the tested compds. I had a pIC<sub>50</sub> ≥ 5.0 when tested in in vitro assay for Wee-1 inhibitory activity. The present invention relates also to compns. and medicaments containing compound I, as well as processes for the preparation and use of such compds., compns. and medicaments.


IT 1062165-74-5P 1062166-21-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of dianilinopyrimidines for treating diseases associated with inappropriate Wee-1 kinase activity)

RN 1062165-74-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1062166-21-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:1155852 CAPLUS  
 DN 149:394705  
 TI Dianilinopyrimidine derivs. for treatment of diseases associated with  
 inappropriate Weel kinase activity  
 IN Reid, Paul; Drewry, David Harold; Deanda, Felix, Jr.; Linn, James Andrew  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 33pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008115738	A1	20080925	WO 2008-US56591	20080312
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-895893P P 20070320

OS MARPAT 149:394705

AB The present invention relates to dianilinopyrimidine derivs., compns. and  
 medicaments containing the same, as well as processes for the preparation and  
 use

of such compds., compns. and medicaments. Such dianilinopyrimidine  
 derivs. are useful in the treatment of diseases associated with inappropriate  
 Weel kinase activity.


IT 1042434-43-4P 1042434-44-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(dianilinopyrimidine derivs. for treatment of diseases associated with  
 inappropriate Weel kinase activity such as cancer)


RN 1042434-43-4 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-  
 pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 1042434-44-5 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:1009042 CAPLUS  
 DN 149:293683  
 TI Combinations of therapeutic agents comprising  
 N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-  
 2E-2-propenamide for treating cancer  
 IN Atadja, Peter Wisdom; Shao, Wenlin; Bhalla, Kapil N.  
 PA Novartis A.-G., Switz.  
 SO PCT Int. Appl., 73pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008100985	A2	20080821	WO 2008-US53798	20080213
	WO 2008100985	A3	20081030		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2007-890005P P 20070215

AB The invention relates to a combination comprising the  
 N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-  
 2E-2-propenamide; and one or more pharmaceutically active agents;  
 pharmaceutical compns. comprising said combination; methods of treatment  
 comprising said combination; processes for making said combination; and a  
 com. package comprising said combination. Thus, combination of LBH589 and  
 velcade exhibited synergistic efficiency in treating pancreatic tumor,  
 tested with MIA PaCa-2 cells.

IT 761437-28-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(combinations of therapeutic agents comprising  
 N-hydroxy-3-[4-[[[2-(2-Me-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-  
 2-propenamide for treating cancer)


RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)





L7 ANSWER 9 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:942122 CAPLUS  
 DN 149:399201  
 TI Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in  $\beta$ -thalassemia  
 AU Libani, Ilaria V.; Guy, Ella C.; Melchiori, Luca; Schiro, Raffaella; Ramos, Pedro; Breda, Laura; Scholzen, Thomas; Chadburn, Amy; Liu, YiFang; Kernbach, Margrit; Baron-Luhr, Bettina; Porotto, Matteo; de Sousa, Maria; Rachmilewitz, Eliezer A.; Hood, John D.; Cappellini, M. Domenica; Giardina, Patricia J.; Grady, Robert W.; Gerdes, Johannes; Rivella, Stefano  
 CS Department of Pediatric Hematology-Oncology, Children's Cancer and Blood Foundation Laboratories, Weill Medical College of Cornell University, New York, NY, USA  
 SO Blood (2008), 112(3), 875-885  
 CODEN: BLOOAW; ISSN: 0006-4971  
 PB American Society of Hematology  
 DT Journal  
 LA English  
 AB In  $\beta$ -thalassemia, the mechanism driving ineffective erythropoiesis (IE) is insufficiently understood. We analyzed mice affected by  $\beta$ -thalassemia and observed, unexpectedly, a relatively small increase in apoptosis of their erythroid cells compared with healthy mice. Therefore, we sought to determine whether IE could also be characterized by limited erythroid cell differentiation. In thalassemic mice, we observed that a greater than normal percentage of erythroid cells was in S-phase, exhibiting an erythroblast-like morphol. Thalassemic cells were associated with expression of cell cycle-promoting genes such as EpoR, Jak2, Cyclin-A, Cdk2, and Ki-67 and the antiapoptotic protein Bcl-XL. The cells also differentiated less than normal erythroid ones in vitro. To investigate whether Jak2 could be responsible for the limited cell differentiation, we administered a Jak2 inhibitor, TG101209, to healthy and thalassemic mice. Exposure to TG101209 dramatically decreased the spleen size but also affected anemia. Although our data do not exclude a role for apoptosis in IE, we propose that expansion of the erythroid pool followed by limited cell differentiation exacerbates IE in thalassemia. In addition, these results suggest that use of Jak2 inhibitors has the potential to profoundly change the management of this disorder.  
 IT 936091-14-4, TG 101209  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (decreased differentiation of erythroid cells and ineffective erythropoiesis in  $\beta$ -thalassemia)  
 RN 936091-14-4 CAPLUS  
 CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



10/507,060 (amended)

RE.CNT 63      THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:916378 CAPLUS  
 DN 149:224273  
 TI Anthranilamide inhibitors of aurora kinase and their preparation,  
 pharmaceutical compositions and use in the treatment of cancer  
 IN Axten, Jeffrey Michael; Bryan, Deborah L.; Drewry, David Harold; Faitg,  
 Thomas H.; Gallagher, Timothy Francis; Johnson, Neil W.; Kaspavec, Jiri;  
 Ralph, Jeffrey M.; Silva, Domingos J.  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 98pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008092049	A1	20080731	WO 2008-US51985	20080125
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20080182852	A1	20080731	US 2008-19730	20080125
PRAI	US 2007-886676P	P	20070126		

OS MARPAT 149:224273

AB The invention relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. Comps. of the invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer. Comps. of formula I wherein each R1 is H, (CH2)0-3-N(R5)2, O(CH2)2-3-N(R5)2, CON(R5)2, CO2H, etc.; R2 is H, halo, C1-3 alkyl, C1-3 alkoxy, CN, NO2, and CF3; each R3 is H, heterocycloalkyl, cycloalkyl, Ph, etc.; R4 is halo, C1-3 alkyl and C1-3 alkoxy; each R5 is independently C1-6 alkyl and COCH3; R5R5N taken together to form a (un)substituted 5- to 6-membered heterocyclic ring; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amination of 2-[(2,5-dichloro-4-pyrimidinyl)amino]benzamide with 3-(1-pyrrolidinylmethyl)aniline. All the invention comps. were evaluated for their aurora kinase inhibitory activity.

IT 1042433-42-0P 1042434-40-1P 1042434-63-8P  
 1042434-64-9P 1042434-66-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of anthranilamide as aurora kinase inhibitors useful in the treatment of cancer)

RN 1042433-42-0 CAPLUS


CN Benzamide, N-(1-methylethyl)-2-[[5-methyl-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

10/507,060 (amended)




RN 1042434-40-1 CAPLUS

CN Benamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylthio)ethyl]- (CA INDEX NAME)




RN 1042434-63-8 CAPLUS

CN Benzoic acid, 4-[[5-fluoro-4-[[2-[[1-methylethyl]amino]carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1042434-64-9 CAPLUS

CN Benamide, 2-[[5-fluoro-2-[[4-(hydroxymethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042434-66-1 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[(4-formylphenyl)amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



IT 1042432-41-6P 1042432-42-7P 1042432-43-8P  
 1042432-44-9P 1042432-45-0P 1042432-46-1P  
 1042432-47-2P 1042432-48-3P 1042432-49-4P  
 1042432-50-7P 1042432-51-8P 1042432-52-9P  
 1042432-53-0P 1042432-54-1P 1042432-55-2P  
 1042432-56-3P 1042432-57-4P 1042432-58-5P  
 1042432-59-6P 1042432-60-9P 1042432-61-0P  
 1042432-62-1P 1042432-63-2P 1042432-64-3P  
 1042432-65-4P 1042432-66-5P 1042432-68-7P  
 1042432-70-1P 1042432-71-2P 1042432-72-3P  
 1042432-73-4P 1042432-74-5P 1042432-75-6P


1042432-76-7P 1042432-77-8P 1042432-78-9P  
1042432-79-0P 1042432-80-3P 1042432-81-4P  
1042432-82-5P 1042432-83-6P 1042432-84-7P  
1042432-86-9P 1042432-87-0P 1042432-88-1P  
1042432-89-2P 1042432-90-5P 1042432-91-6P  
1042432-92-7P 1042432-93-8P 1042432-94-9P  
1042432-95-0P 1042432-96-1P 1042432-97-2P  
1042432-98-3P 1042432-99-4P 1042433-01-1P  
1042433-02-2P 1042433-03-3P 1042433-04-4P  
1042433-05-5P 1042433-06-6P 1042433-08-8P  
1042433-09-9P 1042433-10-2P 1042433-11-3P  
1042433-12-4P 1042433-13-5P 1042433-14-6P  
1042433-15-7P 1042433-17-9P 1042433-18-0P  
1042433-19-1P 1042433-20-4P 1042433-21-5P  
1042433-22-6P 1042433-23-7P 1042433-24-8P  
1042433-25-9P 1042433-26-0P 1042433-27-1P  
1042433-28-2P 1042433-29-3P 1042433-30-6P  
1042433-31-7P 1042433-32-8P 1042433-33-9P  
1042433-34-0P 1042433-36-2P 1042433-37-3P  
1042433-38-4P 1042433-39-5P 1042433-40-8P  
1042433-41-9P 1042433-44-2P 1042433-45-3P  
1042433-46-4P 1042433-47-5P 1042433-48-6P  
1042433-49-7P 1042433-51-1P 1042433-52-2P  
1042433-53-3P 1042433-54-4P 1042433-55-5P  
1042433-56-6P 1042433-57-7P 1042433-59-9P  
1042433-60-2P 1042433-61-3P 1042433-62-4P  
1042433-63-5P 1042433-64-6P 1042433-66-8P  
1042433-67-9P 1042433-68-0P 1042433-69-1P  
1042433-71-5P 1042433-72-6P 1042433-73-7P  
1042433-74-8P 1042433-75-9P 1042433-76-0P  
1042433-77-1P 1042433-78-2P 1042433-79-3P  
1042433-80-6P 1042433-81-7P 1042433-82-8P  
1042433-83-9P 1042433-85-1P 1042433-86-2P  
1042433-87-3P 1042433-88-4P 1042433-89-5P  
1042433-91-9P 1042433-92-0P 1042433-93-1P  
1042433-94-2P 1042433-95-3P 1042433-96-4P  
1042433-97-5P 1042433-98-6P 1042433-99-7P  
1042434-00-3P 1042434-01-4P 1042434-02-5P  
1042434-03-6P 1042434-04-7P 1042434-05-8P  
1042434-06-9P 1042434-07-0P 1042434-09-2P  
1042434-11-6P 1042434-12-7P 1042434-13-8P  
1042434-14-9P 1042434-16-1P 1042434-17-2P  
1042434-18-3P 1042434-19-4P 1042434-23-0P  
1042434-24-1P 1042434-25-2P 1042434-26-3P  
1042434-27-4P 1042434-28-5P 1042434-29-6P  
1042434-30-9P 1042434-36-5P 1042434-37-6P  
1042434-41-2P 1042434-42-3P 1042434-43-4P  
1042434-44-5P 1042434-46-7P 1042434-47-8P  
1042434-49-0P 1042434-51-4P 1042434-53-6P  
1042434-55-8P 1042434-57-0P 1042434-59-2P  
1042434-60-5P 1042434-61-6P 1042434-62-7P  
1042434-67-2P 1042434-68-3P 1042434-69-4P  
1042434-70-7P 1042434-71-8P 1042434-72-9P  
1042434-73-0P 1042434-75-2P 1042435-14-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of anthranilamide as aurora kinase inhibitors useful in the treatment of cancer)


RN 1042432-41-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-42-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042432-43-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042432-44-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[ethyl(2-hydroxyethyl)amino]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 1042432-45-0 CAPLUS

CN Benzamide, 2-[[2-[[3-[2-(4-acetyl-1-piperazinyl)ethyl]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-46-1 CAPLUS

CN Benzamide, 2-[[2-[[3-[(4-acetyl-1-piperazinyl)methyl]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-47-2 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-48-3 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042432-49-4 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-[(5-methyl-3-isoxazolyl)amino]sulfonyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-50-7 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-51-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-piperazinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-52-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-53-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-54-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 1042432-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-56-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-57-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-58-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-59-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-60-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-61-0 CAPLUS

CN Benzoic acid, 4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-62-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-63-2 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[4-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-64-3 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-[(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-65-4 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-[(4-methyl-1-piperazinyl)]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-66-5 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1042432-68-7 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-70-1 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-71-2 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)







RN 1042432-72-3 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1042432-73-4 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 1042432-74-5 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 1042432-75-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 1042432-76-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-77-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-78-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-79-0 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-[4-(diethylamino)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042432-80-3 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-81-4 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042432-82-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042432-83-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 1042432-84-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 1042432-86-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

10/507,060 (amended)




RN 1042432-87-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 1042432-88-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 1042432-89-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 1042432-90-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 1042432-91-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylamino)ethyl]- (CA INDEX NAME)




RN 1042432-92-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1042432-93-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[3-[2-(4-morpholinyl)ethyl]phenyl]- (CA INDEX NAME)




RN 1042432-94-9 CAPLUS

CN Benzamide, 2-[[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-5-nitro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-95-0 CAPLUS

CN Benzamide, 2-[[5-nitro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-96-1 CAPLUS

CN Benzamide, 2-[[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-97-2 CAPLUS

CN Benzamide, 2-[[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-98-3 CAPLUS

CN Benzamide, 2-[[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042432-99-4 CAPLUS


CN Benzamide, 2-[[5-methoxy-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042433-01-1 CAPLUS




CN Benzamide, 2-[[5-methoxy-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-02-2 CAPLUS

CN Benzamide, 2-[[5-methoxy-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-03-3 CAPLUS

CN Benzamide, 2-[[5-methoxy-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-04-4 CAPLUS

CN Benzamide, 2-[[5-methoxy-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-05-5 CAPLUS

CN Benzamide, 2-[[5-methoxy-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-06-6 CAPLUS

CN Benzamide, 2-[[5-methoxy-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-08-8 CAPLUS

CN Benzamide, 2-[[5-methoxy-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-09-9 CAPLUS

CN Benzamide, 2-[[5-methoxy-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-10-2 CAPLUS

CN Benzamide, 2-[[5-methoxy-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-11-3 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-12-4 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-13-5 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-14-6 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-15-7 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-17-9 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-18-0 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-19-1 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-20-4 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-21-5 CAPLUS

CN Benzamide, 2-[[2-[[3-[4-(diethylamino)-1-piperidinyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-22-6 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-23-7 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-24-8 CAPLUS

CN Benzamide, 2-[[5-cyano-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-25-9 CAPLUS

CN Benzamide, 2-[[5-cyano-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-26-0 CAPLUS

CN Benzamide, 2-[[5-cyano-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-27-1 CAPLUS

CN Benzamide, 2-[[5-cyano-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042433-28-2 CAPLUS


CN Benzamide, 2-[[5-cyano-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 1042433-29-3 CAPLUS

CN Benzamide, 2-[[5-cyano-2-[[4-methoxy-3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-30-6 CAPLUS

CN Benzamide, 2-[[5-cyano-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-31-7 CAPLUS

CN Benzamide, 2-[[5-methyl-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-32-8 CAPLUS

CN Benzamide, 2-[[5-methyl-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-33-9 CAPLUS

CN Benzamide, 2-[[5-methyl-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-34-0 CAPLUS

CN Benzamide, N-methyl-2-[[5-methyl-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-36-2 CAPLUS

CN Benzamide, N-methyl-2-[[5-methyl-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-37-3 CAPLUS

CN Benzamide, N-methyl-2-[[5-methyl-2-[[4-  
[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX  
NAME)




RN 1042433-38-4 CAPLUS

CN Benzamide, N-methyl-2-[[5-methyl-2-[[4-(4-morpholinyl)phenyl]amino]-4-  
pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-39-5 CAPLUS

CN Benzamide, N-methyl-2-[[5-methyl-2-[[3-(4-methyl-2-oxo-1-  
piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-40-8 CAPLUS

CN Benzamide, 2-[[2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-5-  
methyl-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-41-9 CAPLUS

CN Benzamide, N-methyl-2-[[5-methyl-2-[[3-  
[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX  
NAME)




RN 1042433-44-2 CAPLUS

CN Benzamide, N-(1-methylethyl)-2-[[5-methyl-2-[[3-(4-methyl-1-  
piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-45-3 CAPLUS

CN Benzamide, N-(1-methylethyl)-2-[[5-methyl-2-[[4-  
[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX  
NAME)




RN 1042433-46-4 CAPLUS

CN Benzamide, 2-[[2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-47-5 CAPLUS

CN Benzamide, N-(1-methylethyl)-2-[[5-methyl-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-48-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro- (CA INDEX NAME)




RN 1042433-49-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro- (CA INDEX NAME)




RN 1042433-51-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro- (CA INDEX NAME)




RN 1042433-52-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro- (CA INDEX NAME)




RN 1042433-53-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro- (CA INDEX NAME)




RN 1042433-54-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)



RN 1042433-55-5 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)



RN 1042433-56-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)

4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-57-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)



RN 1042433-59-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-60-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)







RN 1042433-61-3 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)



RN 1042433-62-4 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-63-5 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 1042433-64-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro- (CA INDEX NAME)




RN 1042433-66-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro- (CA INDEX NAME)




RN 1042433-67-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro- (CA INDEX NAME)




RN 1042433-68-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-69-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-71-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-72-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-73-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-74-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-75-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-76-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-77-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-78-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-79-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)-  
(CA INDEX NAME)




RN 1042433-80-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-81-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-82-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-83-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(3,4-dimethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-85-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro-N-methyl- (CA INDEX NAME)




RN 1042433-86-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro-N-methyl- (CA INDEX NAME)



RN 1042433-87-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro-N-methyl- (CA INDEX NAME)



RN 1042433-88-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-5-fluoro- (CA INDEX NAME)






RN 1042433-89-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-5-fluoro- (CA INDEX NAME)




RN 1042433-91-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-5-fluoro- (CA INDEX NAME)




RN 1042433-92-0 CAPLUS


CN Benzamide, 5-bromo-2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-93-1 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro- (CA INDEX NAME)



RN 1042433-94-2 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro- (CA INDEX NAME)




RN 1042433-95-3 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-4-fluoro- (CA INDEX NAME)




RN 1042433-96-4 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)

10/507,060 (amended)




●x HCl

RN 1042433-97-5 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042433-98-6 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 1042433-99-7 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[4-[4-(1-methylethyl)-1-

10/507,060 (amended)


piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-,  
hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-00-3 CAPLUS


CN Benzamide, 2-[[[5-fluoro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-01-4 CAPLUS


CN Benzamide, 2-[[[5-fluoro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●<sub>x</sub> HCl

RN 1042434-02-5 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●<sub>x</sub> HCl

RN 1042434-03-6 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●<sub>x</sub> HCl

10/507,060 (amended)


RN 1042434-04-7 CAPLUS  
CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 1042434-05-8 CAPLUS  
CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1042434-06-9 CAPLUS  
CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-07-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-09-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-1-(hydroxymethyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-11-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-1-(hydroxymethyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-12-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(2S)-2-hydroxypropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-13-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(2R)-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1042434-14-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 1042434-16-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)




Absolute stereochemistry.



RN 1042434-17-2 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1042434-18-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(3-methylbutyl)- (CA INDEX NAME)



RN 1042434-19-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 1042434-23-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-24-1 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1042434-25-2 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1042434-26-3 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1042434-27-4 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-28-5 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-

pyrimidinyl]amino]-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-29-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-1-(hydroxymethyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1042434-30-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1,3-dioxolan-2-ylmethyl)- (CA INDEX NAME)



RN 1042434-36-5 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)

RN 1042434-37-6 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)


RN 1042434-41-2 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylsulfinyl)ethyl]- (CA INDEX NAME)




RN 1042434-42-3 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 1042434-43-4 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 1042434-44-5 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 1042434-46-7 CAPLUS


CN Benzamide, 2-[[2-[[4-[[[2-(ethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042434-47-8 CAPLUS  
 CN Benzamide, 2-[[2-[[4-[[[2-(ethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 1042434-46-7  
 CMF C25 H31 F N6 O3 S



10/507,060 (amended)

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 1042434-49-0 CAPLUS  
CN Benzamide, 2-[[2-[[4-[[[2-(diethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 1042434-48-9  
CMF C27 H35 F N6 O3 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2






RN 1042434-51-4 CAPLUS  
 CN Benzamide, 2-[[2-[[4-[[[2-(dimethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 1042434-50-3  
 CMF C25 H31 F N6 O3 S



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 1042434-53-6 CAPLUS

CN Benzamide, 2-[[2-[[4-[[[(2-aminoethyl)sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-52-5


CMF C23 H27 F N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1042434-55-8 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(4-methyl-1-piperazinyl)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-54-7


CMF C28 H36 F N7 O3 S

10/507,060 (amended)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 1042434-57-0 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(4-morpholinyl)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-56-9  
CMF C27 H33 F N6 O4 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 1042434-59-2 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(methylamino)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-58-1


CMF C24 H29 F N6 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1042434-60-5 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-(4-piperidinyl)phenyl]amino]-4-

pyrimidinyl]amino]-N-(1-methylethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 1042434-61-6 CAPLUS  
CN Benzamide, N-(1-methylethyl)-2-[[5-methyl-2-[[4-(4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-62-7 CAPLUS  
CN Benzamide, 2-[[5-fluoro-2-[[4-(4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)


10/507,060 (amended)



●x HCl


RN 1042434-67-2 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-68-3 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(hydroxyethyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-69-4 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-[(2-hydroxyethyl)sulfonyl]ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-70-7 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-(2-methoxyethyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042434-71-8 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[3-[(5R)-5-methyl-2-oxo-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-72-9 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[3-[(5S)-5-methyl-2-oxo-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.






RN 1042434-73-0 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042434-75-2 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-(4-piperidiny)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042435-14-2 CAPLUS

CN Benzamide, N-(1-methylethyl)-2-[[5-methyl-2-[[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

IT 1042435-07-3P 1042435-09-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of anthranilamide as aurora kinase inhibitors  
 useful in the treatment of cancer)  
 RN 1042435-07-3 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-  
 hydroxyethyl)sulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-  
 methylethyl)- (CA INDEX NAME)




RN 1042435-09-5 CAPLUS  
 CN Benzamide, 2-[[2-[[4-[(ethenylsulfonyl)methyl]phenyl]amino]-5-fluoro-4-  
 pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




IT 1042434-08-1P  
 RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prophetic drug candidate; preparation of anthranilamide as aurora kinase inhibitors useful in the treatment of cancer)  
 RN 1042434-08-1 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 11 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:821047 CAPLUS  
 DN 149:282622  
 TI FAK and IGF-1R interact to provide survival signals in human pancreatic adenocarcinoma cells  
 AU Liu, Weiguo; Bloom, David A.; Cance, William G.; Kurenova, Elena V.; Golubovskaya, Vita M.; Hochwald, Steven N.  
 CS Division of Surgical Oncology, University of Florida College of Medicine, Gainesville, FL, 32610, USA  
 SO Carcinogenesis (2008) 29(6), 1096-1107  
 CODEN: CRNGDP; ISSN: 0143-3334  
 PB Oxford University Press  
 DT Journal  
 LA English  
 AB Pancreatic cancer is a lethal disease accounting for the fourth leading cause of cancer death in USA. Focal adhesion kinase (FAK) and the insulin-like growth factor-I receptor (IGF-1R) are tyrosine kinases that activate common pathways, leading to increased proliferation and cell survival. Sparse information is available regarding their contribution to the malignant behavior of pancreatic cancer. We analyzed the relationship between FAK and IGF-1R in human pancreatic cancer cells, determined which downstream signaling pathways are altered following kinase inhibition or downregulation and studied whether dual kinase inhibition represents a potential novel treatment strategy in this deadly disease. Using immunopptn. and confocal microscopy, we show for the first time that FAK and IGF-1R phys. interact in pancreatic cancer cells and that inhibition of tyrosine phosphorylation of either kinase disrupts their interaction. Decreasing phosphorylation of either FAK or IGF-1R alone resulted in little inhibition of cell viability or increased apoptosis. However, dual inhibition of FAK, using either a dominant-neg. construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small mol. tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal-regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone. Dual kinase inhibition with FAK-CD and AEW-541 resulted in a marked increase in apoptosis when FAK was displaced from the focal adhesions. Inhibition of both tyrosine kinase activities via a novel single small mol. inhibitor (TAE 226), at low doses specific for FAK and IGF-1R, resulted in significant inhibition of cell viability, decrease in phosphorylation of ERK and Akt and increase in apoptosis accompanied by cleavage of Poly (ADP-ribose) polymerase (PARP) and activation of caspase-3 in pancreatic cancer cells. Thus, simultaneous inhibition of both tyrosine kinases represents a potential novel therapeutic approach in human pancreatic adenocarcinoma.  
 IT 761437-28-9  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (FAK and IGF-1R interact to provide survival signals in human pancreatic adenocarcinoma cells)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 12 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:804513 CAPLUS  
 DN 149:128852  
 TI Preparation of pyrimidines as Aurora kinase inhibitors  
 IN Krueger, Elaine B.; Rawson, Thomas E.; Burdick, Daniel J.; Liang, Jun;  
 Zhu, Bing-Yan  
 PA Genentech, Inc., USA  
 SO PCT Int. Appl., 68pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008079719	A1	20080703	WO 2007-US87454	20071213
	W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2006-870784P	P	20061219		
OS	MARPAT 149:128852				
AB	Title compds. I [Q = -NR4-, -NR4C(O)-, -C(O)NR4-, etc.; X = H, hydroxyl, halo, etc.; Y = O, S or NR4; Z = H, alkyl, carbocycle, etc.; R1 = hydroxyl, halo, amino, etc.; R2 = hydroxyl, halo, amino, etc.; R4 = H or alkyl; m = 0-4; n = 0-3], useful for inhibiting the proliferation of a tumor cell, were prepared For example, treatment of tert-Bu 2-(2,5-dichloropyrimidin-4-ylamino)phenylcarbamate, e.g., prepared from 5-chlorouracil in 2 steps, with HCl followed by acylation with cyclopropanecarbonyl chloride and reaction with 4-morpholinoaniline afforded compound II [R = morpholin-4-yl]. Compds. of this invention that were tested in the ELISA assays were found to inhibit Aurora A and/or B kinase activity with an IC50 of less than 0.5 $\mu$ M, e.g., the IC50 of compound II [R = CN] was 0.0013 $\mu$ M for Aurora A.				
IT	1035561-76-2P 1035561-77-3P 1035561-78-4P 1035561-79-5P 1035561-80-8P 1035561-81-9P 1035561-82-0P 1035561-83-1P 1035561-84-2P 1035561-85-3P 1035561-86-4P 1035561-87-5P 1035561-88-6P 1035561-89-7P 1035561-90-0P 1035561-91-1P 1035561-92-2P 1035561-93-3P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidines as Aurora kinase inhibitors)				
RN	1035561-76-2 CAPLUS				
CN	Benzamide, 2-[[5-chloro-2-[[4-[(cyclopropylamino)carbonyl]phenyl]amino]-4- pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)				




RN 1035561-77-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-78-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-79-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(2-hydroxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-80-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(2-oxo-1-piperidiny)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 1035561-81-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 1035561-82-0 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[4-(4-fluorophenyl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)






RN 1035561-83-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-84-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-85-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-86-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-87-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(dimethylamino)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-88-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(diethylamino)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-89-7 CAPLUS

CN Benzamide, 2-[[2-[[4-(acetylamino)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-90-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(methanesulfonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-91-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(1H-1,2,4-triazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-92-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(1H-pyrrol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 1035561-93-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(1H-pyrazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




IT 1035562-32-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidines as Aurora kinase inhibitors)

RN 1035562-32-3 CAPLUS

CN Benzoic acid, 4-[[5-chloro-4-[[2-[(cyclopropylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:796944 CAPLUS  
 DN 149:104749  
 TI Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway  
 IN Argade, Ankush; Sran, Arvinder; Carroll, David; Clough, Jeffrey Wayne;  
 Tso, Kin; Bhamidipati, Somasekhar; Thota, Sambaiah; Singh, Rajinder;  
 Taylor, Vanessa; Li, Hui; Masuda, Esteban  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 258pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008079907	A1	20080703	WO 2007-US88241	20071219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20070203161	A1	20070830	US 2007-678429	20070223
PRAI	US 2006-871098P	P	20061220		
	US 2007-678429	A	20070223		
	US 2006-776636P	P	20060224		
	US 2006-450901	A2	20060608		

AB The invention encompasses pyrimidine-2,4-diamines I; wherein X = alkyl, alkoxy, amino, carboxy, carboxy ester, cyano, halo, nitro, alkenyl, alkynyl; Y is H, alkyl, amino, halo; ring A = aryl, heteroaryl, cycloalkyl, cyclo-alkenyl and heterocyclic, R = H, alkyl, alkenyl, alkynyl, cycloalkyl; ring A is not indolyl or benzimidazolyl; p = 0-3; q = 1-3; R2 = alkyl, alkoxy, amino, aryl, aryl-oxy, cycloalkyl, cycloalkyl heteroaryl, heteroaryl, heterocycle, heterocyclyl-oxy, carboxyl, carboxyl ester, OH, acylamino, amino-sulfonyl, alkynyl, alkylthio, amino-carbonyl, acyl, oxo, halo; R3 = alkyl, cycloalkyl, halo, heterocyclic, amino-sulfonyl; R4 and R5 are independently = H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, acyl; R4 and R5 together with the N atom to which they are attached, form a heterocycle; and metal or ammonium counterion; and the compns. and methods using these compds. in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. Thus, N4-(3-acetyl-amino-4-hydroxyphenyl)-N2-(3-amino-sulfonyl-phenyl)-5-fluoro-2,4-pyrimidine-diamine was prepared by condensation of 4-amino-benzenesulfonamide with 2-chloro-5-fluoro-N4-[4-(3-fluoro-propyl)phenyl]-4-pyrimidin-amine. Results for an assay for Ramos B-cell line stimulated with IL-4, primary human T-cell proliferation assay stimulated with IL-2, assay for A549 epithelial line stimulated with IFN $\gamma$  and U937 IFN $\gamma$  ICAM1 FACS assay (all of which involve the JAK/Stat pathway) are tabulated for hundreds of examples of I. A method of treating or preventing allograft transplant rejection in a transplant

recipient, comprising administering to the transplant recipient an amount of a compound effective to treat or prevent the allograft transplant rejection wherein the compound is selected from the title compds, is claimed. A method of inhibiting a signal transduction cascade in which JAK3 kinase plays a role, comprising contacting a cell expressing a receptor involved in said signaling cascade with title compds, is claimed.

IT 916744-11-1P 916744-12-2P 916744-13-3P

916744-17-7P 916744-18-8P 916744-19-9P

947677-66-9P 947677-67-0P 947681-02-9P


947681-15-4P 947681-16-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine-2,4-diamine sulfonamides for inhibition of JAK pathway)


RN 916744-11-1 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-12-2 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-13-3 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-17-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-18-8 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-19-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 947677-66-9 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 947677-67-0 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)







RN 947681-02-9 CAPLUS  
 CN Benzenesulfonamide, 4,4'-[[6-[(3,4-dihydro-2,2,4-trimethyl-3-oxo-2H-1,4-benzoxazin-6-yl)amino]-2,4-pyrimidinediyl]diimino]bis- (CA INDEX NAME)



RN 947681-15-4 CAPLUS  
 CN Benzenesulfonamide, 3-[[2-[[4-(2-propyn-1-yloxy)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 947681-16-5 CAPLUS  
 CN Benzenesulfonamide, 4-[[2-[[4-(2-propyn-1-yloxy)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:734100 CAPLUS  
 DN 149:79629  
 TI Preparation of N,N'-diarylpyrimidinediamine for use as protein kinase inhibitors  
 IN Michellys, Pierre-Yves; Pei, Wei; Marsilje, Thomas H.; Lu, Wenshuo; Chen, Bei; Uno, Tetsuo; Jin, Yunho; Jiang, Tao  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 199pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008073687	A2	20080619	WO 2007-US85304	20071120
	WO 2008073687	A3	20080731		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	US 20080176881	A1	20080724	US 2007-943436	20071120
PRAI	US 2006-869299P	P	20061208		
	US 2007-966449P	P	20070828		

OS MARPAT 149:79629

AB Title compds. I [R1 and R2 independently = halo, OR12, (un)substituted alkyl, alkynyl, etc.; or one of R1 or R2 = H; or R1 and R2 together form (un)substituted monocyclic or fused carbocyclic ring, aryl, heteroaryl, etc.; R3 = CN, SO2R12, (CR5)2CO2R12, etc.; R4 = H, NO2, halo, (un)substituted alkyl, alkenyl, etc.; R5 = H or alkyl; R6 = substituted aryl or heteroaryl; R12 = H, alkyl, aryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. Thus, e.g., II was prepared by amidation of 4-aminopiperidine-1-carboxylic acid tert-Bu ester with 2-chloro-4-isopropoxy-5-nitrobenzoyl chloride (preparation given), followed by coupling with vinylboronic acid di-Bu ester, cyclization, reduction, substitution with (2,5-dichloropyrimidin-4-yl)-[2-(propane-2-sulfonyl)phenyl]amine (preparation given), and deprotection. I were evaluated in BaF3-NPM-ALK cell assays and, in general, demonstrated IC50 values from 1 nM to 10  $\mu$ M.

IT 1032900-37-0P 1032900-40-5P 1032900-41-6P  
 1032900-42-7P 1032900-49-4P 1032900-68-7P  
 1032900-82-5P 1032900-86-9P 1032900-87-0P  
 1032901-11-3P 1032901-13-5P 1032901-14-6P  
 1032901-15-7P 1032901-16-8P 1032901-18-0P  
 1032901-22-6P 1032901-28-2P 1032901-32-8P  
 1032901-33-9P 1032901-34-0P 1032901-36-2P  
 1032901-38-4P 1032901-40-8P 1032901-42-0P  
 1032901-44-2P 1032901-45-3P 1032901-46-4P


1032901-47-5P 1032901-53-3P 1032901-54-4P  
 1032901-55-5P 1032901-56-6P 1032901-58-8P  
 1032901-59-9P 1032901-61-3P 1032901-62-4P  
 1032901-63-5P 1032901-64-6P 1032903-11-9P  
 1032903-23-3P 1032903-40-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of N,N'-diarylpyrimidinediamine for use as protein kinase  
 inhibitors)

RN 1032900-37-0 CAPLUS


CN Benamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-  
 piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX  
 NAME)



RN 1032900-40-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[cis-4-(dimethylamino)cyclohexyl]-5-  
 methyl-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl-  
 (CA INDEX NAME)


Relative stereochemistry.



RN 1032900-41-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[trans-4-(dimethylamino)cyclohexyl]-  
 5-methyl-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl-  
 (CA INDEX NAME)

Relative stereochemistry.




RN 1032900-42-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 1032900-49-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1032900-68-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-methyl-2-(1-methylethoxy)-5-(4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1032900-82-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-methyl-2-(1-methylethoxy)-5-(3-methyl-5-isoxazolyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032900-86-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-(5-isoxazolyl)-4-methyl-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032900-87-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-methyl-2-(1-methylethoxy)-5-(2-methyl-1H-imidazol-5-yl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-11-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-13-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 1032901-14-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-15-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1032901-16-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1032901-18-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-5-methyl-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 1032901-22-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-methoxy-2-methyl[1,1'-biphenyl]-4-yl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-28-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4'-(dimethylamino)-5-methoxy-2,3'-dimethyl[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-32-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-4'-(4-morpholinyl)[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-33-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-34-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-2'-methyl- (CA INDEX NAME)




RN 1032901-36-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4'-acetyl-5-methoxy-2-methyl[1,1'-biphenyl]-4-yl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-38-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1032901-40-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-2'-methyl- (CA INDEX NAME)




RN 1032901-42-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-methyl-4-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-44-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 1032901-45-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-[(1-methyl-4-piperidinyl)oxy]-4-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 1032901-46-4 CAPLUS


CN Benzamide, 5-[[2-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-(4-pyridinyl)- (CA INDEX NAME)

NAME)




RN 1032901-47-5 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-(2-fluoro-4-pyridinyl)-N-methyl-4-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-53-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2'-cyano-N-methyl-5'-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-54-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[4-[[2-(aminosulfonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-N,2'-dimethyl-5'-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-55-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-cyclopropyl-5'-methoxy-2'-methyl- (CA INDEX NAME)




RN 1032901-56-6 CAPLUS

CN Acetamide, N-[[4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-2'-methyl[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1032901-58-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[[[(cyclopropylmethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1032901-59-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(cyclobutylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1032901-61-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-2'-methyl- (CA INDEX NAME)




RN 1032901-62-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1032901-63-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-4'-(4-morpholinylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 1032901-64-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-4'-(4-methyl-1-piperazinyl) sulfonyl][1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 1032903-11-9 CAPLUS


CN Benzamide, 2-[[2-[[5-ethynyl-4-methyl-2-(1-methylethoxy)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)






RN 1032903-23-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032903-40-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



L7 ANSWER 15 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:605237 CAPLUS  
 DN 149:44292  
 TI Development and Experimental Validation of a Docking Strategy for the  
 Generation of Kinase-Targeted Libraries  
 AU Gozalbes, Rafael; Simon, Laurence; Froloff, Nicolas; Sartori, Eric;  
 Monteils, Claude; Baudelle, Romuald  
 CS Cerep, Courtaboeuf, 91951, Fr.  
 SO Journal of Medicinal Chemistry (2008), 51(11), 3124-3132  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB A high-throughput docking strategy for the filtering of in silico compds.  
 and the generation of kinase-targeted libraries is described. Systematic  
 docking and scoring in three kinase crystal 3D structures of 123  
 structurally diverse kinase ligands led to the determination of six thresholds  
 for each kinase. These thresholds were used as filters for the virtual  
 screening of two collections of compds.: a collection of more than 2500  
 drugs and drug-like compds. (neg. control) and a kinase-targeted library  
 of 1440 compds. This strategy was then exptl. validated by testing 60  
 compds. from the kinase-targeted library on 41 kinases from five different  
 families. The 60 compds. were split into those passing all the thresholds  
 and the others (30 compds. in each group). The overall hit enrichment was  
 6.70-fold higher in the first group, validating our approach for the  
 generation of kinase-targeted libraries and the identification of  
 scaffolds with high kinase inhibitory potential.  
 IT 1032182-71-0 1032183-86-0  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (development and validation of docking strategy for generation of  
 kinase-targeted libraries)  
 RN 1032182-71-0 CAPLUS  
 CN Benzamide, N-[2-[4-(dimethylamino)phenyl]ethyl]-4-[[2-[(3-  
 methylphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1032183-86-0 CAPLUS  
 CN Benzamide, N-methyl-3-[[2-[(3-methylphenyl)amino]-4-pyrimidinyl]amino]-N-  
 [2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/507,060 (amended)

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:593601 CAPLUS  
 DN 149:215269  
 TI Selective inhibition of JAK2-driven erythroid differentiation of  
 polycythemia vera progenitors. [Erratum to document cited in CA148:576239]  
 AU Geron, Ifat; Abrahamsson, Annelie E.; Barroga, Charlene F.; Kavalierchik,  
 Edward; Gotlib, Jason; Hood, John D.; Durocher, Jeffrey; Mak, Chi Ching;  
 Noronha, Glenn; Soll, Richard M.; Tefferi, Ayalew; Kaushansky, Ken;  
 Jamieson, Catriona H. M.  
 CS Department of Medicine, University of California, San Diego, La Jolla, CA,  
 92093, USA  
 SO Cancer Cells (2008), 13(5), 464  
 CODEN: CCAECI; ISSN: 1535-6108  
 PB Cell Press  
 DT Journal  
 LA English  
 AB The following sentence was omitted from the Acknowledgements section of  
 this paper on page 328: "J.D.H., C.C.M., G.N., and R.M.S. are employees  
 and/or shareholders of TargeGen Inc."  
 IT 936091-26-8, TG 101348  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (selective inhibition of JAK2-driven erythroid differentiation of  
 polycythemia vera progenitors (Erratum))  
 RN 936091-26-8 CAPLUS  
 CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-  
 pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



L7 ANSWER 17 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:585320 CAPLUS  
 DN 148:535534  
 TI Immunocompromised non-human mammal comprising human hematopoietic stem cells genetically altered to express a mutant JAK2 protein and uses as models of erythropoiesis for drug screening  
 IN Jamieson, Catriona Helen M.; Kaushansky, Ken; Barroga, Charlene; Geron, Ifat; Abrahamson, Annelie; Kavalierchik, Edward  
 PA The Regents of the University of California, USA  
 SO PCT Int. Appl., 42pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008057233	A2	20080515	WO 2007-US22600	20071024
WO 2008057233	A9	20080724		
WO 2008057233	A3	20081030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2006-854488P P 20061025

AB Non human animal models are provided for diseases involving erythroid function, particularly myeloproliferative disease. The models are useful for testing and screening of biol. active agents that affect erythropoiesis, and erythroid function. In the animal models of the invention, a hematopoietic stem or progenitor cell (HSC) population that has been genetically altered by the introduction of a mutant JAK2 coding sequence is transplanted into an immunocompromised, xenogeneic, non-human recipient. The recipient animal is engrafted with the cell population at a high frequency, and develops a myeloproliferative disorder characterized by polycythemia. JAK2 driven erythroid signal transduction pathway or JAK2 V617F driven erythroid engraftment were inhibited by TG101348. JAK2 V617F driven erythroid differentiation was also inhibited by TG101348. The invention also provided a non-human animal model of malaria.


IT 936091-26-8, TG 101348

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(immunocompromised non-human mammal comprising human hematopoietic stem cells genetically altered to express a mutant JAK2 protein and uses as models of erythropoiesis for drug screening)

RN 936091-26-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



L7 ANSWER 18 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:529900 CAPLUS  
 DN 148:538288  
 TI Preparation of fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors  
 IN Ahmed, Gulzar; Bohnstedt, Adolph; Breslin, Henry Joseph; Burke, Jason; Curry, Matthew A.; Diebold, James L.; Dorsey, Bruce; Dugan, Benjamin J.; Feng, Daming; Gingrich, Diane E.; Guo, Tao; Ho, Koc-Kan; Learn, Keith S.; Lisko, Joseph G.; Liu, Rong-Qiang; Mesaros, Eugen F.; Milkiewicz, Karen; Ott, Gregory R.; Parrish, Jonathan; Theroff, Jay P.; Thieu, Tho V.; Tripathy, Rabindranath; Underiner, Theodore L.; Wagner, Jason C.; Weinberg, Linda; Wells, Gregory J.; You, Ming; Zificsak, Craig A.  
 PA Cephalon, Inc., USA; Pharmacoepia Drug Discovery, Inc.  
 SO PCT Int. Appl., 1297pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008051547	A1	20080502	WO 2007-US22496	20071023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2006-853562P P 20061023

OS MARPAT 148:538288


AB Title compds. I and II [R1 = H, halo, NO<sub>2</sub>, OH and derivs., aryl, alkyl, etc.; R2 = (un)substituted alk(en/yn)yl, (hetero)aryl, R3-R5 = independently H, CO<sub>2</sub>H and derivs., NH<sub>2</sub> and derivs., OCHF<sub>2</sub>, etc.; A1-A5 = independently (CH<sub>2</sub>)<sub>1-2</sub> and derivs., CO, NH and derivs., S, SO, SO<sub>2</sub>, O, with provisos; with the exception of specified compds.; and their pharmaceutically acceptable salts] were prepared as ALK and c-Met kinase inhibitors for treating proliferative disorders. Thus, nitration of 1,3,4,5-tetrahydrobenzo[b]azepin-2-one with HNO<sub>3</sub>/H<sub>2</sub>SO<sub>4</sub>, alkylation with Me iodide, reduction of the nitro intermediate and amination of 2-[(2,5-dichloropyrimidin-4-yl)amino]-N-methylbenzamide gave benzazepinylaminopyrimidine III. III inhibited ALK and C-Met kinases with IC<sub>50</sub> < 0.1 μM.

IT 1022965-78-1P, 2-[[2-[[3-(3-Amino-3-oxopropyl)-4-(prop-1-en-2-yl)phenyl]amino]-5-chloropyrimidin-4-yl]amino]-3-fluoro-N-methylbenzamide  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of fused bicyclic derivs. of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors)

RN 1022965-78-1 CAPLUS

CN Benzenepropanamide, 5-[[5-chloro-4-[[2-fluoro-6-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-(1-methylethenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 19 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:502588 CAPLUS  
 DN 148:472065  
 TI Preparation of 2,4-pyrimidinediamine derivatives as JAK kinase inhibitors  
 IN Li, Hui; Argade, Ankush; Thota, Sambaiah; Carroll, David; Sran, Arvinder;  
 Cooper, Robin; Singh, Rajinder; Tso, Kin; Bhamidipati, Somasekhar  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 142pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008049123	A2	20080424	WO 2007-US82020	20071019
	WO 2008049123	A3	20080619		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,  
 GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,  
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080194603	A1	20080814	US 2007-875772	20071019
----------------	----	----------	----------------	----------

PRAI US 2006-862162P P 20061019

OS MARPAT 148:472065

AB The title 2,4-pyrimidinediamine derivs. I [wherein A = (hetero)aryl; p = 0-5; q = 0-3; X = H, OH, (un)substituted alkyl, alkoxy, NH<sub>2</sub>, etc.; Y = H, (un)substituted aminosulfonylalkyl, etc.; Z1-Z3 = independently CH or N; R1 = H, (un)substituted (cyclo)alkyl, alkenyl, or alkynyl; R2 = independently (un)substituted alkyl, alkoxy, alkynyl, amino, etc.; R3 = independently (un)substituted alkyl, alkoxy, alkynyl, etc.; R4 = (un)substituted aminosulfonyl, aminosulfonylalkyl, etc.] or pharmaceutically acceptable salts thereof were prepared as JAK kinase inhibitors for the treatment of autoimmune disease, transplant rejection, type IV hypersensitivity, etc. For example, II was prepared in a multi-step synthesis. The compds. showed inhibitory activity with EC<sub>50</sub> of 40-100 nM against human U937 monocytic cell lines.


IT 1019855-56-1P 1019855-57-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2,4-pyrimidinediamine derivs. as JAK kinase inhibitors)


RN 1019855-56-1 CAPLUS

CN Benzenemethanesulfonamide, 3-[[5-fluoro-4-[[3-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1019855-57-2 CAPLUS

CN Benzenemethanesulfonamide, 3-[[4-[[3-  
[(dimethylamino)sulfonyl]phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]- (CA  
INDEX NAME)



L7 ANSWER 20 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:474245 CAPLUS  
 DN 148:447347  
 TI An oncogene arising from a fusion of the EML4 and ALK genes of human and its use in the diagnosis and treatment of cancers  
 IN Mano, Hiroyuki; Kuromitsu, Sadao; Shindo, Nobuaki; Soga, Takatoshi; Furutani, Takashi  
 PA Astellas Pharma Inc., Japan; Curegene K.K.  
 SO Can. Pat. Appl., 156pp.  
 CODEN: CPXXEB  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2598893	A1	20080411	CA 2007-2598893	20070824
	US 20080090776	A1	20080417	US 2007-845498	20070827
	EP 1914240	A1	20080423	EP 2007-254044	20071011
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2008295444	A	20081211	JP 2007-265917	20071011
PRAI	JP 2006-277718	A	20061011		
	JP 2007-120670	A	20070501		
	CA 2007-2598893	A	20070824		

AB A chimeric gene arising from a fusion of the EML4 and ALK genes as a result of an inversion on human chromosome 2 is identified in a number of cancers. Detection of the oncogene, or its gene product, may be useful in the diagnosis of cancers, and the gene product may be a target for drug therapy. The fusion gene mRNA was identified in a lung adenocarcinoma patient and was found in tissue from non-small cell lung cancer patients. The fusion protein is active as a kinase, retaining the kinase activity of the ALK anaplastic lymphoma kinase gene product. Inhibitors of the kinase activity were effective at inhibiting growth of cells expressing the oncogene. SiRNAs directed against the mRNA of the chimeric gene were also effective at inhibiting cell proliferation.


IT 761436-81-1  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (as kinase inhibitor of EML4-ALK fusion protein; oncogene arising from fusion of EML4 and ALK genes of human and its use in diagnosis and treatment of cancers)

RN 761436-81-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




L7 ANSWER 21 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:470046 CAPLUS  
 DN 148:576239  
 TI Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors  
 AU Geron, Ifat; Abrahamsson, Annelie E.; Barroga, Charlene F.; Kavalierchik, Edward; Gotlib, Jason; Hood, John D.; Durocher, Jeffrey; Mak, Chi Ching; Noronha, Glenn; Soll, Richard M.; Tefferi, Ayalew; Kaushansky, Ken; Jamieson, Catriona H. M.  
 CS Department of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA  
 SO Cancer Cell (2008), 13(4), 321-330  
 CODEN: CCAECI; ISSN: 1535-6108  
 PB Cell Press  
 DT Journal  
 LA English  
 AB Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overprod., and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia. In this study, JAK2V617F expression by human hematopoietic progenitors promoted erythroid colony formation and erythroid engraftment in a bioluminescent xenogeneic immunocompromised mouse transplantation model. A selective JAK2 inhibitor, TG101348 (300 nM), significantly inhibited JAK2V617F+ progenitor-derived colony formation as well as engraftment (120 mg/kg) in xenogeneic transplantation studies. TG101348 treatment decreased GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibited STAT5 as well as GATA S310 phosphorylation. Thus, TG101348 may be an effective inhibitor of JAK2V617F+ MPDs in clin. trials.  
 IT 936091-26-8, TG 101348  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors)  
 RN 936091-26-8 CAPLUS  
 CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 22 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:470045 CAPLUS  
 DN 149:739  
 TI Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera  
 AU Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary  
 CS Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA  
 SO Cancer Cell (2008), 13(4), 311-320  
 CODEN: CCAECI; ISSN: 1535-6108  
 PB Cell Press  
 DT Journal  
 LA English  
 AB We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of .apprx.3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation. In treated animals, there was a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis. There were no apparent toxicities and no effect on T cell number. In vivo responses were correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.  
 IT 936091-26-8, TG 101348  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (efficacy of JAK2 inhibitor G101348 in treatment of murine model of JAK2V617F-induced polycythemia vera)  
 RN 936091-26-8 CAPLUS  
 CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:410630 CAPLUS  
 DN 148:426905  
 TI Preparation of bicyclic pyrimidine kinase inhibitors  
 IN Connolly, Peter J.; Emanuel, Stuart; Lin, Ronghui; Lu, Yanhua; Middleton, Steven A.  
 PA Janssen Pharmaceutica N.V., Belg.  
 SO PCT Int. Appl., 60pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008039359	A2	20080403	WO 2007-US20434	20070920
	WO 2008039359	A3	20080508		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2006-826776P P 20060925

OS MARPAT 148:426905

AB The title compds. I [X = O or NR1; Y = O or NH; R1 = H, alkyl, alkylcarbonyl or cycloalkyl; R2 = alkyl, cycloalkyl, (un)substituted Ph, indazolyl, etc.; R3 = (un)substituted Ph, indazolyl, indolyl or benzothiazolyl], useful as inhibitors of ATP-protein kinase interactions, were prepared E.g., a 2-step synthesis of I [X, Y = NH; R2, R3 = 4-(aminosulfonyl)phenyl], starting from 4,6-dihydroxypyrazolo[3,4-d]pyrimidine, was given. The ability of the compds. I to treat or ameliorate protein kinase mediated disorders was determined using various procedures (data given for exemplified compds. I).


IT 1017246-10-4P 1017246-15-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of novel bicyclic pyrimidine compds. as kinase inhibitors useful in treatment and prophylaxis of kinase-mediated diseases)


RN 1017246-10-4 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[4-(aminosulfonyl)phenyl]amino]-6-chloro-5-formyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1017246-15-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-chloro-5-formyl-6-[[4-[[2-hydroxyethyl]amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)



L7 ANSWER 24 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:161408 CAPLUS  
 DN 149:143328  
 TI TAE226 Inhibits Human Neuroblastoma Cell Survival  
 AU Beierle, Elizabeth A.; Trujillo, Angelica; Nagaram, Abhilasha;  
 Golubovskaya, Vita M.; Cance, William G.; Kurenova, Elena V.  
 CS Department of Surgery, College of Medicine, University of Florida,  
 Gainesville, FL, USA  
 SO Cancer Investigation (2008), 26(2), 145-151  
 CODEN: CINVD7; ISSN: 0735-7007  
 PB Informa Healthcare  
 DT Journal  
 LA English  
 AB Purpose. Neuroblastoma is one of the most devastating pediatric solid tumors and is unresponsive to many interventions. TAE226 is a novel small mol. FAK inhibitor. We investigated the effects of TAE226 on neuroblastoma cells in vitro. Materials and Methods. Human neuroblastoma cell lines were treated with varying concns. of TAE226. Following treatment, cell viability, cell cycle, and apoptosis were evaluated. Results. Treatment of human neuroblastoma cell lines with TAE226 resulted in a concentration dependent decrease in FAK phosphorylation, decrease in cellular viability, cell cycle arrest, and an increase in apoptosis. Conclusions. Targeting FAK provides potential therapeutic options for the treatment of neuroblastoma and deserves further investigation.  
 IT 761437-28-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (TAE226 decreased focal adhesion kinase Y397 phosphorylation, viability, resulted cell cycle arrest and increased apoptosis in human neuroblastoma cell)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 25 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:91035 CAPLUS  
 DN 148:191950  
 TI Preparation of 2,4-di(arylamino)-pyrimidine-5-carboxamides as JAK kinases inhibitors  
 IN Duthaler, Rudolf; Gerspacher, Marc; Holzer, Philipp; Streiff, Markus; Thoma, Gebhard; Waelchli, Rudolf; Zerwes, Hans-Guenter  
 PA Novartis AG, Switz.; Novartis Pharma GmbH  
 SO PCT Int. Appl., 49pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008009458	A1	20080124	WO 2007-EP6452	20070719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2006-117632 A 20060721

OS MARPAT 148:191950

AB The title compds. I [R1, R2 = H, XSOMY (wherein X = a direct bond, alkylene, O or NR5; R5 = H or alkyl; Y = alkyl or (un)substituted NH2; m = 1 or 2); R3 = CO2H, CONH2 or CSNH2; R4 = (un)substituted (hetero)aryl; n = 1 or 2; with the proviso], exhibiting JAK-3 and JAK-2 kinase inhibiting activities, were prepared E.g., a 5-step synthesis of II, starting from Et 2-methylsulfonyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate and 3,5-dimethoxyphenylamine, was given. Compds. I have a IC50 value of from 1-1000 nM when tested in JAK kinase assays. Pharmaceutical composition comprising the compound I is claimed.


IT 1003602-77-4P 1003602-78-5P 1003602-80-9P  
 1003602-82-1P 1003602-83-2P 1003602-84-3P  
 1003602-85-4P 1003602-86-5P 1003602-87-6P  
 1003602-88-7P 1003603-14-2P 1003603-17-5P  
 1003603-20-0P 1003603-21-1P 1003603-22-2P  
 1003603-23-3P 1003603-24-4P 1003603-26-6P  
 1003603-27-7P 1003603-30-2P 1003603-31-3P  
 1003603-33-5P 1003603-37-9P 1003603-39-1P  
 1003603-47-1P 1003603-48-2P 1003603-49-3P  
 1003603-50-6P 1003603-51-7P 1003603-52-8P  
 1003603-53-9P 1003603-54-0P 1003603-55-1P  
 1003603-56-2P 1003603-57-3P 1003603-74-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(arylamino)-pyrimidine-5-carboxamides as JAK kinases inhibitors)


RN 1003602-77-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(2-fluoro-5-methoxyphenyl)amino]- (CA INDEX NAME)




RN 1003602-78-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-fluoro-5-methoxyphenyl)amino]-4-[[2-[(methylamino)sulfonyl]phenyl]amino]- (CA INDEX NAME)




RN 1003602-80-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(3,5-dimethoxyphenyl)amino]- (CA INDEX NAME)




RN 1003602-82-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(3,4-dimethoxyphenyl)amino]- (CA INDEX NAME)




RN 1003602-83-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(2-fluoro-5-nitrophenyl)amino]- (CA INDEX NAME)




RN 1003602-84-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(5-amino-2-fluorophenyl)amino]-4-[[2-(aminosulfonyl)phenyl]amino]- (CA INDEX NAME)




RN 1003602-85-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-amino-5-nitrophenyl)amino]-4-[[2-(aminosulfonyl)phenyl]amino]- (CA INDEX NAME)




RN 1003602-86-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-[(1-oxopropyl)amino]phenyl]amino]- (CA INDEX NAME)




RN 1003602-87-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-[(4-pyridinylcarbonyl)amino]phenyl]amino]- (CA INDEX NAME)




RN 1003602-88-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-[[2-(2-hydroxyethoxy)ethyl]amino]phenyl]amino]- (CA INDEX NAME)




RN 1003603-14-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(4-fluoro[1,1'-biphenyl]-3-yl)amino]- (CA INDEX NAME)




RN 1003603-17-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(5-cyclopentyl-2-fluorophenyl)amino]- (CA INDEX NAME)




RN 1003603-20-0 CAPLUS

CN Benzoic acid, 3-[[5-(aminocarbonyl)-4-[[2-(aminosulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-4-fluoro-, methyl ester (CA INDEX NAME)




RN 1003603-21-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)



RN 1003603-22-2 CAPLUS


CN Benzoic acid, 3-[[5-(aminocarbonyl)-4-[[2-(aminosulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 1003603-23-3 CAPLUS


CN Benzoic acid, 3-[[5-(aminocarbonyl)-4-[[2-(aminosulfonyl)phenyl]amino]-2-

pyrimidinyl]amino]- (CA INDEX NAME)




RN 1003603-24-4 CAPLUS

CN 1H-Indene-1-carboxylic acid, 5-[[[5-(aminocarbonyl)-4-[[2-(aminosulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-2,3-dihydro-, methyl ester (CA INDEX NAME)




RN 1003603-26-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-acetylphenyl)amino]-4-[[2-(aminosulfonyl)phenyl]amino]- (CA INDEX NAME)




RN 1003603-27-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(5-chloro-2-fluorophenyl)amino]- (CA INDEX NAME)



RN 1003603-30-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-[(methylamino)carbonyl]phenyl]amino]- (CA INDEX NAME)



RN 1003603-31-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[5-[(dimethylamino)carbonyl]-2-fluorophenyl]amino]- (CA INDEX NAME)






RN 1003603-33-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(2-fluoro-5-methylphenyl)amino]- (CA INDEX NAME)




RN 1003603-37-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(5-acetyl-2-fluorophenyl)amino]-4-[[2-(aminosulfonyl)phenyl]amino]- (CA INDEX NAME)




RN 1003603-39-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]- (CA INDEX NAME)




RN 1003603-47-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4'-(aminocarbonyl)-4-fluoro[1,1'-biphenyl]-3-yl]amino]-4-[[2-(aminosulfonyl)phenyl]amino]- (CA INDEX NAME)




RN 1003603-48-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-(3-pyridinyl)phenyl]amino]- (CA INDEX NAME)




RN 1003603-49-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[5-(5-acetyl-2-thienyl)-2-fluorophenyl]amino]-4-[[2-(aminosulfonyl)phenyl]amino]- (CA INDEX NAME)




RN 1003603-50-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-(1H-pyrazol-4-yl)phenyl]amino]- (CA INDEX NAME)




RN 1003603-51-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(6-fluoro-2,3-dihydro-3-oxo-1H-inden-5-yl)amino]- (CA INDEX NAME)




RN 1003603-52-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[(6-fluoro-2,3-dihydro-1-oxo-1H-inden-5-yl)amino]- (CA INDEX NAME)




RN 1003603-53-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[2-fluoro-5-(1-methylethyl)phenyl]amino]- (CA INDEX NAME)




RN 1003603-54-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(5-acetyl-2-chlorophenyl)amino]-4-[[2-(aminosulfonyl)phenyl]amino]- (CA INDEX NAME)




RN 1003603-55-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-(aminosulfonyl)phenyl]amino]-2-[[5-[(dimethylamino)methyl]-2-fluorophenyl]amino]- (CA INDEX NAME)




RN 1003603-56-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[3-(aminosulfonyl)phenyl]amino]-2-[(3,4,5-trimethoxyphenyl)amino]- (CA INDEX NAME)




RN 1003603-57-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[3-(aminosulfonyl)phenyl]amino]-2-[(3,4-dimethoxyphenyl)amino]- (CA INDEX NAME)



RN 1003603-74-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[4-(aminocarbonyl)phenyl]amino]-2-[(3,4,5-trimethoxyphenyl)amino]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/507,060 (amended)

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 26 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2008:71777 CAPLUS  
 DN 148:144795  
 TI Preparation of 2-amino-5-substituted pyrimidine kinase inhibitors and use  
 in therapy  
 IN Noronha, Glenn; Cao, Jianguo; Gritzen, Colleen; Mak, Chi Ching; Mcpherson,  
 Andrew; Pathak, Ved P.; Renick, Joel; Soll, Richard M.; Zeng, Binqi;  
 Dneprovskaja, Elena  
 PA Targen, Inc., USA  
 SO PCT Int. Appl., 175pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008008234	A1	20080117	WO 2007-US15357	20070702
	W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20080027070	A1	20080131	US 2007-772572	20070702
PRAI	US 2006-819170P	P	20060707		

OS MARPAT 148:144795


AB Comps. having the general structure I (wherein G1 is a bond, H, (un)substituted aryl, or (un)substituted heteroaryl; L1 is O, SO, etc.; L2 is H, (un)substituted alkyl, etc.; or when G1 is heteroaryl or H, L1 or L2 can be absent; A1 is a bond, C(O), S(O), etc.; A2 is C(O), S(O), S(O)2, etc.; R3 is H, alkyl, branched alkyl, etc.; n is 0-4; L3 and L4 are NH, substituted amino, etc.; s and t are 0-1; L5 is lower alkyl, branched alkyl, etc.) are provided. The comps. of the invention are capable of inhibiting kinases, such as members of the Src kinase family, VEGFR and various other specific receptor and non-receptor kinases. Kinase inhibitors are useful for treating various diseases, for example, cancer, vascular disorders, and ocular diseases. The synthetic preparation of I is exemplified. Example compound II was prepared by reacting 5-[3-(trifluoromethyl)benzamido]-2-chlorobenzoic acid and N-[4-(3-pyrrolidin-1-ylpropane-1-sulfonyl)phenyl]pyrimidine-2,5-diamine. II had an IC50 of 4.5 nM as an inhibitor of human Src kinase in vitro.

IT 1001341-75-8P, N-Benzyl-4-Methyl-3-[[2-[[4-[[2-(Pyrrolidin-1-yl)ethyl]sulfamoyl]Phenyl]amino]Pyrimidin-5-yl]amino]benzenesulfonamide  
 1001341-78-1P, 4-Methyl-3-[[2-[[4-[[2-(Pyrrolidin-1-yl)ethyl]sulfamoyl]Phenyl]amino]pyrimidin-5-yl]amino]benzenesulfonamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-amino-5-substituted pyrimidine kinase inhibitors and use in therapy)


RN 1001341-75-8 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-(phenylmethyl)-3-[[2-[[4-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]amino]-5-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1001341-78-1 CAPLUS


CN Benzenesulfonamide, 4-methyl-3-[[2-[[4-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]amino]-5-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 27 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:1306239 CAPLUS  
DN 148:623  
TI Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in  
Ovarian Carcinoma  
AU Halder, Jyotsnabaran; Lin, Yvonne G.; Merritt, William M.; Spannuth,  
Whitney A.; Nick, Alpa M.; Honda, Toshiyuki; Kamat, Aparna A.; Han, Liz  
Y.; Kim, Tae Jin; Lu, Chunhua; Tari, Ana M.; Bornmann, William; Fernandez,  
Ariel; Lopez-Berestein, Gabriel; Sood, Anil K.  
CS Department of Gynecologic Oncology, The University of Texas M. D. Anderson  
Cancer Center, Houston, TX, USA  
SO Cancer Research (2007), 67(22), 10976-10983  
CODEN: CNREA8; ISSN: 0008-5472  
PB American Association for Cancer Research  
DT Journal  
LA English  
AB Focal adhesion kinase (FAK) overexpression is frequently found in ovarian  
and other cancers and is predictive of poor clin. outcome. In the current  
study, we characterized the biol. and therapeutic effects of a novel FAK  
inhibitor, TAE226. Taxane-sensitive (SKOV3i.p.1 and HeyA8) and  
taxane-resistant (HeyA8-MDR) cell lines were used for in vitro and in vivo  
therapy expts. using TAE226 alone and in combination with docetaxel.  
Assessment of cytotoxicity, cell proliferation [proliferating cell nuclear  
antigen (PCNA)], angiogenesis (CD31), and apoptosis (terminal nucleotidyl  
transferase-mediated nick end labeling) were done by immunohistochem. and  
immunofluorescence. In vitro, TAE226 inhibited the phosphorylation of FAK  
at both Y397 and Y861 sites, inhibited cell growth in a time- and  
dose-dependent manner, and enhanced docetaxel-mediated growth inhibition  
by 10- and 20-fold in the taxane-sensitive and taxane-resistant cell  
lines, resp. In vivo, FAK inhibition by TAE226 significantly reduced  
tumor burden in the HeyA8, SKOV3i.p.1, and HeyA8-MDR models (46-64%)  
compared with vehicle-treated controls. However, the greatest efficacy  
was observed with concomitant administration of TAE226 and docetaxel in all  
three models (85-97% reduction, all P values <0.01). In addition, TAE226 alone  
and in combination with chemotherapy significantly prolonged survival in  
tumor-bearing mice. Even in larger tumors, combination therapy with  
TAE226 and docetaxel resulted in tumor regression. The therapeutic  
efficacy was related to reduced pericyte coverage, induction of apoptosis  
of tumor-associated endothelial cells, and reduced microvessel d. and tumor  
cell proliferation. The novel FAK inhibitor, TAE226, offers an attractive  
therapeutic approach in ovarian carcinoma.  
IT 761437-28-9  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(antitumor efficacy of a novel focal adhesion kinase inhibitor TAE226  
in ovarian carcinoma)  
RN 761437-28-9 CAPLUS  
CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-  
pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:1274493 CAPLUS  
 DN 147:522260  
 TI Preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of kinases  
 IN Noronha, Glenn; Mak, Chi Ching; Cao, Jianguo; Renick, Joel; McPherson, Andrew; Zeng, Binqi; Pathak, Ved P.; Lohse, Daniel L.; Hood, John D.; Soll, Richard M.  
 PA Targen, Inc., USA  
 SO U.S. Pat. Appl. Publ., 255pp., Cont.-in-part of U.S. Ser. No. 588,638. CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070259904	A1	20071108	US 2007-796717	20070426
	US 20070191405	A1	20070816	US 2006-588638	20061026
PRAI	US 2005-732629P	P	20051101		
	US 2006-838003P	P	20060815		
	US 2006-588638	A2	20061026		

OS MARPAT 147:522260

AB The title compds. I [X = a bond, C(O), SO<sub>2</sub>, CH<sub>2</sub>; Y = a bond, NR<sub>9</sub>; or X and Y taken together is a bond; R<sub>1</sub>, R<sub>2</sub> = H, alkyl, cycloalkyl, etc.; or R<sub>1</sub> and R<sub>2</sub> taken together is a bond; or R<sub>1</sub> and R<sub>2</sub> taken together form (CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>r</sub>S(CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>r</sub>O(CH<sub>2</sub>)<sub>m</sub>, etc.; p, q, r, n, m = 0-6; R<sub>9</sub> = H, alkyl, cycloalkyl, etc.; G<sub>0</sub> = N, O, H, CH; R<sub>3</sub>, R<sub>4</sub> = H, alkyl, hydrocyalkyl, etc.; G = N or CR<sub>6</sub>; R<sub>5</sub> = Me; Q = (un)substituted Ph, indolyl, indazolyl, etc.; with provisos] that are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases, were prepared E.g., a 2-step synthesis of II, starting from 4-chloropyrimidin-2-ylamine and 4-methoxyphenylamine, was given. Exemplified compds. I were tested for inhibition of JAK2 kinase (data given). The invention also relates to pharmaceutical composition comprising the compound I alone or in combination with other therapeutic agents.


IT 936091-15-5P 936091-97-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of JAK kinases for treating diseases)


RN 936091-15-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-97-3 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




IT 936090-58-3P 936090-59-4P 936091-14-4P  
 936091-16-6P 936091-17-7P 936091-19-9P  
 936091-20-2P 936091-21-3P 936091-22-4P  
 936091-23-5P 936091-24-6P 936091-25-7P  
 936091-26-8P 936091-27-9P 936091-28-0P  
 936091-29-1P 936091-30-4P 936091-32-6P  
 936091-33-7P 936091-35-9P 936091-37-1P  
 936091-39-3P 936091-52-0P 936091-56-4P  
 936091-69-9P 936091-72-4P 936091-73-5P  
 936091-74-6P 936091-76-8P 936091-77-9P  
 936091-78-0P 936091-79-1P 936091-80-4P  
 936091-81-5P 936091-82-6P 936091-83-7P  
 936091-84-8P 936091-85-9P 936091-86-0P  
 936091-94-0P 936091-98-4P 936091-99-5P  
 936092-00-1P 936092-07-8P 936092-08-9P  
 936092-09-0P 936092-10-3P 936092-11-4P  
 936092-24-9P 936092-25-0P 936093-00-4P  
 936093-03-7P 936093-04-8P 956404-51-6P  
 956404-52-7P 956404-53-8P 956404-54-9P  
 956404-55-0P 956404-56-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of JAK kinases  
 for treating diseases)

RN 936090-58-3 CAPLUS

CN Benzamide, N-methyl-3-[[5-methyl-2-[[4-[2-(1-  
 pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936090-59-4 CAPLUS

CN Benzamide, N-methyl-3-[[5-methyl-2-[[4-[2-(1-  
 pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-,  
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 936090-58-3


CMF C25 H30 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 936091-14-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-16-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[(4-oxido-4-morpholinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-17-7 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-pyrazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-19-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-pyrazol-1-yl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-20-2 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperidinylsulfonyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-21-3 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-22-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperazinyl)-3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-23-5 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(4-(1,1-dimethylethyl)piperazinyl)-3-(trifluoromethyl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 936091-24-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-25-7 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperazinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-26-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-27-9 CAPLUS

CN Benzenesulfonamide, 3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-28-0 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-29-1 CAPLUS


CN Benzenesulfonamide, N,N-dimethyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-30-4 CAPLUS


CN Benzenesulfonamide, N-(1-methylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 936091-32-6 CAPLUS

CN Benzenesulfonamide, N-cyclohexyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-33-7 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-35-9 CAPLUS

CN Benzamide, 3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-37-1 CAPLUS

CN Benzamide, 2-methyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-39-3 CAPLUS

CN Benzenesulfonamide, 3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-52-0 CAPLUS

CN Benzenesulfonamide, 3-[[5-methyl-2-[[4-(4-methyl-1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(4-piperidinyl)- (CA INDEX NAME)




RN 936091-56-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-69-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-72-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-73-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-(1H-imidazol-1-ylmethyl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-74-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-(2-hydroxyethoxy)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-76-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(2-methyl-1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-77-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[(2-methyl-1H-imidazol-1-yl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-78-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-pyridinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-79-1 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-80-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-81-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-82-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-1,2,4-triazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-83-7 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-(2H-tetrazol-5-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-84-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(2H-tetrazol-5-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-85-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(4-acetyl-1-piperazinyl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 936091-86-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[1-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-94-0 CAPLUS


CN Benzenesulfonamide, N-cyclopentyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 936091-98-4 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 936091-99-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936092-00-1 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 936092-07-8 CAPLUS


CN Benzenesulfonamide, N,2-dimethyl-5-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 936092-08-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-5-[[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 936092-09-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936092-10-3 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936092-11-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperazinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936092-24-9 CAPLUS

CN Benzamide, N-(1-methylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936092-25-0 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936093-00-4 CAPLUS


CN Benzenesulfonamide, N-cyclopentyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936093-03-7 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-[4-(2-hydroxyethyl)-1-

piperazinyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936093-04-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956404-51-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956404-52-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-[2-(3,3-difluoro-1-pyrrolidinyl)ethoxy]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 956404-53-8 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-[2-(3,3-difluoro-1-azetidinyloxy)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 956404-54-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-(1-piperidinylsulfonyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956404-55-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-piperidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 956404-56-1 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[3-[[1,1-dimethylethyl]amino]sulfonyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



IT 936092-65-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of JAK kinases  
 for treating diseases)  
 RN 936092-65-8 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[[3-[[5-methyl-2-[[4-(4-methyl-1-  
 piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]sulfonyl]amino]-,  
 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me


L7 ANSWER 29 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:1204147 CAPLUS  
 DN 147:469371  
 TI Preparation of pyrimidines as aurora kinase inhibitors  
 IN Burdick, Daniel J.; Liang, Jun  
 PA Genentech, Inc., USA  
 SO PCT Int. Appl., 54pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007120339	A1	20071025	WO 2006-US62181	20061215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1968950	A1	20080917	EP 2006-850972	20061215
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRAI	US 2005-752013P	P	20051219		
	WO 2006-US62181	W	20061215		
OS	MARPAT 147:469371				
AB	Title compds. [I; A = atoms to form 5-7 membered carbocyclyl, heterocyclyl; Y = O, NR <sub>4</sub> ; Z = NR <sub>4</sub> CO; R <sub>1</sub> = alkyl, carbocyclyl, heterocyclyl optionally substituted with OH, halo, O, amino, CO <sub>2</sub> H, alkoxy; R <sub>2</sub> = OH, halo, amino, CO <sub>2</sub> H, alkyl, acyl, alkoxy, alkylthio optionally substituted with OH, halo, O, S, amino, CO <sub>2</sub> H, alkoxy; R <sub>3</sub> = OH, halo, amino, O, S, (substituted) alkyl, carbocyclyl, heterocyclyl; (R <sub>3</sub> ) <sub>2</sub> = atoms to form (substituted) carbocyclyl, heterocyclyl; R <sub>4</sub> = H, alkyl; m = 0-10; n = 0-5], were prepared Thus, title compound (II) was prepared from 2,4-dichloro-5-fluoropyrimidine, 4-hydroxybenzoic acid cyclopropylamide, and 5-amino-1,3,3-trimethyloxindole. Tested I inhibited aurora A kinase with IC <sub>50</sub> = 0.0021-0.0108 $\mu$ M.				
IT	1057344-73-6 1057344-74-7 1057344-75-8 1057344-76-9 1057344-77-0 1057344-78-1 RL: PRPH (Prophetic) (Preparation of pyrimidines as aurora kinase inhibitors)				
RN	1057344-73-6 CAPLUS				
CN	Benzamide, 4-[[5-chloro-2-[(1-ethyl-2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]amino]-N-(2-chlorophenyl)- (CA INDEX NAME)				




RN 1057344-74-7 CAPLUS

CN Benzamide, 4-[[5-chloro-2-[(2,3-dihydro-1,3,3-trimethyl-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]amino]-N-(2-chlorophenyl)- (CA INDEX NAME)




RN 1057344-75-8 CAPLUS

CN Benzamide, 4-[[5-chloro-2-[(2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]amino]-N-(2-chlorophenyl)- (CA INDEX NAME)



RN 1057344-76-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[(2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 1057344-77-0 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[(2,3-dihydro-1,3,3-trimethyl-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)

yl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 1057344-78-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(1-ethyl-2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




IT 953048-72-1 953048-73-2 953048-75-4  
953048-76-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(preparation of pyrimidines as aurora kinase inhibitors)

RN 953048-72-1 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-4-[[2-[(1-ethyl-2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-5-yl)amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 953048-73-2 CAPLUS

CN Benzamide, 4-[[2-[(1-ethyl-2,3-dihydro-3,3-dimethyl-2-oxo-1H-indol-5-yl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-pyridinyl- (CA INDEX NAME)




10/507,060 (amended)




RN 953048-75-4 CAPLUS

CN Benzamide, 2-[[2-[(1-acetyl-2,3-dihydro-1H-indol-5-yl)amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 953048-76-5 CAPLUS

CN Benzamide, 2-[[2-[(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-5-yl)amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 30 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:969605 CAPLUS  
 DN 147:323004  
 TI Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway  
 IN Argade, Ankush; Sran, Arvinder; Carroll, David; Clough, Jeffrey; Tso, Kin;  
 Bhamidipati, Somasekhar; Thota, Sambaiah; Singh, Rajinder; Taylor,  
 Vanessa; Li, Hui; Masuda, Esteban  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 450,901.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070203161	A1	20070830	US 2007-678429	20070223
	US 20060293311	A1	20061228	US 2006-450901	20060608
	WO 2008079907	A1	20080703	WO 2007-US88241	20071219
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,				
	CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,				
	GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,				
	KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,				
	MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,				
	PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,				
	GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM				
	US 20080221089	A1	20080911	US 2008-30069	20080212
	US 20080306099	A1	20081211	US 2008-30031	20080212
PRAI	US 2006-776636P	P	20060224		
	US 2006-450901	A2	20060608		
	US 2006-871098P	P	20061220		
	US 2005-689032P	P	20050608		
	US 2005-706638P	P	20050808		
	US 2007-678429	A	20070223		

OS MARPAT 147:323004

AB The invention encompasses pyrimidine-2,4-diamines I; wherein X = alkyl, alkoxy, amino, carboxy, carboxy ester, cyano, halo, nitro, alkenyl, alkynyl; Y is H, alkyl, amino, halo; ring A = aryl, heteroaryl, cycloalkyl, cyclo-alkenyl and heterocyclic, R = H, alkyl, alkenyl, alkynyl, cycloalkyl; ring A is not indolyl or benzimidazolyl; p = 0-3; q = 1-3; R2 = alkyl, alkoxy, amino, aryl, aryl-oxy, cycloalkyl, cycloalkyl heteroaryl, heteroaryl, heterocycle, heterocyclyl-oxy, carboxyl, carboxyl ester, OH, acylamino, amino-sulfonyl, alkynyl, alkylthio, amino-carbonyl, acyl, oxo, halo; R3 = alkyl, cycloalkyl, halo, heterocyclic, amino-sulfonyl; R4 and R5 are independently = H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, acyl; R4 and R5 together with the N atom to which they are attached, form a heterocycle; and metal or ammonium counterion; and the compns. and methods using these compds. in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. Thus, N4-(3-acetyl-amino-4-hydroxyphenyl)-N2-(3-amino-sulfonyl-phenyl)-5-fluoro-2,4-pyrimidine-diamine was prepared by condensation of 4-amino-benzenesulfonamide with 2-chloro-5-fluoro-N4-[4-(3-fluoro-

propyl)phenyl]-4-pyrimidin-amine. Results for an assay for Ramos B-cell line stimulated with IL-4, primary human T-cell proliferation assay stimulated with IL-2, assay for A549 epithelial line stimulated with IFN $\gamma$  and U937 IFN $\gamma$  ICAM1 FACS assay (all of which involve the JAK/Stat pathway) are tabulated for hundreds of examples of I. A method of treating or preventing allograft transplant rejection in a transplant recipient, comprising administering to the transplant recipient an amount of a compound effective to treat or prevent the allograft transplant rejection wherein the compound is selected from the title compds, is claimed. A method of inhibiting a signal transduction cascade in which JAK3 kinase plays a role, comprising contacting a cell expressing a receptor involved in said signaling cascade with title compds, is claimed.


IT 916744-11-1P 916744-12-2P 916744-13-3P  
916744-17-7P 916744-18-8P 916744-19-9P  
947677-66-9P 947677-67-0P 947681-02-9P  
947681-15-4P 947681-16-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine-2,4-diamine sulfonamides for inhibition of JAK pathway)


RN 916744-11-1 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-12-2 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-13-3 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-17-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-18-8 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-19-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 947677-66-9 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 947677-67-0 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 947681-02-9 CAPLUS

CN Benzenesulfonamide, 4,4'-[[6-[(3,4-dihydro-2,2,4-trimethyl-3-oxo-2H-1,4-benzoxazin-6-yl)amino]-2,4-pyrimidinediyl]diimino]bis- (CA INDEX NAME)




RN 947681-15-4 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(2-propyn-1-yloxy)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 947681-16-5 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[4-(2-propyn-1-yloxy)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



L7 ANSWER 31 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:846097 CAPLUS  
 DN 147:235191  
 TI Pyrimidine derivatives as EphB4 inhibitors and their preparation,  
 pharmaceutical compositions and use in the treatment of cancer  
 IN Kettle, Jason Grant; Read, Jon; Leach, Andrew; Barlaam, Bernard  
 Christophe; Ducray, Richard; Lambert-Van Der Brempt, Christine Marie Paul  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 235pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007085833	A2	20070802	WO 2007-GB251	20070125
	WO 2007085833	A3	20070927		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2007209126	A1	20070802	AU 2007-209126	20070125
	CA 2640375	A1	20070802	CA 2007-2640375	20070125
	EP 1981856	A2	20081022	EP 2007-700405	20070125
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
	KR 2008089504	A	20081006	KR 2008-720606	20080822
PRAI	US 2006-762387P	P	20060126		
	WO 2007-GB251	W	20070125		

OS MARPAT 147:235191

AB The invention concerns benzamide compds. of formula I, or a pharmaceutically acceptable salt thereof,. The invention also relates to processes for the preparation of such compds., pharmaceutical compns.

containing

them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases. Compds. of formula I wherein R1 is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, and (un)substituted C2-6 alkynyl; ring A is (un)saturated (un)substituted fused 5- to 6-membered carbocyclic or heterocyclic ring; each R3 is independently halo, CF3, CN, NO2, etc.; R4 is (un)substituted phenyl; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amination of 2,4-dichloropyrimidine with (5-chloro-1,3-benzodioxol-4-yl)amine; the resulting 2-chloro-N-(5-chloro-1,3-benzodioxol-4-yl)pyrimidin-4-amine underwent amination with 3,4,5-trimethoxyaniline to give compound II. All the invention compds. were evaluated for their EphB4 inhibitory activity.

IT 945396-46-3P




10/507,060 (amended)

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrimidine derivs. as EphB4 inhibitors useful in the treatment of cancer)

RN 945396-46-3 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, 4-[[2-[[3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




L7 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:783664 CAPLUS  
 DN 149:118797  
 TI TG101209, a small molecule JAK2-selective kinase inhibitor potentially inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations  
 AU Pardanani, A.; Hood, J.; Lasho, T.; Levine, R. L.; Martin, M. B.; Noronha, G.; Finke, C.; Mak, C. C.; Mesa, R.; Zhu, H.; Soll, R.; Gilliland, D. G.; Tefferi, A.  
 CS Division of Hematology, Mayo Clinic, Rochester, MN, USA  
 SO Leukemia (2007), 21(8), 1658-1668  
 CODEN: LEUKED; ISSN: 0887-6924  
 PB Nature Publishing Group  
 DT Journal  
 LA English  
 AB JAK2V617F and MPLW515L/K represent recently identified mutations in myeloproliferative disorders (MPD) that cause dysregulated JAK-STAT signaling, which is implicated in MPD pathogenesis. The authors developed TG101209, an orally bioavailable small mol. that potentially inhibits JAK2 (IC50 = 6 nM), FLT3 (IC50 = 25 nM) and RET (IC50 = 17 nM) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC50 = 169 nM). TG101209 inhibited growth of Ba/F3 cells expressing JAK2V617F or MPLW515L mutations with an IC50 of .apprx.200 nM. In a human JAK2V617F-expressing acute myeloid leukemia cell line, TG101209-induced cell cycle arrest and apoptosis, and inhibited phosphorylation of JAK2V617F, STAT5 and STAT3. Therapeutic efficacy of TG101209 was demonstrated in a nude mouse model. Furthermore, TG101209 suppressed growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations.  
 IT 936091-14-4, TG 101209  
 RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (TG101209 is small mol. JAK2-selective kinase inhibitor which inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations and mechanisms associated)  
 RN 936091-14-4 CAPLUS  
 CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 33 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:746527 CAPLUS  
 DN 147:202997  
 TI N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics  
 AU Bamborough, Paul; Angell, Richard M.; Bhamra, Inder; Brown, David; Bull, James; Christopher, John A.; Cooper, Anthony W. J.; Fazal, Lynsey H.; Giordano, Ilaria; Hind, Lucy; Patel, Vipulkumar K.; Ranshaw, Lisa E.; Sims, Martin J.; Skone, Philip A.; Smith, Kathryn J.; Vickerstaff, Emma; Washington, Melanie  
 CS Medicines Research Centre, GlaxoSmithKline R&D, Hertfordshire, SG1 2NY, UK  
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4363-4368  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 147:202997  
 AB 2,4-Dianilino pyrimidines are well-known inhibitors of tyrosine kinases including lymphocyte specific kinase (Lck). Structure-activity relationships at the 4-position are discussed and rationalized. Examples bearing a 2-methyl-5-hydroxyaniline substituent at the 4-position were especially potent but showed poor oral pharmacokinetics. Replacement of this substituent by 4-amino(5-methyl-1H-indazole) yielded compds. with comparable enzyme potency and improved pharmacokinetic properties.  
 IT 944795-18-0P 944795-19-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (pyrimidinylindazolamine inhibitors of Lck as phenol isosteres with improved pharmacokinetics)  
 RN 944795-18-0 CAPLUS  
 CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-4-methyl- (CA INDEX NAME)



RN 944795-19-1 CAPLUS  
 CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N,4-trimethyl- (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 34 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:703875 CAPLUS  
 DN 147:95692  
 TI Sulfoximine-substituted pyrimidines as kinase inhibitors, their  
 preparation and use as drugs  
 IN Luecking, Ulrich; Nguyen, Duy; Von Bonin, Arne; Von Ahsen, Oliver;  
 Krueger, Martin; Briem, Hans; Ketttschau, Hans; Prien, Olaf; Mengel, Anne;  
 Krolikiewicz, Konrad; Boemer, Ulf; Bothe, Ulrich; Hartung, Ingo  
 PA Schering Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 331pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007071455	A1	20070628	WO 2006-EP12634	20061219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	DE 102005062742	A1	20070628	DE 2005-102005062742	20051222
	DE 102006031224	A1	20080117	DE 2006-102006031224	20060630
	CA 2632881	A1	20070628	CA 2006-2632881	20061219
	EP 1963282	A1	20080903	EP 2006-829901	20061219
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 20070232632	A1	20071004	US 2006-642961	20061221
PRAI	DE 2005-102005062742	A	20051222		
	DE 2006-102006031224	A	20060630		
	US 2006-757859P	P	20060111		
	US 2006-818501P	P	20060706		
	WO 2006-EP12634	W	20061219		

OS MARPAT 147:95692

AB The invention relates to sulfoximine-substituted pyrimidines of the general formula I processes for the preparation thereof and their use as kinase inhibitors for treating for example cancer or inflammation. Compds. of formula I wherein R1 is (un)substituted (un)saturated (mono/bi)cyclic heteroaryl and (un)substituted aryl; R2 is H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-8 cycloalkyl, C3-8 heterocyclyl, etc.; R3 is OH, halo, NO2, CN, CONH2 and derivs., CSNH2 and derivs., CF3, OCF3, etc.; R4 is H, acyl, CONH2 and derivs., carboxylate, CSNH2 and derivs., NO2, etc.; R3R5 taken together to form a (un)substituted 5- to 7-membered ring; R4R5 taken together form 5- to 8-membered heterocyclic ring; R5 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, (un)substituted C3-7 cycloalkyl, etc.; X is O, S and NH and derivs.; XR2 taken together to form a (un)substituted 3 - 8-membered heterocyclic ring; m is 0 to 4; Q is C6-10 arylene, 5- to 10-membered heteroarylene; are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were

evaluated for their kinase inhibitory activity.


IT 942408-80-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of sulfoximine-substituted pyrimidines as kinase inhibitors useful in the treatment of cancer and inflammation)

RN 942408-80-2 CAPLUS

CN Carbamic acid, N-[[4-[[4-[[4-(aminosulfonyl)phenyl]amino]-5-(2-thienyl)-2-pyrimidinyl]amino]phenyl]methyloxido-λ4-sulfanylidene]-, ethyl ester (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 35 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:667606 CAPLUS

DN 147:63669

TI A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth

AU Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.

CS Department of Surgery, Duke University Medical Center, Durham, NC, USA

SO Molecular Carcinogenesis (2007) 46(6), 488-496

CODEN: MOCAE8; ISSN: 0899-1987

PB Wiley-Liss, Inc.

DT Journal

LA English

AB Glioblastomas are highly lethal cancers that resist current therapies. Novel therapies under development target mol. mechanisms that promote glioblastoma growth. In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed. Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on critical tyrosine residues. Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation. We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925. As all glioma cell lines examined expressed phosphorylated FAK, we examined the efficacy of a novel low-mol. weight inhibitor of FAK, TAE226, against human glioma cell lines. TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines. TAE226 induced a concentration-dependent decrease

in


cellular proliferation with an associated G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner. TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.

IT 761437-28-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(low-mol. weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



10/507,060 (amended)

RE.CNT 19      THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 36 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:510223 CAPLUS  
 DN 146:501071  
 TI Preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of kinases  
 IN Cao, Jon Jianguo; Hood, John; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Noronha, Glenn; Pathak, Ved; Renick, Joel; Soll, Richard M.; Zeng, Binqi  
 PA Targen, Inc., USA  
 SO PCT Int. Appl., 336 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007053452	A1	20070510	WO 2006-US42044	20061026
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, ZM, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006309013	A1	20070510	AU 2006-309013	20061026
	CA 2628283	A1	20070510	CA 2006-2628283	20061026
	EP 1951684	A1	20080806	EP 2006-836583	20061026
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	MX 200805810	A	20080710	MX 2008-5810	20080430
	KR 2008066066	A	20080715	KR 2008-713115	20080530
PRAI	US 2005-732629P	P	20051101		
	US 2006-838003P	P	20060815		
	WO 2006-US42044	W	20061026		

OS MARPAT 146:501071

AB The title compds. I [X = a bond, C(O), SO<sub>2</sub>, CH<sub>2</sub>; Y = a bond, NR<sub>9</sub>; or X and Y taken together is a bond; R<sub>1</sub>, R<sub>2</sub> = H, alkyl, cycloalkyl, etc.; or R<sub>1</sub> and R<sub>2</sub> taken together is a bond; or R<sub>1</sub> and R<sub>2</sub> taken together form (CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>r</sub>S(CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>r</sub>O(CH<sub>2</sub>)<sub>m</sub>, etc.; p, q, r, n, m = 0-6; R<sub>9</sub> = H, alkyl, cycloalkyl, etc.; G<sub>0</sub> = N, O, H, CH; R<sub>3</sub>, R<sub>4</sub> = H, alkyl, hydrocyalkyl, etc.; G = N or CR<sub>6</sub>; R<sub>5</sub> = Me; Q = (un)substituted Ph, indolyl, indazolyl, etc.; with provisos] that are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases, were prepared E.g., a 2-step synthesis of II, starting from 4-chloropyrimidin-2-ylamine and 4-methoxyphenylamine, was given. Exemplified compds. I were tested for inhibition of JAK2 kinase (data given). The invention also relates to pharmaceutical composition comprising the compound I alone or in combination with other therapeutic agents.

IT 936091-15-5P 936091-97-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of JAK kinases)

for treating diseases)


RN 936091-15-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-97-3 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




IT 936090-58-3P 936090-59-4P 936091-14-4P  
 936091-16-6P 936091-17-7P 936091-19-9P  
 936091-20-2P 936091-21-3P 936091-22-4P  
 936091-23-5P 936091-24-6P 936091-25-7P  
 936091-26-8P 936091-27-9P 936091-28-0P  
 936091-29-1P 936091-30-4P 936091-32-6P  
 936091-33-7P 936091-35-9P 936091-37-1P  
 936091-39-3P 936091-52-0P 936091-56-4P  
 936091-69-9P 936091-72-4P 936091-73-5P  
 936091-74-6P 936091-76-8P 936091-77-9P  
 936091-78-0P 936091-79-1P 936091-80-4P  
 936091-81-5P 936091-82-6P 936091-83-7P  
 936091-84-8P 936091-85-9P 936091-86-0P  
 936091-94-0P 936091-98-4P 936091-99-5P  
 936092-00-1P 936092-07-8P 936092-08-9P  
 936092-09-0P 936092-10-3P 936092-11-4P  
 936092-24-9P 936092-25-0P 936093-00-4P  
 936093-03-7P 936093-04-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of JAK kinases for treating diseases)

RN 936090-58-3 CAPLUS

CN Benzamide, N-methyl-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936090-59-4 CAPLUS

CN Benzamide, N-methyl-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 936090-58-3


CMF C25 H30 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 936091-14-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-16-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[(4-oxido-4-morpholinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-17-7 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-pyrazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-19-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-pyrazol-1-yl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-20-2 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperidinylsulfonyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-21-3 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-[(4-methyl-1-

piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-22-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperazinyl)-3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-23-5 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(4-acetyl-1-piperazinyl)-3-(trifluoromethyl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 936091-24-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-25-7 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1-piperazinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-26-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-27-9 CAPLUS

CN Benzenesulfonamide, 3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-28-0 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-29-1 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-30-4 CAPLUS

CN Benzenesulfonamide, N-(1-methylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-32-6 CAPLUS

CN Benzenesulfonamide, N-cyclohexyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-33-7 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-35-9 CAPLUS

CN Benzamide, 3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-37-1 CAPLUS

CN Benzamide, 2-methyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-39-3 CAPLUS

CN Benzenesulfonamide, 3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-52-0 CAPLUS

CN Benzenesulfonamide, 3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-4-piperidinyl- (CA INDEX NAME)




NAME)




RN 936091-56-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-69-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-72-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-73-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-(1H-imidazol-1-yl)methyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-74-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-(2-hydroxyethoxy)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-76-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(2-methyl-1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-77-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[(2-methyl-1H-imidazol-1-yl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-78-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-pyridinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-79-1 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-80-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-81-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-82-6 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-1,2,4-triazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-83-7 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-(2H-tetrazol-5-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-84-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(2H-tetrazol-5-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936091-85-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(4-acetyl-1-piperazinyl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 936091-86-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[1-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936091-94-0 CAPLUS


CN Benzenesulfonamide, N-cyclopentyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 936091-98-4 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 936091-99-5 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[3-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936092-00-1 CAPLUS


CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 936092-07-8 CAPLUS

CN Benzenesulfonamide, N,2-dimethyl-5-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936092-08-9 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-5-[[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 936092-09-0 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 936092-10-3 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 936092-11-4 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)




RN 936092-24-9 CAPLUS

CN Benzamide, N-(1-methylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936092-25-0 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936093-00-4 CAPLUS

CN Benzenesulfonamide, N-cyclopentyl-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 936093-03-7 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[4-[4-(2-hydroxyethyl)-1-




piperazinyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 936093-04-8 CAPLUS

CN Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



IT 936092-65-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of JAK kinases for treating diseases)

RN 936092-65-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

10/507,060 (amended)


RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:412514 CAPLUS  
 DN 147:28253  
 TI Inhibition of both focal adhesion kinase and insulin-like growth factor-I  
 receptor kinase suppresses glioma proliferation in vitro and in vivo  
 AU Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu;  
 Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung,  
 W. K. Alfred  
 CS Brain Tumor Center, Department of Neuro-Oncology, The University of Texas  
 M. D. Anderson Cancer Center, USA  
 SO Molecular Cancer Therapeutics (2007), 6(4), 1357-1367  
 CODEN: MCTOCF; ISSN: 1535-7163  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 AB Multiple genetic aberrations in human gliomas contribute to their highly  
 infiltrative and rapid growth characteristics. Focal adhesion kinase  
 (FAK) regulates tumor migration and invasion. Insulin-like growth  
 factor-I receptor (IGF-IR), whose expression correlates with tumor grade,  
 is involved in proliferation and survival. We hypothesized that  
 inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter  
 called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR,  
 would suppress the growth and invasion of glioma cells. In culture,  
 TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK  
 (Tyr397). TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR  
 and activity of its downstream target genes such as MAPK and Akt. TAE226  
 retarded tumor cell growth as assessed by a cell viability assay and  
 attenuated G2-M cell cycle progression associated with a decrease in cyclin  
 B1 and phosphorylated cdc2 (Tyr15) protein expression. TAE226 treatment  
 inhibited tumor cell invasion by at least 50% compared with the control in  
 an in vitro Matrigel invasion assay. Interestingly, TAE226 treatment of  
 tumor cells containing wild-type p53 mainly exhibited G2-M arrest, whereas  
 tumor cells bearing mutant p53 underwent apoptosis. Induction of  
 apoptosis by TAE226 was substantiated by detection of caspase-3/7  
 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V  
 apoptosis assay. More importantly, TAE226 treatment significantly  
 increased the survival rate of animals in an intracranial glioma xenograft  
 model. Collectively, these data show that blocking the signaling pathways  
 of FAK and IGF-IR with TAE226 has the potential to be an efficacious  
 treatment for human gliomas.  
 IT 761437-28-9, NVP-TAE 226  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (inhibition of FAK and IGF-I receptor kinase-related mutated  
 p53-regulated multiple pathways suppressed glioma proliferation by  
 TAE226)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 38 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:81237 CAPLUS  
 DN 146:316871  
 TI Discovery of a new class of 4-anilinopyrimidines as potent c-Jun  
 N-terminal kinase inhibitors: Synthesis and SAR studies  
 AU Liu, Mei; Wang, Sanyi; Clampit, Jill E.; Gum, Rebecca J.; Haasch, Deanna  
 L.; Rondinone, Cristina M.; Trevillyan, James M.; Abad-Zapatero, Cele;  
 Fry, Elizabeth H.; Sham, Hing L.; Liu, Gang  
 CS Metabolic Disease Research, Global Pharmaceutical Research and  
 Development, Abbott Laboratories, Abbott Park, IL, 60064-6098, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(3), 668-672  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 146:316871  
 AB A series of 4-anilinopyrimidines has been synthesized and evaluated as  
 JNK1 inhibitors. SAR studies led to the discovery of potent JNK1  
 inhibitors with good enzymic activity as well as cellular potency  
 represented by compound I. Kinase selectivity profile and the crystal  
 structure of I are also described.  
 IT 929007-72-7P 929007-73-8P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation, JNK inhibitory activity, and structure-activity relationship  
 of anilinopyrimidines using substitution reaction with alcs. or amines  
 as the key step)  
 RN 929007-72-7 CAPLUS  
 CN Benzamide, 2-[[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX  
 NAME)



RN 929007-73-8 CAPLUS  
 CN Benzamide, 2-[[2-(phenylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 39 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:1312027 CAPLUS  
 DN 146:62737  
 TI Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway  
 IN Li, Hui; Thota, Sambaiah; Carroll, David; Argade, Ankush; Tso, Kin; Sran, Arvinder; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar; Taylor, Vanessa; Cooper, Robin; Singh, Rajinder; Wong, Brian  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 488pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006133426	A2	20061214	WO 2006-US22590	20060608
	WO 2006133426	A3	20071108		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2006254840	A1	20061214	AU 2006-254840	20060608
	CA 2608367	A1	20061214	CA 2006-2608367	20060608
	EP 1904457	A2	20080402	EP 2006-784727	20060608
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	JP 2008543778	T	20081204	JP 2008-515989	20060608
	MX 200715464	A	20080304	MX 2007-15464	20071206
	IN 2007KN04776	A	20080718	IN 2007-KN4776	20071210
	CN 101282945	A	20081008	CN 2006-80020533	20071210
	NO 2008000075	A	20080303	NO 2008-75	20080104
	KR 2008017454	A	20080226	KR 2008-700447	20080107
	US 20080306099	A1	20081211	US 2008-30031	20080212
PRAI	US 2005-689032P	P	20050608		
	US 2005-706638P	P	20050808		
	US 2006-776636P	P	20060224		
	US 2006-450901	A1	20060608		
	WO 2006-US22590	W	20060608		
OS	MARPAT 146:62737				
AB	The invention encompasses pyrimidine-2,4-diamines (shown as I and other Markush structures shown in the claims; variables defined below; e.g. N-(3-aminosulfonylphenyl)-5-fluoro-N'-[4-[(5-methylisoxazol-3-yl)methoxy]phenyl]-2,4-pyrimidinediamine (shown as II)) and the compns. and methods using these compds. in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. For I: X = (un)substituted alkyl, (un)substituted alkoxy, (un)substituted amino, carboxy, carboxy ester, cyano, halo, nitro, (un)substituted alkenyl, (un)substituted alkynyl; R =				

H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl; ring A = aryl, heteroaryl, cycloalkyl, cycloalkenyl and heterocyclic, wherein ring A is not indolyl or benzimidazolyl; Y = a bond, -NR7-, -C(O)NR7-, -NR7C(O)-, -NR7C(O)O-, -OC(O)NR7-, -NR7C(O)NR7-, O and S, where R7 = H, (un)substituted alkyl; alk is a bond or a straight or branched chain alkylene group, wherein when alk and Y each are a bond then R1 is attached to ring A by a single covalent bond; R1 = cyano, acylamino, aminoacyl, (un)substituted aryl, carboxy, carboxy ester, carboxy ester oxy, (un)substituted heteroaryl, (un)substituted heterocyclic, acyl, aminoacyloxy, and aminocarbonylamino; or R1-alk-Y is R10-C(O)-S-alk-C(O)-, wherein alk is as defined herein and R10 is (un)substituted alkyl; or R1-alk-Y- is R11R12NS(O)2-, wherein R11 and R12 independently are (un)substituted alkyl; p = 0-3 when ring A is a single ring or p is 0-5 when ring A comprises multiple rings. Each R2 = (un)substituted alkyl, (un)substituted alkoxy, (un)substituted amino, (un)substituted aryl, (un)substituted aryloxy, cyano, (un)substituted cycloalkyl, (un)substituted cycloalkoxy, et al. or two R2 can form an oxo; Z1, Z2, and Z3 each independently is C or N with provisos; q = 0-3; each R3 = H, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted cycloalkyl, halo, (un)substituted heterocyclic; R4 and R5 = H, (un)substituted alkyl, acyl and metal or ammonium counterion; addnl. details including provisos are given in the claims. Results for an assay for Ramos B-cell line stimulated with IL-4, primary human T-cell proliferation assay stimulated with IL-2, assay for A549 epithelial line stimulated with IFN $\gamma$  and U937 IFN $\gamma$  ICAM1 FACS assay (all of which involve the JAK/Stat pathway) are tabulated for hundreds of examples of I. Although the methods of preparation are not claimed, preps. and/or characterization data for many examples of I are included. For example, II was prepared by N-alkylation of 3-aminobenzenesulfonamide by 2-chloro-5-fluoro-N-[4-[(5-methylisoxazol-3-yl)methoxy]phenyl]-4-pyrimidinamine, which was prepared from 5-methyl-3-[(4-aminophenoxy)methyl]isoxazole (preparation given) and 2,4-dichloro-5-fluoropyrimidine.

IT 916742-30-8P, N-(3-Aminosulfonyl-5-methylphenyl)-5-fluoro-N'-[4-[[[(1-methylpyrazol-3-yl)amino]carbonyl]phenyl]-2,4-pyrimidinediamine  
 916742-31-9P, N-(3-Aminosulfonyl-5-methylphenyl)-5-fluoro-N'-[4-[[[(1-ethylpyrazol-5-yl)amino]carbonyl]phenyl]-2,4-pyrimidinediamine  
 916742-32-0P, N-(3-Aminosulfonyl-5-methylphenyl)-5-fluoro-N'-[4-[[[(1-methylpyrazol-5-yl)amino]carbonyl]phenyl]-2,4-pyrimidinediamine  
 916742-33-1P, N-(3-Aminosulfonyl-5-methylphenyl)-5-fluoro-N'-[4-[[[(1H-pyrazol-3-yl)amino]carbonyl]phenyl]-2,4-pyrimidinediamine  
 916744-11-1P, N-(3-Aminosulfonylphenyl)-5-fluoro-N'-[4-(prop-2-ynylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916744-12-2P, N-(3-Aminosulfonyl-4-methylphenyl)-5-fluoro-N'-[4-(prop-2-ynylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916744-13-3P, N-(4-Aminosulfonylphenyl)-5-fluoro-N'-[4-(prop-2-ynylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916744-17-7P, N-(3-Aminosulfonyl-4-methylphenyl)-5-fluoro-N'-[3-(prop-2-ynylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916744-18-8P, N-(4-Aminosulfonylphenyl)-5-fluoro-N'-[3-(prop-2-ynylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916744-19-9P, N-(3-Aminosulfonylphenyl)-5-fluoro-N'-[3-(prop-2-ynylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916745-20-5P, N-(3-Aminosulfonyl-4-methylphenyl)-5-fluoro-N'-[3-(N-methylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916745-21-6P, N-(3-Aminosulfonylphenyl)-5-fluoro-N'-[3-(N,N-dimethylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916745-22-7P




, N-(3-Aminosulfonyl-4-methylphenyl)-5-fluoro-N'-[3-(N,N-dimethylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916745-23-8P  
 , N-(3-Aminosulfonylphenyl)-5-fluoro-N'-[3-(N-methylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916745-50-1P,  
 N,N'-Bis(3-aminosulfonylphenyl)-5-fluoro-2,4-pyrimidinediamine 916745-52-3P, N,N'-Bis(3-aminosulfonyl-4-methylphenyl)-5-fluoro-2,4-pyrimidinediamine 916745-54-5P,  
 N,N'-Bis(3-aminosulfonyl-4-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine-2,4-diamine sulfonamides for inhibition of JAK pathway)


RN 916742-30-8 CAPLUS

CN Benzamide, 4-[[2-[[3-(aminosulfonyl)-5-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 916742-31-9 CAPLUS

CN Benzamide, 4-[[2-[[3-(aminosulfonyl)-5-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-ethyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 916742-32-0 CAPLUS

CN Benzamide, 4-[[2-[[3-(aminosulfonyl)-5-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 916742-33-1 CAPLUS

CN Benzamide, 4-[[2-[[3-(aminosulfonyl)-5-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-1H-pyrazol-3-yl- (CA INDEX NAME)




RN 916744-11-1 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-12-2 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-13-3 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-17-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-18-8 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[4-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-19-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916745-20-5 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 916745-21-6 CAPLUS


CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 916745-22-7 CAPLUS


CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 916745-23-8 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 916745-50-1 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 916745-52-3 CAPLUS

CN Benzenesulfonamide, 5-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)



RN 916745-54-5 CAPLUS


CN Benzenesulfonamide, 5-[[2-[[3-(aminosulfonyl)-4-chlorophenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-2-chloro- (CA INDEX NAME)



L7 ANSWER 40 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:1256680 CAPLUS  
 DN 146:20278  
 TI 2,4-Pyrimidinediamine compound JAK kinase inhibitors, and their  
 therapeutic use  
 IN Wong, Brian  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO U.S. Pat. Appl. Publ., 26pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060270694	A1	20061130	US 2006-416652	20060502
	CA 2604551	A1	20070308	CA 2006-2604551	20060502
	WO 2007027238	A2	20070308	WO 2006-US17008	20060502
	WO 2007027238	A3	20070913		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	EP 1883302	A2	20080206	EP 2006-824733	20060502
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	JP 2008540436	T	20081120	JP 2008-510173	20060502
PRAI	US 2005-678241P	P	20050503		
	WO 2006-US17008	W	20060502		
AB	The invention provides 2,4-pyrimidinediamine compds. that selectively inhibit JAK kinase as compared to Syk kinase, as well as various methods of using the JAK-selective compds. for treating e.g. an immune-related disease.				
IT	844435-03-6 845820-93-1 916044-26-3 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pyrimidinediamine compound JAK kinase inhibitors, and therapeutic use)				
RN	844435-03-6 CAPLUS				
CN	Benzamide, 4,4'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis- (CA INDEX NAME)				






RN 845820-93-1 CAPLUS

CN Glycine, N-[4-[[4-[[4-(aminocarbonyl)phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)



RN 916044-26-3 CAPLUS

CN Glycine, N-[4-[[5-fluoro-2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)



L7 ANSWER 41 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:1157254 CAPLUS  
 DN 145:438639  
 TI Preparation of 2,4-di[(hetero)arylamino]pyrimidine derivatives as ZAP-70  
 and/or Syk inhibitors  
 IN Baenteli, Rolf; Bernhard, Marie Claude; Buehlmayer, Peter; Cooke, Nigel  
 Graham; Duthaler, Rudolf; Hinterding, Klaus; Thoma, Gebhard; Van Eis,  
 Maurice; Von Matt, Anette; Walliser, Louis; Zenke, Gerhard  
 PA Switz.  
 SO U.S. Pat. Appl. Publ., 28pp., Cont.-in-part of Appl. No. PCT/EP04/010348.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

common inventor  
 not prior

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060247262	A1	20061102	US 2006-377716	20060316
	WO 2005026158	A1	20050324	WO 2004-EP10348	20040915
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	GB 2003-21710	A	20030916		
	GB 2004-14440	A	20040628		
	WO 2004-EP10348	A2	20040915		
OS	MARPAT 145:438639				
AB	The title compds. [I; Z = CR2, N; R0-R4 = H, OH, alkyl, etc.; or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a 5-10 membered heterocyclic ring; or R1-R3 = halo, haloalkyl, alkoxy, etc.; or R1 and R2 form aryl, 5-10 membered heteroaryl, 5-15 membered non-aromatic carbocyclic or heterocyclic residue; R5, R6 = H, halo, CN, etc.; at least one of R7-R9 = halo, tetrahydropyran-2-ylmethoxy, alkylsulfanyl, etc.; or R7 and R8 or R8 and R9, resp. form together a 5-membered heterocyclic ring, 5-6 membered heterocyclic ring comprising 1 nitrogen atom, 5-20 membered heterocyclic residue comprising 1-7 oxygen atoms] which have ZAP-70 and/or Syk inhibitory activities, were prepared E.g., a multi-step synthesis of II, starting from 3,4,5-trimethoxyphenylamine and 2-methylsulfanylpurimidin-4-ol, was given. The compds. I were tested in various in vitro assays against ZAP-70, Syk, ALK, etc. (biol. data were given for selected compds. I). The pharmaceutical composition comprising the compound I is claimed.				
IT	848479-04-9P	848479-05-0P	848479-06-1P		
	848479-07-2P	848479-08-3P	848479-09-4P		
	848479-10-7P	848479-11-8P	848479-12-9P		
	848479-13-0P	848479-14-1P	848479-15-2P		
	848479-16-3P	848479-17-4P	848479-18-5P		
	848479-19-6P	848479-20-9P	848479-21-0P		
	848479-22-1P	848479-23-2P	848479-24-3P		
	848479-25-4P	848479-26-5P	848479-27-6P		
	848479-28-7P	848479-29-8P	848479-30-1P		


848479-31-2P 848479-32-3P 848479-33-4P  
 848479-34-5P 848479-35-6P 848479-36-7P  
 848479-37-8P 848479-38-9P 848479-39-0P  
 848479-40-3P 848479-41-4P 848479-42-5P  
 848479-43-6P 848479-44-7P 848479-45-8P  
 848479-46-9P 848479-47-0P 848479-48-1P  
 848479-49-2P 848479-50-5P 848479-51-6P  
 848479-52-7P 848479-53-8P 848479-54-9P  
 848479-55-0P 848479-56-1P 848479-57-2P  
 848479-58-3P 848479-59-4P 848479-60-7P  
 848479-61-8P 848479-62-9P 848479-63-0P  
 848479-64-1P 848479-65-2P 848479-66-3P  
 848479-67-4P 848479-68-5P 848479-69-6P  
 848479-70-9P 848479-71-0P 848479-72-1P  
 848479-73-2P 848479-74-3P 848479-75-4P  
 848479-76-5P 848479-77-6P 848479-78-7P  
 848479-79-8P 848479-80-1P 848479-81-2P  
 848479-82-3P 848479-83-4P 848479-84-5P  
 848479-85-6P 848479-86-7P 848479-87-8P  
 848479-88-9P 848479-89-0P 848479-90-3P  
 848479-91-4P 848479-92-5P 848479-93-6P  
 848479-94-7P 848479-95-8P 848479-96-9P  
 848479-97-0P 848479-98-1P 848479-99-2P  
 848480-00-2P 848480-01-3P 848480-02-4P  
 848480-03-5P 848480-04-6P 848480-05-7P  
 848480-06-8P 848480-07-9P 848480-08-0P  
 848480-09-1P 848480-10-4P 848480-11-5P  
 848480-12-6P 848480-13-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 2,4-di[(hetero)arylaminopyrimidines as ZAP-70 and/or SYK inhibitors)


RN 848479-04-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(3,4,5-  
 trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-05-0 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[(3,4-dimethoxyphenyl)amino]-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-06-1 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-07-2 CAPLUS

CN Benzenesulfonamide, 2-(dimethylamino)-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-08-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-(2-propen-1-yloxy)- (CA INDEX NAME)




RN 848479-09-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 848479-10-7 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(2-methoxyethyl)amino]-4-methylphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-11-8 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)



RN 848479-12-9 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-13-0 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-14-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-15-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-16-3 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-bromo-2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)







RN 848479-17-4 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-18-5 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-bromo-2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)



RN 848479-19-6 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-bromo-2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-20-9 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[4-(dimethylamino)-3-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-21-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-22-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(tetrahydro-2-furanyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-23-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-24-3 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-25-4 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[5-methyl-2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-26-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-27-6 CAPLUS

CN Benzoic acid, 4-[[4-[[5-(aminosulfonyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-2-pyrimidinyl]amino]-2-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 848479-28-7 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-29-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(4-methoxy-2-naphthalenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-30-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(8-methoxy-6-quinolinyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-31-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-32-3 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-33-4 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-(phenylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-34-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-methoxy-4-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-35-6 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-36-7 CAPLUS

CN Acetic acid, 2-[3-[[4-[[5-(aminosulfonyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-2-pyrimidinyl]amino]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)




RN 848479-37-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-38-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(4-fluoro-3-methoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-39-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-40-3 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-41-4 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 848479-42-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-43-6 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-(4-thiazolylmethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-44-7 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methyl-3-[(tetrahydro-2-furanyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-45-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(2-cyclohexylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-46-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,2,3,3-tetrafluoro-2,3-dihydro- (CA INDEX NAME)




RN 848479-47-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-methoxy-4-(methylthio)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-48-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2,3,3-tetrafluoro-2,3-dihydro- (CA INDEX NAME)




RN 848479-49-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,2,3,3-tetrafluoro-2,3-dihydro-6-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-50-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(3-methylphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-51-6 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(4-methylphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-52-7 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(3-ethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-53-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(3-acetylphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-54-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-55-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-fluoro-2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-56-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-57-2 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-methyl-4-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-58-3 CAPLUS  
 CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,2-difluoro- (CA INDEX NAME)



RN 848479-59-4 CAPLUS  
 CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[[3,4-dimethoxyphenyl]amino]-4-pyrimidinyl]amino]-2,2-difluoro- (CA INDEX NAME)




RN 848479-60-7 CAPLUS  
 CN 1,3-Benzodioxole-4-sulfonamide, 2,2-difluoro-5-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-61-8 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-62-9 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-63-0 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-64-1 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 2,2-difluoro-5-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-65-2 CAPLUS


CN 1H-Indene-4-sulfonamide, 5-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)



RN 848479-66-3 CAPLUS


CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 848479-67-4 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-68-5 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-69-6 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-70-9 CAPLUS

CN 1H-Indene-4-sulfonamide, 5-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-71-0 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-72-1 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-73-2 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-74-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]-6-(2-propen-1-yloxy)- (CA INDEX NAME)




RN 848479-75-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-(2-propen-1-yloxy)- (CA INDEX NAME)




RN 848479-76-5 CAPLUS

CN Benzenesulfonamide, 2-[(2-chloro-2-propen-1-yl)oxy]-6-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-77-6 CAPLUS

CN Benzenesulfonamide, 2-[(2-chloro-2-propen-1-yl)oxy]-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-78-7 CAPLUS

CN Benzenesulfonamide, 2-[(2-chloro-2-propen-1-yl)oxy]-6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-79-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-[(1,1,2-trifluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-80-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-[(2,3,3-trifluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-81-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-[(2,3,3-trifluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-82-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]-6-[(2,3,3-trifluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-83-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-[(2-fluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-84-5 CAPLUS

CN Benzenesulfonamide, 2-[(2-fluoro-2-propen-1-yl)oxy]-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-85-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-[(2-fluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-86-7 CAPLUS  
 CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
 7-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-3,4-dihydro- (CA  
 INDEX NAME)



RN 848479-87-8 CAPLUS  
 CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
 3,4-dihydro-7-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-88-9 CAPLUS  
 CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
 7-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-3,4-  
 dihydro- (CA INDEX NAME)




RN 848479-89-0 CAPLUS  
 CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
 3,4-dihydro-7-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)






RN 848479-90-3 CAPLUS

CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
3,4-dihydro-7-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-  
pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-91-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methyl-3-(methylamino)phenyl]amino]-4-  
pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 848479-92-5 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-  
pyrimidinyl]amino]-6-(phenylmethoxy)- (CA INDEX NAME)



RN 848479-93-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-[(4,4,5,5,5-pentafluoropentyl)oxy]- (CA INDEX NAME)




RN 848479-94-7 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-[(4,4,5,5,5-pentafluoropentyl)oxy]- (CA INDEX NAME)




RN 848479-95-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-propoxy- (CA INDEX NAME)




RN 848479-96-9 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)



RN 848479-97-0 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 848479-98-1 CAPLUS  
 CN Benzenesulfonamide, 2-(difluoromethoxy)-6-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-99-2 CAPLUS

CN Benzenesulfonamide, 2-(difluoromethoxy)-6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848480-00-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 848480-01-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2-[[1-methyl-1H-indazol-6-yl]amino]-4-pyrimidinyl]amino]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 848480-02-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 848480-03-5 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848480-04-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-amino-3-methylphenyl)amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)



RN 848480-05-7 CAPLUS


CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[(2-methoxyethyl)amino]-4-methylphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

10/507,060 (amended)



RN 848480-06-8 CAPLUS


CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methyl-3-(methylethylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848480-07-9 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methyl-3-(methylethylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 848480-08-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(2,3-dihydro-1H-indol-6-yl)amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)




RN 848480-09-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(1-ethyl-2,3-dihydro-1H-indol-6-yl)amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)




RN 848480-10-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indol-6-ylamino)-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)




RN 848480-11-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(2,3-dihydro-1H-indol-6-yl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848480-12-6 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(1-ethyl-2,3-dihydro-1H-indol-6-yl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)



RN 848480-13-7 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-(1H-indol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




IT 848480-20-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4-di[(hetero)aryl]amino]pyrimidines as ZAP-70 and/or SYK inhibitors)

RN 848480-20-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methyl-3-[methyl(phenylmethyl)amino]phenyl]amino]-4-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)



L7 ANSWER 42 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:513675 CAPLUS  
 DN 145:34151  
 TI Combinations of JAK kinase inhibitors  
 IN Cooke, Nigel Graham Manley, Paul W.  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 SO PCT Int. Appl., 61 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

common inventor not prior no pending US appln.
--

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006056399	A2	20060601	WO 2005-EP12480	20051122
	WO 2006056399	A3	20060831		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DR, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005309019	A1	20060601	AU 2005-309019	20051122
	CA 2586605	A1	20060601	CA 2005-2586605	20051122
	CN 101106983	A	20080116	CN 2005-80046883	20051122
	EP 1885352	A2	20080213	EP 2005-814596	20051122
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008520612	T	20080619	JP 2007-541823	20051122
	BR 2005017887	A	20081021	BR 2005-17887	20051122
	IN 2007DN03463	A	20070831	IN 2007-DN3463	20070509
	MX 200706204	A	20070620	MX 2007-6204	20070523
	KR 2007085433	A	20070827	KR 2007-711743	20070523
PRAI	US 2004-630713P	P	20041124		
	WO 2005-EP12480	W	20051122		


AB The invention provides a pharmaceutical combination comprising (a) at least one agent selected from Bcr-Abl, Flt-3, FAK and RAF kinase inhibitors; and (b) at least one JAK kinase inhibitor, and a method for treating or preventing a proliferative disease using such a combination. A preferred embodiment of the invention is the combination of a RAF inhibitor, e.g., (4-tert-butylphenyl)-(4-pyridin-4-yl-methyl-isoquinolin-1-yl)amine or [4,7']bi-isoquinolinyl-1-yl-4-(tert-butylphenyl)amine, and a JAK kinase inhibitor, such as PNU 156804 or WHI-P 131 for the treatment of myelomas, especially multiple myeloma.

IT 761437-28-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combinations of JAK kinase inhibitors with other protein kinase inhibitors for treatment or prevention of proliferative disease)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



L7 ANSWER 43 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:193590 CAPLUS  
 DN 144:274291  
 TI Preparation of bis(arylamino)pyrimidine derivatives as antitumor agents  
 IN Imbach, Patricia; Kawahara, Eiji; Konishi, Kazuhide; Matsuura, Naoko;  
 Miyake, Takahiro; Ohmori, Osamu; Roesel, Johannes; Teno, Naoki; Umemura,  
 Ichiro  
 PA Novartis AG, Switz.; Novartis Pharma GmbH  
 SO PCT Int. Appl., 118 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021454	A2	20060302	WO 2005-EP9251	20050826
	WO 2006021454	A3	20060504		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	AU 2005276582	A1	20060302	AU 2005-276582	20050826
	CA 2577251	A1	20060302	CA 2005-2577251	20050826
	EP 1784392	A2	20070516	EP 2005-776772	20050826
	R:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR		
	CN 101048386	A	20071003	CN 2005-80036888	20050826
	JP 2008510763	T	20080410	JP 2007-528754	20050826
	BR 2005014681	A	20080617	BR 2005-14681	20050826
	IN 2007DN01410	A	20070824	IN 2007-DN1410	20070221
	MX 200702254	A	20070420	MX 2007-2254	20070223
	KR 2007054223	A	20070528	KR 2007-706800	20070326
	NO 2007001593	A	20070522	NO 2007-1593	20070327
PRAI	GB 2004-19161	A	20040827		
	WO 2005-EP9251	W	20050826		

OS MARPAT 144:274291

AB Title compds. I [R1 = H, (substituted) 5- or 6-membered heterocyclyl; R2 = H; R3 = (substituted) sulfamoyl, carbamoyl, 5- or 6-membered heterocyclyl; R2R3 together with N to which they are attached form heterocyclyl; R5 = halo; R7 = H, alkoxy, carbamoyl, (substituted) 5- or 6-membered heterocyclyl; R8 = H, halo, alkoxy, carbamoyl, (substituted) 5- or 6-membered heterocyclyl; R7R8 together form a 6-membered heterocyclyl; R9 = H, (substituted) 5- or 6-membered heterocyclyl; R10 = H, alkoxy], or salts thereof, were prepared For example, title compound II was prepared from 2-(2,5-dichloropyrimidin-4-ylamino)-N-isobutylbenzenesulfonamide and 4-amino-3-methoxy-N-methylbenzamide. I inhibited ALK (anaplastic lymphoma kinase) with IC50 = 0.01-1  $\mu$ M.

IT 845813-84-5P 845814-57-5P 878158-44-2P  
 878158-45-3P 878158-46-4P 878158-47-5P


878158-48-6P 878158-49-7P 878158-50-0P  
 878158-51-1P 878158-52-2P 878158-53-3P  
 878158-54-4P 878158-55-5P 878158-56-6P  
 878158-57-7P 878158-58-8P 878158-59-9P  
 878158-60-2P 878158-61-3P 878158-62-4P  
 878158-63-5P 878158-64-6P 878158-65-7P  
 878158-66-8P 878158-67-9P 878158-68-0P  
 878158-69-1P 878158-70-4P 878158-71-5P  
 878158-72-6P 878158-73-7P 878158-74-8P  
 878158-75-9P 878158-76-0P 878158-77-1P  
 878158-78-2P 878158-79-3P 878158-80-6P  
 878158-81-7P 878158-82-8P 878158-83-9P  
 878158-84-0P 878158-85-1P 878158-86-2P  
 878158-87-3P 878158-88-4P 878158-89-5P  
 878158-90-8P 878158-91-9P 878158-92-0P  
 878158-93-1P 878158-94-2P 878158-95-3P  
 878158-96-4P 878158-98-6P 878159-00-3P  
 878159-01-4P 878159-03-6P 878159-04-7P  
 878159-05-8P 878159-06-9P 878159-07-0P  
 878159-09-2P 878159-10-5P 878159-11-6P  
 878159-12-7P 878159-13-8P 878159-14-9P  
 878159-15-0P 878159-16-1P 878159-17-2P  
 878159-18-3P 878159-19-4P 878159-20-7P  
 878159-61-6P 878159-62-7P 878159-63-8P  
 878159-64-9P 878159-65-0P 878159-66-1P  
 878159-67-2P 878159-68-3P 878159-69-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of bis(arylamino)pyrimidine derivs. as kinase inhibitors and antitumor agents)


RN 845813-84-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(1-  
 piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX  
 NAME)




RN 845814-57-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-  
 morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA  
 INDEX NAME)




RN 878158-44-2 CAPLUS

CN Benzamide, 4-[[5-chloro-4-[[2-[[2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxy-N-methyl- (CA INDEX NAME)



RN 878158-45-3 CAPLUS


CN Benzamide, 3-[[5-chloro-4-[[2-[[2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-4-methoxy-N-methyl- (CA INDEX NAME)



RN 878158-46-4 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl- (CA INDEX NAME)






RN 878158-47-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-48-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-49-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878158-50-0 CAPLUS


CN Benzenesulfonamide, 2-[[[5-chloro-2-[[2-methoxy-4-[(2S)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 878158-51-1 CAPLUS

CN Benzenesulfonamide, 2-[[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-52-2 CAPLUS


CN Benzenesulfonamide, 2-[[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-53-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 878158-54-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 878158-55-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 878158-56-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 878158-57-7 CAPLUS


CN Benzenesulfonamide, 2-[[[5-chloro-2-[[4-(4-hydroxy-1-piperidinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-58-8 CAPLUS


CN Benzenesulfonamide, 2-[[[2-[[5-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)





RN 878158-62-4 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl- (CA INDEX NAME)



RN 878158-63-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878158-64-6 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 878158-65-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 878158-66-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 878158-67-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(4-hydroxy-1-piperidiny-2-methoxyphenyl]amino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-68-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[[1-(1-methylethyl)-4-piperidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 878158-69-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-fluoro-2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-70-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[[2-(2-methoxy-5-[[1-(1-methylethyl)-2-pyrrolidinyl]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 878158-71-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[[ (2R)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 878158-72-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,4-dimethoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-73-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(3,4-dihydro-7-methoxy-4-methyl-3-oxo-2H-1,4-benzoxazin-6-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-74-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,4-dimethoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-75-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,4-dimethoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-76-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-77-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-78-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-dimethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-79-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-80-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[2-(4-hydroxy-1-piperidinyl)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-81-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 878158-82-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 878158-83-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,4-dimethoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-84-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-85-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(4-hydroxy-1-piperidinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-86-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-87-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[[1-(1-methylethyl)-4-piperidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-88-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-89-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-90-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-91-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-92-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-93-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-94-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 878158-95-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 878158-96-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methoxyethyl)- (CA INDEX NAME)






RN 878158-98-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxypropyl)- (CA INDEX NAME)




RN 878159-00-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(3-hydroxypropyl)- (CA INDEX NAME)




RN 878159-01-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 878159-03-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (CA INDEX NAME)




RN 878159-04-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 878159-05-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-propyl- (CA INDEX NAME)




RN 878159-06-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-(2-methylpropyl)- (CA INDEX NAME)




RN 878159-07-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 878159-09-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 878159-10-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-propyl- (CA INDEX NAME)




RN 878159-11-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878159-12-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 878159-13-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-14-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[5-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 878159-15-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 878159-16-1 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




RN 878159-17-2 CAPLUS  
 CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878159-18-3 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878159-19-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-(4-hydroxy-1-piperidinyl)-N-methyl- (CA INDEX NAME)



RN 878159-20-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-(4-hydroxy-1-piperidinyl)-N-methyl- (CA INDEX NAME)




RN 878159-61-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 878159-62-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 878159-63-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-64-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-65-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-66-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 878159-67-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 878159-68-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 878159-69-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(cyclopropylmethoxy)-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A



10/507,060 (amended)

PAGE 2-A

$\begin{array}{c} || \\ O \end{array}$

L7 ANSWER 44 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:1238920 CAPLUS  
 DN 144:6801  
 TI Preparation of 2-arylamino-pyrimidines as polo-like kinase inhibitors  
 IN Engelhardt, Harald; Reiser, Ulrich; Zahn, Stephan Karl; Hauptmann, Rudolf;  
 Steegmaier, Martin; Guertler, Ulrich; Hoffmann, Matthias; Grauert,  
 Matthias; Stadtmueller, Heinz  
 PA Boehringer Ingelheim International G.m.b.H., Germany  
 SO Eur. Pat. Appl., 72 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1598343	A1	20051123	EP 2004-11911	20040519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CA 2565568	A1	20051201	CA 2005-2565568	20050513
	WO 2005113515	A1	20051201	WO 2005-EP52214	20050513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1751118	A1	20070214	EP 2005-747883	20050513
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008505855	T	20080228	JP 2007-517246	20050513
	US 20050261295	A1	20051124	US 2005-132091	20050518
	US 7241769	B2	20070710		
PRAI	EP 2004-11911	A	20040519		
	WO 2005-EP52214	W	20050513		

OS MARPAT 144:6801

AB Title compds. I [X = O, S, etc.; Y = CH, N; Z = H, halo, alkyl, etc.; A = mono or bicyclic aryl with provisos; R1 = H, CH3; R2 = halo, alkyl, alkenyl, etc.; R4, R5, R6 = H, halo, NO2, etc.; R3 = L-Q3-Q4-R9, etc; L = alkyl, alkenyl, alkynyl, etc.; Q3, Q4 = bond, heterocycle with provisos; R9 = alkyl, alkenyl, alkynyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of chloropyrimidine II and 2-amino-6-fluorobenzoic acid afforded in 18% yield. Compds. I are claimed to be useful as polo-like kinase (PLK1) inhibitors.

IT 869936-12-9P 869936-13-0P 869936-16-3P  
 869936-17-4P 869936-18-5P 869936-19-6P  
 869936-20-9P 869936-21-0P 869936-22-1P  
 869936-23-2P 869936-24-3P 869936-25-4P  
 869936-26-5P 869936-27-6P 869936-28-7P  
 869936-30-1P 869936-31-2P 869936-32-3P  
 869936-33-4P 869936-34-5P 869936-35-6P


869936-37-8P 869936-38-9P 869936-39-0P  
 869936-40-3P 869936-41-4P 869936-42-5P  
 869936-43-6P 869936-44-7P 869936-45-8P  
 869936-46-9P 869936-47-0P 869936-48-1P  
 869936-49-2P 869936-50-5P 869936-58-3P  
 869936-68-5P 869936-72-1P 869936-73-2P  
 869936-74-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 2-arylamino pyrimidines as polo-like kinase inhibitors)

RN 869936-12-9 CAPLUS


CN Benzamide, 4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)



close compound  
 instant claims are unsubstituted at  
 the ortho position of the phenyl.  
 However, R7-R9 may represent  
 alkoxy, so this compound is a  
 positional isomer


RN 869936-13-0 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-fluorophenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-16-3 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-methylphenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-17-4 CAPLUS

CN Benzamide, 3-methoxy-4-[[4-[[2-[(methylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 869936-18-5 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-5-(trifluoromethyl)phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)



RN 869936-19-6 CAPLUS


CN Benzamide, 2-[[2-[[2-methoxy-4-[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 869936-20-9 CAPLUS


CN Benzamide, 4-[[4-[[2-(aminocarbonyl)phenyl]methylamino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)






RN 869936-21-0 CAPLUS

CN Benzoic acid, 2-[[2-[[2-methoxy-4-[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]-6-methyl-, 2,2-dimethylhydrazide (CA INDEX NAME)




RN 869936-22-1 CAPLUS

CN Benzamide, 4,5-difluoro-2-[[2-[[2-methoxy-4-[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]-6-methyl-, 2,2-dimethylhydrazide (CA INDEX NAME)




RN 869936-23-2 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-chlorophenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-24-3 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-(trifluoromethyl)phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-25-4 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]- (CA INDEX NAME)




RN 869936-26-5 CAPLUS


CN Benzamide, 2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 869936-27-6 CAPLUS  
 CN Benzamide, N-[3-(dimethylamino)propyl]-2-fluoro-6-[[2-[[2-methoxy-4-  
 [(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)




RN 869936-28-7 CAPLUS  
 CN Benzamide, N-(2-amino-2-oxoethyl)-2-fluoro-6-[[2-[[2-methoxy-4-  
 [(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)




RN 869936-30-1 CAPLUS

CN Benzamide, 2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 869936-31-2 CAPLUS

CN Benzamide, 2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 869936-32-3 CAPLUS

CN Benzamide, 2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 869936-33-4 CAPLUS

CN Benzamide, 2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 869936-34-5 CAPLUS

CN Benzamide, 2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 869936-35-6 CAPLUS

CN  $\beta$ -Alanine, N-[2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]benzoyl]-, ethyl ester (CA INDEX NAME)



RN 869936-37-8 CAPLUS


CN Benzamide, 2-fluoro-N-(2-fluoroethyl)-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]- (CA INDEX NAME)



RN 869936-38-9 CAPLUS


CN Benzamide, 2-fluoro-6-[[2-[[2-methoxy-4-  
[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)






RN 869936-39-0 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-(2-aminoethoxy)phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-40-3 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-methoxyphenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-41-4 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-hydroxyphenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-42-5 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-(2-amino-3-methylbutoxy)phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-43-6 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-(2-pyrrolidinylmethoxy)phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)



RN 869936-44-7 CAPLUS


CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-(2-aminopropoxy)phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)



RN 869936-45-8 CAPLUS


CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-[[[(2R)-2-amino-4-methylpentyl]oxy]phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 869936-46-9 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-[2-[(2-hydroxypropyl)amino]-1-methylethoxy]phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-47-0 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-5-fluorophenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)




RN 869936-48-1 CAPLUS


CN Benzamide, N-[2-(dimethylamino)ethyl]-4-fluoro-2-[[2-[[2-methoxy-4-[(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 869936-49-2 CAPLUS  
 CN Benzamide, N-(2-amino-2-oxoethyl)-4-fluoro-2-[[2-[[2-methoxy-4-  
 [(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)




RN 869936-50-5 CAPLUS  
 CN Benzamide, 4-fluoro-2-[[2-[[2-methoxy-4-  
 [(propylamino)carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-  
 pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)



RN 869936-58-3 CAPLUS


CN Benzamide, 4-[[4-[[2-[(2-hydroxyethyl)amino]carbonyl]phenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-propyl- (CA INDEX NAME)



RN 869936-68-5 CAPLUS


CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-fluorophenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-[trans-4-(4-morpholinyl)cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 869936-72-1 CAPLUS


CN Benzamide, 4-[[4-[[2-(aminocarbonyl)-3-fluorophenyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 869936-73-2 CAPLUS

CN Benzamide, 2-fluoro-N-(2-fluoroethyl)-6-[[2-[[2-methoxy-4-[[[trans-4-(4-morpholinyl)cyclohexyl]amino]carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)


Relative stereochemistry.





RN 869936-74-3 CAPLUS

CN Benzamide, 2-fluoro-N-(2-fluoroethyl)-6-[[2-[[2-methoxy-4-[[1-methyl-4-piperidinyl]amino]carbonyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 45 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:260061 CAPLUS  
 DN 142:336385  
 TI Preparation of 2,4-di[(hetero)arylamino]pyrimidine derivatives as ZAP-70  
 and/or SYK inhibitors  
 IN Baenteli, Rolf; Bernhard Marie Claude; Buehlmayer, Peter; Cooke, Nigel  
 Graham; Duthaler, Rudolf; Hinterding, Klaus; Thoma, Gebhard; Van Eis,  
 Maurice; Von Matt, Anette; Walliser, Louis; Zenke, Gerhard  
 PA Novartis AG, Switz.; Novartis Pharma GmbH  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

common inventor

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026158	A1	20050324	WO 2004-EP10348	20040915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004272283	A1	20050324	AU 2004-272283	20040915
	AU 2004272283	B2	20081002		
	AU 2004272283	B9	20081023		
	CA 2538909	A1	20050324	CA 2004-2538909	20040915
	EP 1664035	A1	20060607	EP 2004-786952	20040915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004014480	A	20061114	BR 2004-14480	20040915
	CN 1882578	A	20061220	CN 2004-80033671	20040915
	JP 2007505856	T	20070315	JP 2006-526583	20040915
	SG 132676	A1	20070628	SG 2007-3520	20040915
	IN 2006CN00889	A	20070622	IN 2006-CN889	20060314
	KR 2006056388	A	20060524	KR 2006-705207	20060315
	KR 813384	B1	20080312		
	MX 2006PA02966	A	20060531	MX 2006-PA2966	20060315
	US 20060247262	A1	20061102	US 2006-377716	20060316
	NO 2006001656	A	20060616	NO 2006-1656	20060411
PRAI	GB 2003-21710	A	20030916		
	GB 2004-14440	A	20040628		
	WO 2004-EP10348	W	20040915		
OS	CASREACT 142:336385; MARPAT 142:336385				
AB	The title compds. [I; Z = CR2, N; R0-R4 = H, OH, alkyl, etc.; or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a 5-10 membered heterocyclic ring; or R1-R3 = halo, haloalkyl, alkoxy, etc.; or R1 and R2 form aryl, 5-10 membered heteroaryl, 5-15 membered non-aromatic carbocyclic or heterocyclic residue; R5, R6 = H, halo, CN, etc.; at least one of R7-R9 = halo, tetrahydropyran-2-ylmethoxy, alkylsulfanyl, etc.; or R7 and R8 or R8 and R9, resp. form together a 5-membered heterocyclic ring, 5-6 membered heterocyclic ring comprising 1				

ODP

nitrogen atom, 5-20 membered heterocyclic residue comprising 1-7 oxygen atoms] which have ZAP-70 and/or Syk inhibitory activities, were prepared E.g., a multi-step synthesis of II, starting from 3,4,5-trimethoxyphenylamine and 2-methylsulfanylpurimidin-4-ol, was given. The compds. I were tested in various in vitro assays against ZAP-70, Syk, ALK, etc. (biol. data were given for selected compds. I). The pharmaceutical composition comprising the compound I is claimed.


IT 1044658-80-1 1044658-81-2 1044658-82-3  
 1044658-86-7 1044658-87-8 1044658-88-9  
 1044658-90-3 1044658-91-4 1044658-92-5  
 1044658-94-7 1044658-95-8 1044658-96-9  
 1044658-97-0 1044658-99-2 1044659-00-8  
 1044659-01-9 1044659-02-0 1044659-04-2  
 1044659-05-3 1044659-07-5 1044659-08-6  
 1044659-09-7 1044659-11-1 1044659-12-2  
 1044659-13-3 1044659-14-4 1044659-16-6  
 1044659-17-7 1044659-18-8 1044659-20-2  
 1044659-21-3 1044659-22-4 1044659-23-5  
 1044659-24-6 1044659-25-7 1044659-26-8  
 1044659-27-9

RL: PRPH (Prophetic)

(Preparation of 2,4-di[(hetero)aryl]amino]pyrimidine derivatives as ZAP-70 and/or SYK inhibitors)


RN 1044658-80-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(diethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 1044658-81-2 CAPLUS


CN 7-Benzofuransulfonamide, 2,3-dihydro-6-[[2-[[4-methyl-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044658-82-3 CAPLUS  
 CN 7-Benzofuransulfonamide, 2,3-dihydro-2-methyl-6-[[2-[[4-methyl-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044658-86-7 CAPLUS  
 CN 7-Benzofuransulfonamide, 6-[[2-[[4-methyl-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1044658-87-8 CAPLUS  
 CN 2H-1-Benzopyran-8-sulfonamide, 3,4-dihydro-7-[[2-[[4-methyl-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044658-88-9 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[4-ethyl-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 1044658-90-3 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[4-fluoro-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 1044658-91-4 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[4-chloro-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 1044658-92-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[4-bromo-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 1044658-94-7 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[4-amino-3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 1044658-95-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-(methylamino)-3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044658-96-9 CAPLUS

CN Benzoic acid, 2-amino-5-[[4-[[5-(aminosulfonyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044658-97-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(ethylamino)-4-methylphenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 1044658-99-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methyl-3-(propylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044659-00-8 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(3-methoxypropyl)amino]-4-methylphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1044659-01-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 1044659-02-0 CAPLUS  
CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-methyl-4-(propylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044659-04-2 CAPLUS  
CN Benzenesulfonamide, 2-[[2-[[3,4-bis[(E)-(2-methylhydrazinylidene)methyl]phenyl]amino]-4-pyrimidinyl]amino]-6-[2-(2-methoxyethoxy)ethoxy]- (CA INDEX NAME)

Double bond geometry as shown.






RN 1044659-05-3 CAPLUS  
 CN Benzenesulfonamide, 2-[2-(2-methoxyethoxy)ethoxy]-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044659-07-5 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[3,4-bis[(E)-(2-methylhydrazinylidene)methyl]phenyl]amino]-4-pyrimidinyl]amino]-6-(phenylmethoxy)- (CA INDEX NAME)

Double bond geometry as shown.


10/507,060 (amended)




RN 1044659-08-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED




RN 1044659-09-7 CAPLUS  
CN Benzenesulfonamide, 2-[[2-[[4-methyl-3-(methylanino)phenyl]amino]-4-pyrimidinyl]amino]-6-(2-propen-1-yldioxy)- (CA INDEX NAME)



RN 1044659-11-1 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[4-methyl-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-6-(2-propyn-1-yldioxy)- (CA INDEX NAME)




RN 1044659-12-2 CAPLUS  
 CN Benzenesulfonamide, 2-[(2-cyanoethyl)dioxy]-6-[[2-[[4-methyl-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044659-13-3 CAPLUS

CN Benzenesulfonamide, 2-[(2-methoxyethyl)dioxy]-6-[[2-[[4-methyl-3-(methylanino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1044659-14-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-ethyl-3-(methylanino)phenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)




RN 1044659-16-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-chloro-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)




RN 1044659-17-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-fluoro-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)




RN 1044659-18-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-bromo-3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)




RN 1044659-20-2 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-amino-3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)



RN 1044659-21-3 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[4-(methylanino)-3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)




RN 1044659-22-4 CAPLUS  
 CN Benzoic acid, 2-amino-5-[[4-[[2-(aminosulfonyl)-3-(methyldioxy)phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1044659-23-5 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-(ethylamino)-4-methylphenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)




RN 1044659-24-6 CAPLUS

CN Benzenesulfonamide, 2-(methyldioxy)-6-[[2-[[4-methyl-3-(propylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)







RN 1044659-25-7 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[3-[(3-methoxypropyl)amino]-4-methylphenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)



RN 1044659-26-8 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[4-(ethylamino)-3-methylphenyl]amino]-4-pyrimidinyl]amino]-6-(methyldioxy)- (CA INDEX NAME)



RN 1044659-27-9 CAPLUS  
 CN Benzenesulfonamide, 2-(methyldioxy)-6-[[2-[[3-methyl-4-(propylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



IT 848479-04-9P 848479-05-0P 848479-06-1P  
 848479-07-2P 848479-08-3P 848479-09-4P  
 848479-10-7P 848479-11-8P 848479-12-9P  
 848479-13-0P 848479-14-1P 848479-15-2P  
 848479-16-3P 848479-17-4P 848479-18-5P  
 848479-19-6P 848479-20-9P 848479-21-0P  
 848479-22-1P 848479-23-2P 848479-24-3P  
 848479-25-4P 848479-26-5P 848479-27-6P  
 848479-28-7P 848479-29-8P 848479-30-1P  
 848479-31-2P 848479-32-3P 848479-33-4P  
 848479-34-5P 848479-35-6P 848479-36-7P  
 848479-37-8P 848479-38-9P 848479-39-0P  
 848479-40-3P 848479-41-4P 848479-42-5P  
 848479-43-6P 848479-44-7P 848479-45-8P  
 848479-46-9P 848479-47-0P 848479-48-1P


848479-49-2P 848479-50-5P 848479-51-6P  
 848479-52-7P 848479-53-8P 848479-54-9P  
 848479-55-0P 848479-56-1P 848479-57-2P  
 848479-58-3P 848479-59-4P 848479-60-7P  
 848479-61-8P 848479-62-9P 848479-63-0P  
 848479-64-1P 848479-65-2P 848479-66-3P  
 848479-67-4P 848479-68-5P 848479-69-6P  
 848479-70-9P 848479-71-0P 848479-72-1P  
 848479-73-2P 848479-74-3P 848479-75-4P  
 848479-76-5P 848479-77-6P 848479-78-7P  
 848479-79-8P 848479-80-1P 848479-81-2P  
 848479-82-3P 848479-83-4P 848479-84-5P  
 848479-85-6P 848479-86-7P 848479-87-8P  
 848479-88-9P 848479-89-0P 848479-90-3P  
 848479-91-4P 848479-92-5P 848479-93-6P  
 848479-94-7P 848479-95-8P 848479-96-9P  
 848479-97-0P 848479-98-1P 848479-99-2P  
 848480-00-2P 848480-01-3P 848480-02-4P  
 848480-03-5P 848480-04-6P 848480-05-7P  
 848480-06-8P 848480-07-9P 848480-08-0P  
 848480-09-1P 848480-10-4P 848480-11-5P  
 848480-12-6P 848480-13-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 2,4-di[(hetero)arylaminopyrimidines as ZAP-70 and/or SYK inhibitors)


RN 848479-04-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(3,4,5-  
 trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-05-0 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[(3,4-dimethoxyphenyl)amino]-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-06-1 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-07-2 CAPLUS

CN Benzenesulfonamide, 2-(dimethylamino)-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-08-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-(2-propen-1-yloxy)- (CA INDEX NAME)




RN 848479-09-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 848479-10-7 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(2-methoxyethyl)amino]-4-methylphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-11-8 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)



RN 848479-12-9 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-13-0 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-14-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-15-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-16-3 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-bromo-2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-17-4 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-18-5 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-bromo-2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-19-6 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-bromo-2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-20-9 CAPLUS  
 CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[4-(dimethylamino)-3-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)






RN 848479-21-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-22-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(tetrahydro-2-furanyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-23-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-24-3 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-25-4 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[5-methyl-2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-26-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-27-6 CAPLUS

CN Benzoic acid, 4-[[4-[[5-(aminosulfonyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-2-pyrimidinyl]amino]-2-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 848479-28-7 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-29-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(4-methoxy-2-naphthalenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-30-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(8-methoxy-6-quinolinyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-31-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-32-3 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-33-4 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-(phenylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-34-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-methoxy-4-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-35-6 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-36-7 CAPLUS

CN Acetic acid, 2-[3-[[4-[[5-(aminosulfonyl)-2,3-dihydro-1,4-benzodioxin-6-yl]amino]-2-pyrimidinyl]amino]phenoxy]-, 1-methylethyl ester (CA INDEX NAME)




RN 848479-37-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-38-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(4-fluoro-3-methoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-39-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-40-3 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-41-4 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-42-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-43-6 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-(4-thiazolylmethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-44-7 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methyl-3-[(tetrahydro-2-furanyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 848479-45-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(2-cyclohexylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-46-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,2,3,3-tetrafluoro-2,3-dihydro- (CA INDEX NAME)




RN 848479-47-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-methoxy-4-(methylthio)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-48-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2,3,3-tetrafluoro-2,3-dihydro- (CA INDEX NAME)




RN 848479-49-2 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,2,3,3-tetrafluoro-2,3-dihydro-6-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-50-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(3-methylphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-51-6 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[(4-methylphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-52-7 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(3-ethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-53-8 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(3-acetylphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-54-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-55-0 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[5-fluoro-2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-56-1 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-57-2 CAPLUS


CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[3-methyl-4-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-58-3 CAPLUS  
 CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,2-difluoro- (CA INDEX NAME)



RN 848479-59-4 CAPLUS  
 CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-difluoro- (CA INDEX NAME)




RN 848479-60-7 CAPLUS  
 CN 1,3-Benzodioxole-4-sulfonamide, 2,2-difluoro-5-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-61-8 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2-fluoro-2-(difluoromethyl)oxy (CA INDEX NAME)




RN 848479-62-9 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[[1-methyl-1H-indazol-6-yl]amino]-4-pyrimidinyl]amino]-2-methoxy-2-(dimethylamino)oxy (CA INDEX NAME)




RN 848479-63-0 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 5-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-2-(dimethylamino)oxy (CA INDEX NAME)




RN 848479-64-1 CAPLUS

CN 1,3-Benzodioxole-4-sulfonamide, 2,2-difluoro-5-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-65-2 CAPLUS

CN 1H-Indene-4-sulfonamide, 5-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-66-3 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-67-4 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-68-5 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-69-6 CAPLUS


CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-70-9 CAPLUS




CN 1H-Indene-4-sulfonamide, 5-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848479-71-0 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-72-1 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-73-2 CAPLUS

CN 1H-Indene-4-sulfonamide, 2,3-dihydro-5-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-74-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]-6-(2-propen-1-yloxy)- (CA INDEX NAME)




RN 848479-75-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-(2-propen-1-yloxy)- (CA INDEX NAME)




RN 848479-76-5 CAPLUS

CN Benzenesulfonamide, 2-[(2-chloro-2-propen-1-yl)oxy]-6-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-77-6 CAPLUS

CN Benzenesulfonamide, 2-[(2-chloro-2-propen-1-yl)oxy]-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-78-7 CAPLUS

CN Benzenesulfonamide, 2-[(2-chloro-2-propen-1-yl)oxy]-6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-79-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-[(1,1,2-trifluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-80-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-[(2,3,3-trifluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-81-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-[(2,3,3-trifluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-82-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]-6-[(2,3,3-trifluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-83-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-[(2-fluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-84-5 CAPLUS

CN Benzenesulfonamide, 2-[(2-fluoro-2-propen-1-yl)oxy]-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-85-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-[(2-fluoro-2-propen-1-yl)oxy]- (CA INDEX NAME)




RN 848479-86-7 CAPLUS  
 CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
 7-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-3,4-dihydro- (CA  
 INDEX NAME)




RN 848479-87-8 CAPLUS  
 CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
 3,4-dihydro-7-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-88-9 CAPLUS  
 CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
 7-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-3,4-  
 dihydro- (CA INDEX NAME)




RN 848479-89-0 CAPLUS  
 CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
 3,4-dihydro-7-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-  
 pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-90-3 CAPLUS

CN 2H-1,5-Benzodioxepin-6-sulfonamide,  
3,4-dihydro-7-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-  
pyrimidinyl]amino]- (CA INDEX NAME)



RN 848479-91-4 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-methyl-3-(methylamino)phenyl]amino]-4-  
pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 848479-92-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-  
pyrimidinyl]amino]-6-(phenylmethoxy)- (CA INDEX NAME)






RN 848479-93-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-[(4,4,5,5,5-pentafluoropentyl)oxy]- (CA INDEX NAME)




RN 848479-94-7 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-[(4,4,5,5,5-pentafluoropentyl)oxy]- (CA INDEX NAME)




RN 848479-95-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-propoxy- (CA INDEX NAME)




RN 848479-96-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 848479-97-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)




RN 848479-98-1 CAPLUS

CN Benzenesulfonamide, 2-(difluoromethoxy)-6-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848479-99-2 CAPLUS

CN Benzenesulfonamide, 2-(difluoromethoxy)-6-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848480-00-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 848480-01-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2-[[1-methyl-1H-indazol-6-yl]amino]-4-pyrimidinyl]amino]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 848480-02-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-(trifluoromethoxy)- (CA INDEX NAME)




RN 848480-03-5 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848480-04-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-amino-3-methylphenyl)amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)



RN 848480-05-7 CAPLUS


CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[(2-methoxyethyl)amino]-4-methylphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

10/507,060 (amended)




RN 848480-06-8 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methyl-3-(methylethylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848480-07-9 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-[[4-methyl-3-(methylethylamino)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848480-08-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(2,3-dihydro-1H-indol-6-yl)amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)



RN 848480-09-1 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(1-ethyl-2,3-dihydro-1H-indol-6-yl)amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)



RN 848480-10-4 CAPLUS


CN Benzenesulfonamide, 2-[[2-(1H-indol-6-ylamino)-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)






RN 848480-11-5 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(2,3-dihydro-1H-indol-6-yl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)




RN 848480-12-6 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 6-[[2-[(1-ethyl-2,3-dihydro-1H-indol-6-yl)amino]-4-pyrimidinyl]amino]-2,3-dihydro- (CA INDEX NAME)



RN 848480-13-7 CAPLUS

CN 1,4-Benzodioxin-5-sulfonamide, 2,3-dihydro-6-[[2-(1H-indol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)



IT 848480-20-6P


10/507,060 (amended)

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4-di[(hetero)aryl]amino]pyrimidines as ZAP-70 and/or SYK inhibitors)

RN 848480-20-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methyl-3-[methyl(phenylmethyl)amino]phenyl]amino]-4-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 46 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:260035 CAPLUS  
 DN 142:336377  
 TI Preparation of 2,4-di(phenylamino)pyrimidines useful in the treatment of  
 proliferative disorders  
 IN Imbach, Patricia; Roesel, Johannes  
 PA Novartis AG, Switz.; Novartis Pharma GmbH  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent appears to be commonly assigned  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026130	A1	20050324	WO 2004-EP10466	20040917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004272288	A1	20050324	AU 2004-272288	20040917
CA 2538413	A1	20050324	CA 2004-2538413	20040917
EP 1663992	A1	20060607	EP 2004-765358	20040917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1852900	A	20061025	CN 2004-80026942	20040917
BR 2004014544	A	20061107	BR 2004-14544	20040917
JP 2007505858	T	20070315	JP 2006-526595	20040917
US 20070105839	A1	20070510	US 2006-571733	20060314
IN 2006CN00922	A	20070615	IN 2006-CN922	20060316
MX 2006PA03054	A	20060531	MX 2006-PA3054	20060317
PRAI US 2003-504374P	P	20030918		
WO 2004-EP10466	W	20040917		

ODP  
for  
Method  
claims

OS CASREACT 142:336377; MARPAT 142:336377  
 AB The title compds. I [X = CR0, N; R0, R1-R4 = H, OH, alkyl, etc.; or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a 5-10 membered heterocyclic ring and comprising addnl. 1-3 heteroatoms selected from N, O and S; or R1-R3 = halo, haloalkyl, alkoxy, etc.; or R1 and R2 form aryl or 5-10 membered heteroaryl; R5, R6 = H, halo, CN, alkyl, etc.; R7-R9 = H, OH, alkyl, etc.], useful for preventing or treating proliferative disorders such as a tumor disease, by inhibiting ALK activity, were prepared E.g., a 2-step synthesis of 2-[2-(1H-indazol-6-ylamino)-pyrimidin-4-ylamino]benzenesulfonamide, starting from 2-aminobenzenesulfonamide and 2,4-dichloropyrimidine, was given. The compds. I were tested for inhibition of ALK tyrosine kinase in various cellular assays (data were given for representative compds. I).  
 IT 604800-89-7P 604800-91-1P 604800-93-3P  
 604800-97-7P 604801-01-6P 604801-02-7P  
 604801-05-0P 604801-07-2P 604801-09-4P  
 604801-11-8P 604801-13-0P 604801-14-1P  
 604801-18-5P 604801-19-6P 604801-23-2P


604801-25-4P 604801-27-6P 604801-28-7P  
 604801-32-3P 604801-33-4P 604801-34-5P  
 604801-57-2P 604801-58-3P 604801-59-4P  
 604801-60-7P 604801-63-0P 604801-65-2P  
 604801-67-4P 604801-74-3P 604801-80-1P  
 604801-86-7P 604801-87-8P 604801-88-9P  
 604801-89-0P 604801-90-3P 604801-91-4P  
 604801-92-5P 604801-93-6P 604801-94-7P  
 604801-95-8P 604801-97-0P 604802-00-8P  
 604802-05-3P 604802-06-4P 604802-07-5P  
 604802-08-6P 604802-09-7P 604802-10-0P  
 604802-11-1P 604802-12-2P 604802-13-3P  
 604802-14-4P 604802-15-5P 604802-16-6P  
 604802-17-7P 604802-18-8P 604802-19-9P  
 604802-20-2P 604802-21-3P 604802-22-4P  
 604802-23-5P 604802-24-6P 604802-25-7P  
 604802-26-8P 604802-27-9P 604802-28-0P  
 604802-30-4P 604802-41-7P 604802-42-8P  
 604802-43-9P 604802-44-0P 604802-45-1P  
 604802-46-2P 604802-47-3P 604802-48-4P  
 604802-49-5P 604802-50-8P 604802-51-9P  
 604802-52-0P 604802-53-1P 604802-55-3P  
 604802-56-4P 604802-58-6P 604802-59-7P  
 604802-60-0P 604802-62-2P 604803-21-6P  
 848468-24-6P 848468-28-0P 848468-29-1P  
 848468-32-6P 848468-33-7P 848468-34-8P  
 848468-35-9P 848468-37-1P 848468-38-2P  
 848468-39-3P 848468-41-7P 848468-42-8P  
 848468-43-9P 848468-45-1P 848468-46-2P  
 848468-48-4P 848468-50-8P 848468-51-9P  
 848468-55-3P 848468-56-4P 848468-57-5P  
 848468-58-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(phenylamino)pyrimidines useful in the treatment of proliferative disorders)


RN 604800-89-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-91-1 CAPLUS

CN Benzenesulfonamide, 2-methyl-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-93-3 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-97-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[(hexahydro-1-methyl-1H-azepin-4-yl)oxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-01-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[(1H-imidazol-1-yl)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-02-7 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-

piperidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-05-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-07-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-09-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-benzotriazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-11-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 604801-13-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-14-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-18-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-19-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-23-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-25-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-27-6 CAPLUS


CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-28-7 CAPLUS




CN Benamide, 2-[[2-[(3-aminophenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-32-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-33-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-34-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 604801-57-2 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-58-3 CAPLUS

CN Benzenesulfonamide, 3-[[2-(1H-indazol-5-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-59-4 CAPLUS

CN Benzenesulfonamide, 3-[[5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-60-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-63-0 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-65-2 CAPLUS

CN Benzenesulfonamide, 3-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-67-4 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[[5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-74-3 CAPLUS

CN Benzenesulfonamide, N-butyl-3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-80-1 CAPLUS

CN Benzenesulfonamide, 3-[[5-ethyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 604801-86-7 CAPLUS

CN [1,1'-Biphenyl]-3-sulfonamide, 4-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-87-8 CAPLUS

CN Benzenesulfonamide, 4-methyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-88-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-89-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-ethyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-90-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-91-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-92-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-93-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-benzotriazol-6-ylamino)-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-94-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-(1H-indazol-5-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-95-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indazol-6-ylamino)-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-97-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-00-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-5-methyl- (CA INDEX NAME)




RN 604802-05-3 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-06-4 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methyl-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-07-5 CAPLUS


CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-08-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)- (CA INDEX NAME)






RN 604802-09-7 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)





RN 604802-10-0 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-3-methyl- (CA INDEX NAME)




RN 604802-11-1 CAPLUS

CN Benzenesulfonamide, 2-methoxy-3-methyl-6-[[2-[[3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-12-2 CAPLUS

CN Benzenesulfonamide, 2-(1-methylethoxy)-6-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-13-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-14-4 CAPLUS

CN Benzenesulfonamide, 6-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,3-dimethyl- (CA INDEX NAME)




RN 604802-15-5 CAPLUS

CN Benzenesulfonamide, 5-methoxy-2-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-16-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)




RN 604802-17-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-18-8 CAPLUS

CN Benzenesulfonamide, 5-methoxy-2-[[2-[[3-[2-(1-methylpiperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-19-9 CAPLUS

CN Benzenesulfonamide, 5-methoxy-2-[[2-[[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-20-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-21-3 CAPLUS

CN Benzenesulfonamide, 5-ethoxy-2-[[2-[[4-methyl-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-22-4 CAPLUS

CN Benzenesulfonamide, 2,3-dimethoxy-6-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-23-5 CAPLUS

CN Benzenesulfonamide, 2-chloro-6-[[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-24-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-cyclopentyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-25-7 CAPLUS

CN 1-Naphthalenesulfonamide, 2-[[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-26-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-27-9 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-28-0 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-[4-(phenylmethyl)-1-piperazinyl]ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-30-4 CAPLUS

CN Benzenesulfonamide, 5-bromo-2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-41-7 CAPLUS


CN Benzenesulfonamide, N-methyl-2-[[5-(trifluoromethyl)-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-42-8 CAPLUS  
 CN Benzenesulfonamide, 2-methoxy-3-methyl-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-43-9 CAPLUS  
 CN Benzenesulfonamide, 2-(1-piperidinyl)-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-44-0 CAPLUS  
 CN Benzenesulfonamide, 2-(4-morpholinyl)-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 604802-45-1 CAPLUS

CN Benzenesulfonamide, N,2-dimethyl-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-46-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-47-3 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-48-4 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-49-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)- (CA INDEX NAME)




RN 604802-50-8 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-51-9 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-52-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[3-(1-piperidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-53-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-55-3 CAPLUS

CN Benzenesulfonamide, 2-(4-methyl-1-piperazinyl)-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-56-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)




RN 604802-58-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-59-7 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-60-0 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-62-2 CAPLUS  
 CN Benzenesulfonamide, 2-methoxy-6-[[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604803-21-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-fluoro- (CA INDEX NAME)




RN 848468-24-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-4-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-28-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indazol-5-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 848468-29-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indazol-5-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-32-6 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-33-7 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxy-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-1-hydroxyethyl)- (CA INDEX NAME)




RN 848468-34-8 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxy-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-1-hydroxyethyl)- (CA INDEX NAME)




RN 848468-35-9 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-37-1 CAPLUS

CN Benzenesulfonamide, N-propyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-38-2 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-39-3 CAPLUS

CN Benzenesulfonamide, N-[2-(2-hydroxyethoxy)ethyl]-4-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

PAGE 1-A






—OMe

—OMe


RN 848468-41-7 CAPLUS

CN Benzenesulfonamide, N-2-thiazolyl-4-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-42-8 CAPLUS


CN Benzenesulfonamide, N-2-propen-1-yl-3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-43-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-2-propen-1-yl- (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




RN 848468-45-1 CAPLUS  
 CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 848468-46-2 CAPLUS  
 CN Benzenesulfonamide, N-butyl-3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-48-4 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-50-8 CAPLUS

CN Benzenesulfonamide, 5-methyl-2-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-51-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]-5-methyl- (CA INDEX NAME)




RN 848468-55-3 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-56-4 CAPLUS

CN Benzenesulfonamide, 2-(2-methoxyethoxy)-6-[[2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-57-5 CAPLUS

CN Benzenesulfonamide, 2-methyl-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-58-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 47 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:158647 CAPLUS  
 DN 142:261547  
 TI Preparation of 2,4-pyrimidinediamines useful in the treatment of  
 neoplastic diseases, inflammatory and immune system disorders  
 IN Garcia-echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya,  
 Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura,  
 Ichiro; Steensma, Ruof; Chopiuk, Greg; Jiang, Jiqing; Wan, Yongqin; Ding,  
 Qiang; Zhang, Qiong; Gray, Nathanael Schiander; Karanewsky, Donald  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.; IRM LLC  
 SO PCT Int. Appl., 285 pp.  
 CODEN: PIXXD2


DT Patent  
 LA English

common inventors


FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005016894	A1	20050224	WO 2004-EP9099	20040813
W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004264382	A1	20050224	AU 2004-264382	20040813
CA 2533320	A1	20060224	CA 2004-2533320	20040813
EP 1660458	A1	20060531	EP 2004-764093	20040813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1832929	A	20060913	CN 2004-80022725	20040813
BR 2004013616	A	20061017	BR 2004-13616	20040813
JP 2007502260	T	20070208	JP 2006-522998	20040813
SG 145749	A1	20080929	SG 2008-6063	20040813
KR 2006039938	A	20060509	KR 2006-703056	20060214
MX 2006PA01759	A	20060512	MX 2006-PA1759	20060214
IN 2006CN00553	A	20070706	IN 2006-CN553	20060214
NO 2006001214	A	20060515	NO 2006-1214	20060315
US 20080132504	A1	20080605	US 2006-568367	20060818
AU 2008229685	A1	20081030	AU 2008-229685	20080929
PRAI GB 2003-19227	A	20030815		
GB 2003-22370	A	20030924		
AU 2004-264382	A3	20040813		
WO 2004-EP9099	W	20040813		
OS CASREACT 142:261547; MARPAT 142:261547				
AB The title compds. I [R = aryl, heteroaryl, cycloalkyl and heterocycloalkyl; R0-R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl; R5, R6 = H, alkyl, alkoxyalkyl, etc.], useful for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF-IR, were prepared and formulated. E.g., a 2-step synthesis of II, starting from 2,4-dichloro-5-nitropyrimidine and 2-amino-N-methylbenzenesulfonamide, was given. The compds. I have IC50 values in the range of 10 nM to 2 µM in				

cell-free ZAP-70 kinase assay.  
 IT 1044080-82-1  
 RL: PRPH (Prophetic)  
 (Preparation of 2,4-pyrimidinediamines useful in the treatment of  
 neoplastic diseases, inflammatory and immune system disorders)  
 RN 1044080-82-1 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[(3-methoxy-5-phenoxyphenyl)amino]-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



IT 761436-62-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic  
 diseases, inflammatory and immune system disorders)  
 RN 761436-62-8 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-  
 morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



IT 761436-42-4P 761436-43-5P 761436-44-6P  
 761436-45-7P 761436-46-8P 761436-47-9P  
 761436-48-0P 761436-49-1P 761436-50-4P  
 761436-51-5P 761436-52-6P 761436-53-7P  
 761436-54-8P 761436-55-9P 761436-56-0P  
 761436-57-1P 761436-58-2P 761436-59-3P  
 761436-60-6P 761436-61-7P 761436-63-9P  
 761436-64-0P 761436-65-1P 761436-66-2P  
 761436-67-3P 761436-68-4P 761436-69-5P  
 761436-70-8P 761436-71-9P 761436-72-0P  
 761436-73-1P 761436-74-2P 761436-75-3P  
 761436-76-4P 761436-77-5P 761436-78-6P  
 761436-79-7P 761436-80-0P 761436-81-1P  
 761436-82-2P 761436-83-3P 761436-84-4P  
 761436-85-5P 761436-86-6P 761436-87-7P  
 761436-88-8P 761436-89-9P 761436-90-2P  
 761436-91-3P 761436-93-5P 761436-94-6P

761436-95-7P 761436-96-8P 761436-97-9P  
761436-98-0P 761436-99-1P 761437-00-7P  
761437-01-8P 761437-02-9P 761437-03-0P  
761437-04-1P 761437-05-2P 761437-06-3P  
761437-07-4P 761437-08-5P 761437-09-6P  
761437-10-9P 761437-11-0P 761437-12-1P  
761437-13-2P 761437-14-3P 761437-15-4P  
761437-16-5P 761437-17-6P 761437-18-7P  
761437-19-8P 761437-20-1P 761437-21-2P  
761437-22-3P 761437-23-4P 761437-24-5P  
761437-25-6P 761437-26-7P 761437-27-8P  
761437-28-9P 761437-29-0P 761437-30-3P  
761437-31-4P 761437-32-5P 761437-33-6P  
761437-34-7P 761437-35-8P 761437-36-9P  
761437-37-0P 761437-39-2P 761437-40-5P  
761437-41-6P 761437-42-7P 761437-43-8P  
761437-44-9P 761437-45-0P 761437-46-1P  
761437-47-2P 761437-48-3P 761437-49-4P  
761437-50-7P 761437-51-8P 761437-52-9P  
761437-53-0P 761437-54-1P 761437-55-2P  
761437-56-3P 761437-57-4P 761437-58-5P  
761437-59-6P 761437-60-9P 761437-61-0P  
761437-62-1P 761437-63-2P 761437-64-3P  
761437-65-4P 761437-66-5P 761437-67-6P  
761437-68-7P 761437-69-8P 761437-70-1P  
761437-71-2P 761437-72-3P 761437-73-4P  
761437-74-5P 761437-75-6P 761437-76-7P  
761437-84-7P 761437-85-8P 761437-86-9P  
761437-88-1P 761437-91-6P 761437-92-7P  
761437-93-8P 761437-94-9P 761437-95-0P  
761437-96-1P 761437-97-2P 761437-99-4P  
761438-00-0P 761438-01-1P 761438-02-2P  
761438-03-3P 761438-04-4P 761438-05-5P  
761438-06-6P 761438-07-7P 761438-08-8P  
761438-09-9P 761438-10-2P 761438-11-3P  
761438-12-4P 761438-13-5P 761438-14-6P  
761438-15-7P 761438-16-8P 761438-17-9P  
761438-18-0P 761438-19-1P 761438-20-4P  
761438-21-5P 761438-22-6P 761438-23-7P  
761438-24-8P 761438-25-9P 761438-26-0P  
761438-27-1P 761438-28-2P 761438-29-3P  
761438-30-6P 761438-31-7P 761438-32-8P  
761438-33-9P 761438-34-0P 761438-35-1P  
761438-36-2P 761438-37-3P 761438-38-4P  
761438-39-5P 761438-40-8P 761438-41-9P  
761438-42-0P 761438-43-1P 761438-44-2P  
761438-45-3P 761438-46-4P 761438-47-5P  
761438-48-6P 761438-49-7P 761438-50-0P  
761438-51-1P 761438-52-2P 761438-53-3P  
761438-54-4P 761438-55-5P 761438-56-6P  
761438-57-7P 761438-58-8P 761438-59-9P  
761438-60-2P 761438-61-3P 761438-62-4P  
761438-63-5P 761438-64-6P 761438-65-7P  
761438-66-8P 761438-67-9P 761438-68-0P  
761438-69-1P 761438-70-4P 761438-71-5P  
761438-72-6P 761438-73-7P 761438-74-8P  
761438-75-9P 761438-76-0P 761438-77-1P




761438-78-2P 761438-79-3P 761438-80-6P  
 761438-81-7P 761438-82-8P 761438-83-9P  
 761438-84-0P 761438-85-1P 761438-86-2P  
 761438-87-3P 761438-88-4P 761439-95-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic  
 diseases, inflammatory and immune system disorders)


RN 761436-42-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(2,5-dimethoxyphenyl)amino]-5-nitro-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-43-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-dimethoxyphenyl)amino]-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-44-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,2-difluoro-1,3-benzodioxol-4-  
 yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-45-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-46-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-methoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-47-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-fluoro-4-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-48-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-4-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-49-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-50-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-51-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(3-methylphenyl)amino]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-52-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-methoxy[1,1'-biphenyl]-3-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-53-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(4-phenylphenyl)amino]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-54-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-(1H-indol-4-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-55-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3-dihydro-1H-inden-4-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-56-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-(1H-indazol-7-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-57-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-58-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-59-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-60-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4,5-dimethoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-61-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-methylethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-63-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-64-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-65-1 CAPLUS

CN Benzamide, 3-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-cyclohexyl-4-methyl- (CA INDEX NAME)




RN 761436-66-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-piperazinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-67-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4'-methoxy-4-methyl[1,1'-biphenyl]-3-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761436-68-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-69-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-70-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(3'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-71-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-ethoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-72-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-ethoxy-4'-methoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-73-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-74-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-75-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-76-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-77-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-78-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-difluorophenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-79-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-chloro-4-fluorophenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-80-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-chloro-5-fluorophenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-81-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-82-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-cyano-1-piperidiny)l)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-83-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-thiomorpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-84-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[bis(2-methoxyethyl)amino]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-85-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-  
[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
(CA INDEX NAME)




RN 761436-86-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(1,1-dioxido-4-thiomorpholinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-87-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[1-[3-(4-morpholinyl)propyl]-1H-indol-4-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-88-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-89-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-90-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(1H-imidazol-1-yl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-91-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-93-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(2-hydroxyethyl)propylamino]-2-methylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-94-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-chloro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-95-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[3-(dimethylamino)-2-methylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-96-8 CAPLUS




CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-97-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-diethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-98-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4,4'-dimethoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-99-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-00-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-01-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-02-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(2-hydroxyethoxy)-5-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-03-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-ethoxy-5-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-04-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-05-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-methoxy-2-propoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-06-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(dimethylamino)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-07-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-08-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(3-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-09-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(2-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-10-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761437-11-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-12-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-13-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-4-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-14-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-15-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-16-5 CAPLUS

CN	Benzenesulfonamide, 2-[[2-[[4-[(1-acetyl-4-piperidinyl)oxy]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)	
----	---	--




RN 761437-17-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-[(1-acetyl-4-piperidinyl)oxy]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-18-7 CAPLUS

CN	Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-	(CA INDEX NAME)
----	---	-----------------




RN 761437-19-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-difluorophenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-20-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-21-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-22-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761437-23-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-24-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-25-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(2-methyl-1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-26-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-27-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,2-difluoro-1,3-benzodioxol-4-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-29-0 CAPLUS

CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-30-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
(CA INDEX NAME)




RN 761437-31-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-32-5 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-33-6 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-34-7 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-35-8 CAPLUS  
 CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-36-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-hydroxy-1-piperidiny)]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-37-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(2-ethoxyethoxy)-1-piperidiny]]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-39-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(2-methoxyethoxy)-1-piperidiny]]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-40-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-41-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-42-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 761437-43-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-44-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-45-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-46-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-47-2 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 761437-48-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-49-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-(4-methyl-1-piperazinyl)piperidin-1-yl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




piperidiny]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-50-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-51-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-52-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/507,060 (amended)



RN 761437-53-0 CAPLUS


CN Benzamide, 2-[[2-[[5-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-54-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761437-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-56-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-(1H-indol-4-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-57-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(1-methyl-1H-indol-4-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-58-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[1-methyl-7-(4-morpholinyl)-1H-indol-4-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-59-6 CAPLUS

CN Benzamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-60-9 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-61-0 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-62-1 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-63-2 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-64-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-65-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-66-5 CAPLUS


CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

10/507,060 (amended)




RN 761437-67-6 CAPLUS  
CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761437-68-7 CAPLUS  
CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

NAME)




RN 761437-69-8 CAPLUS

CN Benzamide, 2-[[2-[[5-[[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-70-1 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)



RN 761437-71-2 CAPLUS


CN Benzamide, 2-[[2-[[4-[[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)






RN 761437-72-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-73-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-74-5 CAPLUS

CN Benzamide, 2-[[2-[[4-(1,4'-bipiperidin-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-75-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(1-methyl-1H-indol-4-yl)amino]-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-76-7 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-84-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 761437-85-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761437-86-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 761437-88-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-5-fluoro- (CA INDEX NAME)




RN 761437-91-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)-  
(CA INDEX NAME)




RN 761437-92-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)-  
(CA INDEX NAME)




RN 761437-93-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 761437-94-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)




RN 761437-95-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 761437-96-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-5-methoxy-N-methyl- (CA INDEX NAME)




RN 761437-97-2 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-99-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 761438-00-0 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)




RN 761438-01-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-02-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-03-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-04-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-05-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-06-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)






RN 761438-07-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-08-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-09-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-10-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-11-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-12-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-13-5 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[1-(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)



RN 761438-14-6 CAPLUS


CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 761438-15-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 761438-16-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761438-17-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-2-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-18-0 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N,N-diethyl- (CA INDEX NAME)




RN 761438-19-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-20-4 CAPLUS

CN Benzenesulfonamide, 2-[[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-21-5 CAPLUS

CN Benzenesulfonamide, 2-[[[5-chloro-2-[[3-fluoro-2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-22-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3-hydroxy-2,2-dimethylpropyl)amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-23-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(2-hydroxy-1,1-dimethylethyl)amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-24-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-25-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-26-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-27-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-28-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-29-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)



RN 761438-30-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)




RN 761438-31-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.






RN 761438-32-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)amino]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)




RN 761438-33-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-34-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-35-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-36-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(difluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-37-3 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 761438-38-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-39-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-40-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-41-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[1-[3-(4-methyl-1-piperazinyl)propyl]-1H-indol-4-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-42-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[1-[3-(4-morpholinyl)propyl]-1H-indol-4-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-43-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-44-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-dimethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-45-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-dimethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-46-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-47-5 CAPLUS  
 CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
 (CA INDEX NAME)



RN 761438-48-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-  
 (CA INDEX NAME)




RN 761438-49-7 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-50-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-51-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-(4-hydroxy-1-piperidinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-52-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-53-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-

morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-54-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-55-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-56-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761438-57-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-58-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-59-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-60-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-61-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-62-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-63-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-64-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-65-7 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-66-8 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-67-9 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[(4,5-dimethoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-68-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-69-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-70-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-71-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-72-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-73-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-74-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-75-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-76-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-77-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-78-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-79-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-80-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)



RN 761438-81-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)



RN 761438-82-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)






RN 761438-83-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-84-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 761438-85-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 761438-86-2 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-  
[(cyclobutylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-  
methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 761438-87-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-  
morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX  
NAME)




RN 761438-88-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-  
piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA  
INDEX NAME)



RN 761439-95-6 CAPLUS  
 CN Benzamide, 2-[[[5-chloro-2-[[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)]- (CA INDEX NAME)



IT 761439-96-7P 761439-98-9P 845811-03-2P  
 845811-04-3P 845811-05-4P 845811-06-5P  
 845811-07-6P 845811-08-7P 845811-09-8P  
 845811-10-1P 845811-11-2P 845811-12-3P  
 845811-13-4P 845811-14-5P 845811-18-9P  
 845811-19-0P 845811-20-3P 845811-21-4P  
 845811-22-5P 845811-23-6P 845811-24-7P  
 845811-25-8P 845811-26-9P 845811-27-0P  
 845811-29-2P 845811-31-6P 845811-32-7P  
 845811-33-8P 845811-34-9P 845811-48-5P  
 845811-49-6P 845811-50-9P 845811-51-0P  
 845811-52-1P 845811-53-2P 845811-55-4P  
 845811-56-5P 845811-57-6P 845811-58-7P  
 845811-59-8P 845811-60-1P 845811-61-2P  
 845811-63-4P 845811-64-5P 845811-65-6P  
 845811-66-7P 845811-67-8P 845811-68-9P  
 845811-70-3P 845811-73-6P 845811-74-7P  
 845811-75-8P 845811-76-9P 845811-77-0P  
 845811-79-2P 845811-80-5P 845811-82-7P  
 845811-83-8P 845811-85-0P 845811-86-1P  
 845811-87-2P 845811-89-4P 845811-90-7P  
 845811-91-8P 845811-92-9P 845811-93-0P  
 845811-94-1P 845811-95-2P 845811-96-3P  
 845811-97-4P 845811-99-6P 845812-01-3P  
 845812-03-5P 845812-05-7P 845812-07-9P  
 845812-09-1P 845812-11-5P 845812-13-7P  
 845812-15-9P 845812-17-1P 845812-19-3P  
 845812-21-7P 845812-25-1P 845812-27-3P

845812-29-5P 845812-31-9P 845812-32-0P  
 845812-33-1P 845812-34-2P 845812-35-3P  
 845812-37-5P 845812-39-7P 845812-40-0P  
 845812-42-2P 845812-43-3P 845812-44-4P  
 845812-45-5P 845812-46-6P 845812-47-7P  
 845812-48-8P 845812-50-2P 845812-52-4P  
 845812-53-5P 845812-54-6P 845812-55-7P  
 845812-57-9P 845812-58-0P 845812-59-1P  
 845812-60-4P 845812-62-6P 845812-63-7P  
 845812-64-8P 845812-65-9P 845812-67-1P  
 845812-68-2P 845812-69-3P 845812-71-7P  
 845812-72-8P 845812-74-0P 845812-75-1P  
 845812-76-2P 845812-78-4P 845812-79-5P  
 845812-80-8P 845812-81-9P 845812-82-0P  
 845812-83-1P 845812-84-2P 845812-87-5P  
 845812-88-6P 845812-89-7P 845812-91-1P  
 845812-92-2P 845812-93-3P 845812-94-4P  
 845812-95-5P 845812-98-8P 845812-99-9P  
 845813-00-5P 845813-02-7P 845813-03-8P  
 845813-04-9P 845813-06-1P 845813-07-2P  
 845813-09-4P 845813-10-7P 845813-11-8P  
 845813-12-9P 845813-13-0P 845813-14-1P  
 845813-15-2P 845813-16-3P 845813-17-4P  
 845813-18-5P 845813-19-6P 845813-20-9P  
 845813-21-0P 845813-22-1P 845813-23-2P  
 845813-26-5P 845813-27-6P 845813-28-7P  
 845813-30-1P 845813-31-2P 845813-32-3P  
 845813-33-4P 845813-34-5P 845813-35-6P  
 845813-36-7P 845813-37-8P 845813-38-9P  
 845813-39-0P 845813-41-4P 845813-42-5P  
 845813-43-6P 845813-44-7P 845813-45-8P  
 845813-46-9P 845813-47-0P 845813-48-1P  
 845813-49-2P 845813-50-5P 845813-51-6P  
 845813-52-7P 845813-53-8P 845813-54-9P  
 845813-55-0P 845813-56-1P 845813-57-2P  
 845813-58-3P 845813-59-4P 845813-60-7P  
 845813-61-8P 845813-62-9P 845813-63-0P  
 845813-64-1P 845813-65-2P 845813-68-5P  
 845813-70-9P 845813-72-1P 845813-74-3P  
 845813-77-6P 845813-78-7P 845813-80-1P  
 845813-81-2P 845813-82-3P 845813-83-4P  
 845813-84-5P 845813-85-6P 845813-86-7P  
 845813-87-8P 845813-88-9P 845813-89-0P  
 845813-90-3P 845813-91-4P 845813-92-5P  
 845813-93-6P 845813-94-7P 845813-95-8P  
 845813-96-9P 845813-97-0P 845813-98-1P  
 845813-99-2P 845814-00-8P 845814-01-9P  
 845814-02-0P 845814-03-1P 845814-04-2P  
 845814-05-3P 845814-06-4P 845814-07-5P  
 845814-08-6P 845814-09-7P 845814-10-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic  
 diseases, inflammatory and immune system disorders)

RN 761439-96-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[(1-methyl-1H-indol-4-yl)amino]-4-

pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 761439-98-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-03-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-04-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845811-05-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)-  
(CA INDEX NAME)




RN 845811-06-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-07-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-08-7 CAPLUS


CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-((methylamino)sulfonyl]phenyl)amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-

(CA INDEX NAME)




RN 845811-09-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-10-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-11-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-12-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-13-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-14-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-18-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-




methoxyphenyl)amino]-5-bromo-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA  
INDEX NAME)




RN 845811-19-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA  
INDEX NAME)



RN 845811-20-3 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA  
INDEX NAME)



RN 845811-21-4 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-

methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845811-22-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-23-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845811-24-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845811-25-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845811-26-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845811-27-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845811-29-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845811-31-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 845811-32-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 845811-33-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-34-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845811-48-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-49-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[[1,4'-bipiperidin]-1'-yl]-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845811-50-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[[1,4'-bipiperidin]-1'-yl]-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845811-51-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[[1,4'-bipiperidin]-1'-yl]-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845811-52-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-53-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-55-4 CAPLUS


CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845811-56-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-57-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-58-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




Absolute stereochemistry.



RN 845811-59-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-60-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-61-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-63-4 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-64-5 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-65-6 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(cyclopropylmethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-66-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(cyclobutylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-67-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[1-methylethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-68-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-3-ethoxyphenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 845811-70-3 CAPLUS


CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-  
(CA INDEX NAME)



RN 845811-73-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845811-74-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845811-75-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-76-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-77-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845811-79-2 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-80-5 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-4-[[2-[(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-82-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)phenyl]- (CA INDEX NAME)




RN 845811-83-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)phenyl]- (CA INDEX NAME)




RN 845811-85-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1,1-dimethylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-86-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1,1-dimethylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845811-87-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845811-89-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845811-90-7 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 845811-91-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-92-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-morpholinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-93-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-methyl-1-piperazinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-94-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[[2-(dimethylamino)ethyl]amino]-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-95-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(2-methoxyethoxy)-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-96-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(2-methoxyethoxy)-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-97-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[[2-(dimethylamino)ethyl]amino]-2-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-99-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-01-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-03-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-cyano-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-05-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-cyano-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-07-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-cyano-2-[[4-(4-morpholinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-09-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-11-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-13-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-cyano-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-15-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845812-17-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845812-19-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-morpholinyl)-2-propylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-21-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-cyano-2-[[4-(4-morpholinyl)-2-propylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-25-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-27-3 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845812-29-5 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845812-31-9 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845812-32-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-33-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845812-34-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-(2-methylpropoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-35-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-




pyrrolidinyl]-2-(2-methylpropoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845812-37-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(2-methylpropoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845812-39-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845812-40-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-

pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-42-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845812-43-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)propyl]amino]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845812-44-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-


methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845812-45-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-46-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-47-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845812-48-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845812-50-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-52-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-53-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3R)-1-methyl-3-pyrrolidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-54-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3R)-1-methyl-3-pyrrolidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-55-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3R)-1-methyl-3-pyrrolidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-57-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[[ (3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-58-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[[ (3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-59-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[[ (3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-60-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845812-62-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845812-63-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-64-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845812-65-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-67-1 CAPLUS




CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-68-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845812-69-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845812-71-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-72-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845812-74-0 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-75-1 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845812-76-2 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)-  
 (CA INDEX NAME)



RN 845812-78-4 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl-  
 (CA INDEX NAME)




RN 845812-79-5 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclobutyl-  
 (CA INDEX NAME)




RN 845812-80-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845812-81-9 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)





RN 845812-82-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 845812-83-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-  
[[ (cyclopropylmethyl) amino] sulfonyl] phenyl] amino]-2-pyrimidinyl] amino]-3-  
(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 845812-84-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-  
[(methylamino) sulfonyl] phenyl] amino]-2-pyrimidinyl] amino]-3-(1-  
methylethoxy)phenyl]- (CA INDEX NAME)




RN 845812-87-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-88-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-89-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845812-91-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl-  
(CA INDEX NAME)



RN 845812-92-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl-  
(CA INDEX NAME)



RN 845812-93-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl-  
(CA INDEX NAME)






RN 845812-94-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845812-95-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-98-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

NAME)




RN 845812-99-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845813-00-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845813-02-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-

dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-03-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-04-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-06-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

NAME)

PAGE 1-A




PAGE 2-A




RN 845813-07-2 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 845813-09-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-10-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[ (3R)-1-methyl-3-

pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-11-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-12-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-13-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-14-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-15-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-16-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845813-17-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-18-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-19-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)





RN 845813-20-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845813-21-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-22-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-23-2 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-26-5 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-27-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-28-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-30-1 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(cyclopropylmethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-31-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[ (3S)-1-methyl-3-pyrrolidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-32-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845813-33-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(cyclopropylmethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-34-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-35-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-36-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-37-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-38-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 845813-39-0 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[4-([1,4'-bipiperidin]-1'-ylcarbonyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-41-4 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-42-5 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-43-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-44-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-ethoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-45-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 845813-46-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-47-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 845813-48-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 845813-49-2 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-50-5 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845813-51-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[2-ethoxy-4-(4-ethyl-1-piperazinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-52-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-53-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-54-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-55-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[2-(dimethylamino)ethyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-56-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-57-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-ethoxyphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-58-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-59-4 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 845813-60-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845813-61-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[2-(diethylamino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-62-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-([1,4'-bipiperidin]-1'-ylcarbonyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-63-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-64-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-65-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-([1,4'-bipiperidin]-1'-ylcarbonyl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-68-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(cyclopropylmethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-70-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(cyclopropylmethoxy)phenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-72-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(4-methyl-1-




piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-74-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845813-77-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-78-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(1-methylpyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-80-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-81-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(1-(dimethylamino)pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-82-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[2-(ethylmethylanilino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-83-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-84-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-85-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(ethylmethylanino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-86-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(diethylamino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-87-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-88-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-89-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-90-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(1-pyrrolidinyloxy)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845813-91-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(diethylamino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845813-92-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845813-93-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845813-94-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(diethylamino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845813-95-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-96-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-97-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845813-98-1 CAPLUS

CN Acetamide, N-[1-[4-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)



RN 845813-99-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-00-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.






RN 845814-01-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[2-(dimethylamino)ethyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-02-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-03-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-ethoxyphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-04-2 CAPLUS

CN Acetamide, N-[1-[3-ethoxy-4-[[5-fluoro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]phenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 845814-05-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-06-4 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[2-[(2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 845814-07-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-fluoro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845814-08-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845814-09-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845814-10-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)



IT 845814-11-1P 845814-13-3P 845814-15-5P  
 845814-18-8P 845814-19-9P 845814-20-2P  
 845814-21-3P 845814-24-6P 845814-27-9P  
 845814-28-0P 845814-29-1P 845814-31-5P  
 845814-32-6P 845814-33-7P 845814-34-8P  
 845814-35-9P 845814-36-0P 845814-37-1P  
 845814-38-2P 845814-39-3P 845814-40-6P  
 845814-41-7P 845814-42-8P 845814-43-9P  
 845814-44-0P 845814-45-1P 845814-46-2P  
 845814-47-3P 845814-48-4P 845814-49-5P  
 845814-50-8P 845814-51-9P 845814-52-0P  
 845814-53-1P 845814-54-2P 845814-55-3P  
 845814-56-4P 845814-57-5P 845814-59-7P  
 845814-60-0P 845814-61-1P 845814-62-2P  
 845814-63-3P 845814-64-4P 845814-65-5P  
 845814-66-6P 845814-67-7P 845814-68-8P  
 845814-69-9P 845814-70-2P 845814-71-3P  
 845814-72-4P 845814-75-7P 845814-76-8P  
 845814-77-9P 845814-78-0P 845814-79-1P  
 845814-85-9P 845814-86-0P 845814-87-1P  
 845814-88-2P 845814-89-3P 845814-92-8P  
 845814-93-9P 845814-94-0P 845814-95-1P  
 845814-96-2P 845814-97-3P 845814-98-4P  
 845815-00-1P 845815-03-4P 845815-04-5P  
 845815-06-7P 845815-07-8P 845815-09-0P  
 845815-10-3P 845815-12-5P 845815-14-7P  
 845815-15-8P 845815-30-7P 845815-31-8P  
 845815-33-0P 845815-34-1P 845815-35-2P  
 845815-51-2P 845815-64-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)

RN 845814-11-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-13-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-15-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[ (3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-18-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 845814-19-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[ (3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 845814-20-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845814-21-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[ (3S)-1-methyl-3-


pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845814-24-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845814-27-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-28-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-29-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-31-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-5-methyl-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845814-32-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 845814-33-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-fluoro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-34-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845814-35-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)



RN 845814-36-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 845814-37-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 845814-38-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-39-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-phenoxyphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-40-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845814-41-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845814-42-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845814-43-9 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-44-0 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-45-1 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-46-2 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-47-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-48-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-49-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(tetrahydro-2H-1,2-oxazin-2-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-50-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-51-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-52-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-53-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-54-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-55-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845814-56-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845814-57-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)






RN 845814-59-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-60-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-61-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-62-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-63-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-64-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-65-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-66-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-67-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-68-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-69-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-70-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-71-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-72-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-75-7 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-76-8 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-77-9 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845814-78-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845814-79-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845814-85-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845814-86-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 845814-87-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)-  
(CA INDEX NAME)



RN 845814-88-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-89-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-92-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)






RN 845814-93-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845814-94-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845814-95-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 845814-96-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 845814-97-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[3-(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 845814-98-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[3-(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 845815-00-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-3-(1-methylethoxy)phenyl]-


(CA INDEX NAME)



RN 845815-03-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(trifluoromethyl)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl-


(CA INDEX NAME)



RN 845815-04-5 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(trifluoromethyl)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl-


(CA INDEX NAME)



RN 845815-06-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-07-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-09-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-cyano-4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-10-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-cyano-4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845815-12-5 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(2,2,2-trifluoroethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845815-14-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[4-(dimethylamino)-1-piperidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845815-15-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845815-30-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[4-[4-(dimethylamino)-1-piperidinyll]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845815-31-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 845815-33-0 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[4-(dimethylamino)-1-piperidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845815-34-1 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-

dimethyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 845815-35-2 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845815-51-2 CAPLUS




CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2,3-dihydro-2,2-dimethyl-7-benzofuranyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl-  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 845815-64-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)



10/507,060 (amended)

RE.CNT 19      THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 48 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:158646 CAPLUS

DN 142:254587

TI Methods for treating or preventing autoimmune diseases with  
2,4-pyrimidinediamine compounds

IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;  
Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 276 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016893	A2	20050224	WO 2004-US24716	20040730
	WO 2005016893	A3	20050609		
	W:	AE, AG, AL, AM, AT, AU, <del>AX</del> , BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004265288	A1	20050224	AU 2004-265288	20040730
	CA 2533377	A1	20050224	CA 2004-2533377	20040730
	US 20050209224	A1	20050922	US 2004-903870	20040730
	US 7122542	B2	20061017		
	US 20050234049	A1	20051020	US 2004-903263	20040730
	EP 1656372	A2	20060517	EP 2004-786150	20040730
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004013018	A	20061003	BR 2004-13018	20040730
	CN 1849318	A	20061018	CN 2004-80022235	20040730
	JP 2007500722	T	20070118	JP 2006-522105	20040730
	SG 145698	A1	20080929	SG 2008-5659	20040730
	KR 2006056353	A	20060524	KR 2006-701947	20060127
	MX 2006PA01099	A	20060920	MX 2006-PA1099	20060127
	IN 2006KN00449	A	20070622	IN 2006-KN449	20060227
	NO 2006000992	A	20060228	NO 2006-992	20060228
	US 20070167439	A1	20070719	US 2006-539147	20061005
	US 7452879	B2	20081118		
	US 20070225495	A1	20070927	US 2006-539520	20061006
PRAI	US 2003-491641P	P	20030730		
	US 2003-531598P	P	20031219		
	US 2004-572246P	P	20040518		
	US 2004-903263	A1	20040730		
	US 2004-903870	A1	20040730		
	WO 2004-US24716	W	20040730		

OS MARPAT 142:254587

AB The invention provides methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases.

Specific examples of autoimmune diseases that can be treated or prevented with the compds. include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosus and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.


IT 844434-19-1P 844434-20-4P 844434-21-5P  
 844434-27-1P 844435-00-3P 844435-01-4P  
 844435-02-5P 844435-03-6P 845817-88-1P  
 845817-89-2P 845817-90-5P 845817-91-6P  
 845817-93-8P 845817-94-9P 845818-73-7P  
 845820-86-2P 845820-87-3P 845820-88-4P  
 845820-89-5P 845820-90-8P 845820-91-9P  
 845820-92-0P 845820-93-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrimidinediamine compds. for treatment or prevention of autoimmune diseases)


RN 844434-19-1 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-20-4 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[(3,5-dimethylphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-21-5 CAPLUS

CN Benzamide, 2-chloro-4-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-27-1 CAPLUS

CN Benzenesulfonamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-2-methoxy-N-methyl- (CA INDEX NAME)




RN 844435-00-3 CAPLUS

CN Benzamide, 4-[[5-fluoro-2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 844435-01-4 CAPLUS

CN Benzamide, 4-[[2-[(3,5-dichloro-4-hydroxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 844435-02-5 CAPLUS

CN Benzamide, 4-[[2-[(3-chloro-4-methoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 844435-03-6 CAPLUS

CN Benzamide, 4,4'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis- (CA INDEX NAME)




RN 845817-88-1 CAPLUS

CN Benzamide, 2-chloro-5-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845817-89-2 CAPLUS

CN Benzamide, 2-chloro-5-[[5-fluoro-2-[[3-[2-(methyamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845817-90-5 CAPLUS

CN Benzamide, 2-chloro-4-[[4-[[4-chloro-3-[(methyamino)carbonyl]phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845817-91-6 CAPLUS

CN Benzamide, 2-chloro-5-[[5-fluoro-2-(1H-indol-6-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845817-93-8 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[[4-chloro-3-[(methylamino)carbonyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)







RN 845817-94-9 CAPLUS  
 CN Benzamide, 2-chloro-4-[[5-fluoro-2-(1H-indol-6-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845818-73-7 CAPLUS  
 CN 1H-Indole-1-acetamide, 6-[[4-[[3-chloro-4-[(methylamino)carbonyl]phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845820-86-2 CAPLUS  
 CN Glycine, N-[4-[[5-fluoro-2-[[3-(hydroxymethyl)phenyl]amino]-4-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-87-3 CAPLUS  
 CN Glycine, N-[4-[[2-[(3,5-dichloro-4-hydroxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-88-4 CAPLUS

CN Glycine, N-[4-[[2-[(3-chloro-4-hydroxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-89-5 CAPLUS

CN Glycine, N-[4-[[2-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-1,4-benzoxazin-6-yl)amino]-5-fluoro-4-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-90-8 CAPLUS

CN Glycine, N,N'-[(5-fluoro-2,4-pyrimidinediyl)bis(imino-4,1-phenylenecarbonyl)]bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 845820-91-9 CAPLUS

CN Glycine, N-[4-[[2-[[4-(aminocarbonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-92-0 CAPLUS

CN Benzamide, 4-[[2-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-1,4-benzoxazin-6-yl)amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 845820-93-1 CAPLUS

CN Glycine, N-[4-[[4-[[4-(aminocarbonyl)phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)




L7 ANSWER 49 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:136565 CAPLUS  
 DN 142:212327  
 TI 2,4-pyrimidinediamine compounds and uses as antiproliferative agents  
 IN Argade, Ankush; Singh, Rajinder; Li, Hui; Carroll, David; Catalano, Susan  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 179 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013996	A2	20050217	WO 2004-US25409	20040806
	WO 2005013996	A3	20050609		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050113398	A1	20050526	US 2004-913270	20040806
	EP 1663242	A2	20060607	EP 2004-780274	20040806
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2007501793	T	20070201	JP 2006-522744	20040806
	US 20070299060	A1	20071227	US 2006-567506	20061206
	US 20080009494	A1	20080110	US 2006-567276	20061206
	US 20080009484	A1	20080110	US 2006-567824	20061207
	US 20080021020	A1	20080124	US 2006-567817	20061207
	US 20080027045	A1	20080131	US 2006-567820	20061207
PRAI	US 2003-494008P	P	20030807		
	US 2004-572534P	P	20040518		
	US 2004-572507P	P	20040518		
	US 2004-580765P	P	20040618		
	US 2004-913270	A1	20040806		
	WO 2004-US25409	W	20040806		
	US 2004-628199P	P	20041115		
	US 2004-628496P	P	20041115		
	US 2005-650195P	P	20050203		
	US 2005-133419	A1	20050518		
OS	MARPAT 142:212327				
AB	The invention provides 2,4-pyrimidinediamine compds. having antiproliferative activity, compns. comprising the compds. and methods of using the compds. to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.				
IT	844434-19-1P 844434-20-4P 844434-21-5P 844434-27-1P 844435-00-3P 844435-01-4P 844435-02-5P 844435-03-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				

(pyrimidinediamine compds. and uses as antiproliferative agents for treatment of cancer)


RN 844434-19-1 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-20-4 CAPLUS

CN Benzamide, 2-chloro-4-[[2-[(3,5-dimethylphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-21-5 CAPLUS

CN Benzamide, 2-chloro-4-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 844434-27-1 CAPLUS

CN Benzenesulfonamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-2-methoxy-N-methyl- (CA INDEX NAME)




RN 844435-00-3 CAPLUS

CN Benzamide, 4-[[5-fluoro-2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 844435-01-4 CAPLUS

CN Benzamide, 4-[[2-[(3,5-dichloro-4-hydroxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 844435-02-5 CAPLUS

CN Benzamide, 4-[[2-[(3-chloro-4-methoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 844435-03-6 CAPLUS

CN Benzamide, 4,4'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis- (CA INDEX NAME)






L7 ANSWER 50 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:122890 CAPLUS  
 DN 142:219305  
 TI Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors  
 IN Freyne, Eddy Jean Edgard; Love, Christopher John; Coymans, Ludwig Paul; Vandermaesen, Nele; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan  
 PA Janssen Pharmaceutica N.V., Belg.  
 SO PCT Int. Appl., 124 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012307	A1	20050210	WO 2004-EP51455	20040712
	W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260738	A1	20050210	AU 2004-260738	20040712
	CA 2531333	A1	20050210	CA 2004-2531333	20040712
	EP 1658292	A1	20060524	EP 2004-766189	20040712
	EP 1658292	B1	20070815		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1823068	A	20060823	CN 2004-80020148	20040712
	BR 2004012596	A	20060919	BR 2004-12596	20040712
	AT 370142	T	20070915	AT 2004-766189	20040712
	ES 2290754	T3	20080216	ES 2004-766189	20040712
	NZ 545058	A	20080530	NZ 2004-545058	20040712
	MX 2006PA00540	A	20060330	MX 2006-PA540	20060113
	US 20060205721	A1	20060914	US 2006-564844	20060113
	IN 2006DN00265	A	20070810	IN 2006-DN265	20060116
	NO 2006000678	A	20060210	NO 2006-678	20060210
PRAI	WO 2003-EP50310	A	20030716		
	WO 2004-EP51455	W	20040712		
OS	CASREACT 142:219305; MARPAT 142:219305				
AB	The title compds. I [ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, etc.; X = a direct bond, (CH2)n or (CH2)mX1aX1b (n = 1-4; m = 1-2; X1a = O, C(O), NR5; X1b = a direct bond, alkyl); R2 = cycloalkyl, Ph, 4-7 membered monocyclic heterocycle containing at least one heteroatom. selected from O, S or N, benzoxazolyl, etc.; R3 = halo, OH, (un)substituted alkyl, alkenyl or alkynyl, etc.; R4 = H, halo, OH, (un)substituted alkyl, etc.; R5 = H, alkyl, alkenyl], useful for the prevention or the treatment of diseases mediated through GSK3, were prepared E.g., a 4-step synthesis of II which showed pIC50 of > 8 against GSK3β and against GSK3α, was given. The pharmaceutical composition comprising the compound I is disclosed.				

IT 840537-61-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of triazolopyrimidines as glycogen synthase kinase 3  
inhibitors)  
RN 840537-61-3 CAPLUS  
CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-5-nitro-4-  
pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 51 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:122889 CAPLUS  
 DN 142:219304  
 TI Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors  
 IN Freyne, Eddy Jean Edgard; Love, Christopher John; Cooymans, Ludwig Paul; Vandermaesen, Nele; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan  
 PA Janssen Pharmaceutica N.V., Belg.  
 SO PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012304	A2	20050210	WO 2004-EP51457	20040712
	WO 2005012304	A3	20070426		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA			
	AU 2004260739	A1	20050210	AU 2004-260739	20040712
	CA 2531232	A1	20050210	CA 2004-2531232	20040712
	CN 1938308	A	20070328	CN 2004-80020418	20040712
	EP 1781659	A2	20070509	EP 2004-766191	20040712
	EP 1781659	B1	20081105		
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK			
	JP 2007526894	T	20070920	JP 2006-519927	20040712
	AT 413404	T	20081115	AT 2004-766191	20040712
	US 20060183747	A1	20060817	US 2006-565065	20060117
	US 7449465	B2	20081111		
PRAI	WO 2003-EP50314	A	20030716		
	WO 2004-EP51457	W	20040712		
OS	CASREACT 142:219304; MARPAT 142:219304				
AB	The title compds. I [ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, etc.; X = a direct bond, (CH2)n or (CH2)mX1aX1b (n = 1-4; m = 1-2; X1a = O, C(O), NR5; X1b = a direct bond, alkyl); R2 = cycloalkyl, Ph, 4-7 membered monocyclic heterocycle containing at least one heteroatom. selected from O, S or N, benzoxazolyl, etc.; X2 = a direct bond, O, C(O), etc.; R3 = (un)substituted 5-6 membered monocyclic heterocyclyl or 9-10 membered bicyclic heterocyclyl, etc.; R4 = H, halo, OH, (un)substituted alkyl, etc.; R5 = H, alkyl, alkenyl], useful for the prevention or the treatment of diseases mediated through GSK3, were prepared E.g., a 4-step synthesis of II which showed pIC50 of > 8 against GSK3 $\beta$ and against GSK3 $\alpha$ , was given. The pharmaceutical composition comprising the compound I is disclosed.				
IT	521304-20-1				
	RL: RCT (Reactant); RACT (Reactant or reagent)				

(preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)

RN 521304-20-1 CAPLUS

CN Benzamide, 3-[[5-amino-2-[[3-(1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



L7 ANSWER 52 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:99485 CAPLUS  
 DN 142:198090  
 TI Preparation of 2-aminopyrimidines and 2-aminopyridine-4-carbamates for use  
 in the treatment of autoimmune diseases  
 IN Buchanan, John L.; Elbaum, Daniel; Martin, Matthew W.; McGowan, David C.;  
 Novak, Perry M.; Nunes, Joseph J.  
 PA Amgen Inc., USA  
 SO PCT Int. Appl., 267 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009978	A1	20050203	WO 2004-US23233	20040715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 7442698	B2	20081028	US 2004-891636	20040713
	US 20050026914	A1	20050203		
	AU 2004259737	A1	20050203	AU 2004-259737	20040715
	CA 2532980	A1	20050203	CA 2004-2532980	20040715
	EP 1654238	A1	20060510	EP 2004-778640	20040715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007516212	T	20070621	JP 2006-521176	20040715
	MX 2006PA00829	A	20060407	MX 2006-PA829	20060120
PRAI	US 2003-490220P	P	20030724		
	US 2004-891636	A	20040713		
	WO 2004-US23233	W	20040715		
OS	CASREACT 142:198090; MARPAT 142:198090				
AB	Pyrimidine or pyridine carbamates I [wherein X, Y = N or CH, provided that at least one of X and Y is CH; R1 - R3 = certain (un)substituted alkyl, monocyclic or bicyclic ring; or pharmaceutically acceptable salts thereof] were prepared For example, substitution of 2,4-dichloropyrimidine at the C4 with benzylamine followed by acylation of the resultant secondary amine with 2,6-Dimethylphenyl chloroformate, and subsequent amination at the C2 with 4-(2-dimethylaminoethoxy)phenylamine afforded II. Representative compds. I exhibited inhibition with IC50 values of ≤10 μM in the LCK-homogeneous time resolved fluorescent kinase assay and other assays. Therefore, I and pharmaceutical compns. thereof are active protein kinase inhibitors and T cell activation inhibitors, and are useful in the prophylaxis and treatment of many diseases such as autoimmune and hyperproliferative disorders.				
IT	835649-17-7P, 2,6-Dimethylphenyl N-[2-[[3,4-bis(methyloxy)-5-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-(methylpropyl)amino]carbonyl]phenyl]carbamate 835649-18-8P,				

2,6-Dimethylphenyl N-[2-[[3-fluoro-4-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-methylpropyl)amino]carbonyl]phenyl]carbamate 835649-19-9P,

2,6-Dimethylphenyl N-[2-[[3-fluoro-4-[[3-(1-piperidinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-methylpropyl)amino]carbonyl]phenyl]carbamate 835649-20-2P,

2,6-Dimethylphenyl N-[2-[[3-fluoro-4-[[2-[4-(1-methylethyl)-1-piperazinyl]ethyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-methylpropyl)amino]carbonyl]phenyl]carbamate


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines and pyridinecarbamates for use in treatment of autoimmune diseases)


RN 835649-17-7 CAPLUS

CN Carbamic acid, [2-[[3,4-dimethoxy-5-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 835649-18-8 CAPLUS

CN Carbamic acid, [2-[[3-fluoro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)




RN 835649-19-9 CAPLUS

CN Carbamic acid, [2-[[3-fluoro-4-[3-(1-piperidiny)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-(1-methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 835649-20-2 CAPLUS

CN Carbamic acid, [2-[[3-fluoro-4-[2-[4-(1-methylethyl)-1-piperazinyl]ethoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-(1-methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 53 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:99357 CAPLUS  
 DN 142:198088  
 TI Preparation of pyrimidinecarboxamides, pyrimidinylcarbamates and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases  
 IN Nunes, Joseph J.; Zhu, Xiaotian; Amouzegh, Patricia; Ghiron, Chiara; Johnston, David N.; Power, Eoin Christopher  
 PA Amgen Inc., USA  
 SO PCT Int. Appl., 462 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009443	A1	20050203	WO 2004-US20243	20040624
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050209221	A1	20050922	US 2004-875896	20040623
	AU 2004258862	A1	20050203	AU 2004-258862	20040624
	CA 2529734	A1	20050203	CA 2004-2529734	20040624
	EP 1648464	A1	20060426	EP 2004-777011	20040624
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-482375P	P	20030624		
	US 2004-875896	A	20040623		
	WO 2004-US20243	W	20040624		
OS	MARPAT 142:198088				
AB	Pyrimidine and pyridine carboxamides I [wherein X = N or CH; Y = NH, O or S; R1 - R3 = certain (un)substituted monocyclic or bicyclic ring; or pharmaceutically acceptable salts thereof] as well as pyrimidinylcarbamates were prepared as inhibitors of T cell activation. For example, 2,4-dichloropyrimidine-5-carbonyl chloride, obtained by globally chlorination of uracil-5-carboxylic acid monohydrate with POCl <sub>3</sub> in POC13, underwent amidation with 2,6-dimethylaniline, followed by etherification with 3-chlorophenol and subsequent amination with 3-fluoro-4-(3-(4-methyl-1-piperazinyl)propoxy)aniline to give pyrimidinecarboxamide II. Representative compds. I exhibited inhibition with IC <sub>50</sub> values of <10 µM in the LCK-homogeneous time resolved fluorescent kinase assay. Therefore, I and pharmaceutical compns. thereof are useful in the treatment of many diseases such as inflammation.				
IT	835649-17-7P, 2,6-Dimethylphenyl N-[2-[[3,4-bis(methyloxy)-5-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-(methylpropyl)amino]carbonyl]phenyl]carbamate 835649-18-8P, 2,6-Dimethylphenyl N-[2-[[3-fluoro-4-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-				

methylpropyl)amino]carbonyl]phenyl]carbamate 835649-19-9P,  
 2,6-Dimethylphenyl N-[2-[[3-fluoro-4-[[3-(1-  
 piperidinyl)propyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-  
 methylpropyl)amino]carbonyl]phenyl]carbamate 835649-20-2P,  
 2,6-Dimethylphenyl N-[2-[[3-fluoro-4-[[2-[4-(1-methylethyl)-1-  
 piperazinyl]ethyl]oxy]phenyl]amino]-4-pyrimidinyl][2-(methyloxy)-4-[[1-  
 methylpropyl)amino]carbonyl]phenyl]carbamate


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(inhibitor; preparation of pyrimidinecarboxamides and pyrimidinylcarbamates  
 as inhibitors of T cell activation for treatment of inflammatory  
 diseases)


RN 835649-17-7 CAPLUS

CN Carbamic acid, [2-[[3,4-dimethoxy-5-[3-(4-methyl-1-  
 piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-  
 methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA  
 INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 835649-18-8 CAPLUS

CN Carbamic acid, [2-[[3-fluoro-4-[3-(4-methyl-1-  
 piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-  
 methylpropyl)amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA  
 INDEX NAME)




RN 835649-19-9 CAPLUS

CN Carbamic acid, [2-[[3-fluoro-4-[3-(1-piperidiny)propoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-methylpropyl]amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 835649-20-2 CAPLUS


CN Carbamic acid, [2-[[3-fluoro-4-[2-[4-(1-methylethyl)-1-piperazinyl]ethoxy]phenyl]amino]-4-pyrimidinyl][2-methoxy-4-[[1-methylpropyl]amino]carbonyl]phenyl]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 54 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:1124981 CAPLUS  
 DN 142:232330  
 TI Pyrimidine containing RSV fusion inhibitors  
 AU Nikitenko, Antonia; Raifeld, Yuri; Mitsner, Boris; Newman, Howard  
 CS Chemical and Screening Sciences, Wyeth Research, Pearl River, NY, 10965, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(2), 427-430  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 142:232330  
 AB The knowledge of SAR in a series of biphenyl anionic RSV inhibitors has been broadened by synthesis and testing of analogs with pyrimidine linkers. Generally, pyrimidine compds. were much harder to synthesize, and their anti-RSV activity was lower in comparison with triazine analogs.  
 IT 844642-00-8P 844657-43-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (pyrimidine containing respiratory syncytial virus fusion inhibitors)  
 RN 844642-00-8 CAPLUS  
 CN [1,1'-Biphenyl]-2,2'-disulfonic acid, 4,4'-bis[[2,6-bis[[3-[[bis(2-hydroxyethyl)amino]sulfonyl]phenyl]amino]-4-pyrimidinyl]amino]-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B




RN 844657-43-8 CAPLUS

CN [1,1'-Biphenyl]-2,2'-disulfonic acid,  
 4-[[2,6-bis[[3-[[bis(2-amino-2-oxoethyl)amino]sulfonyl]phenyl]amino]-4-pyrimidinyl]amino]-4'-[[2(or 6)-[[3-[[bis(2-amino-2-oxoethyl)amino]sulfonyl]phenyl]amino]-6(or 2)-chloro-4-pyrimidinyl]amino]-  
 (9CI) (CA INDEX NAME)

PAGE 1-A




—NH<sub>2</sub>




D1-C1

IT 844641-98-1P  
 RL: PNU (Preparation, unclassified); PREP (Preparation)  
 (pyrimidine containing respiratory syncytial virus fusion inhibitors)  
 RN 844641-98-1 CAPLUS  
 CN [1,1'-Biphenyl]-2,2'-disulfonic acid,  
 4,4'-bis[[2,6-bis[[3-[[bis(2-amino-2-oxoethyl)amino]sulfonyl]phenyl]amino]-  
 4-pyrimidinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



IT 844641-97-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (pyrimidine containing respiratory syncytial virus fusion inhibitors)  
 RN 844641-97-0 CAPLUS  
 CN Acetamide, 2,2',2'',2'''-[(6-chloro-2,4-pyrimidinediyl)bis(imino-3,1-  
 phenylenesulfonylnitrilo)]tetrakis- (9CI) (CA INDEX NAME)





RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 55 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:780679 CAPLUS  
 DN 141:296041

TI Preparation of novel 2,4-di(phenylamino)pyrimidines useful in the  
 treatment of neoplastic diseases, inflammatory and immune system disorders  
 IN Garcia-Echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya,  
 Keiichi; Matsuura, Naoko; Miyake, Takahiro; Imori, Osamu; Umemura, Ichiro  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 SO PCT Int. Appl., 185 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 2


common inventors

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080980	A1	20040923	WO 2004-EP2616	20040312
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004220338	A1	20040923	AU 2004-220338	20040312
	AU 2004220338	B2	20081009		
	CA 2518932	A1	20040923	CA 2004-2518932	20040312
	EP 1606265	A1	20051221	EP 2004-719989	20040312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008347	A	20060321	BR 2004-8347	20040312
	CN 1788001	A	20060614	CN 2004-80013041	20040312
	JP 2006520354	T	20060907	JP 2006-504673	20040312
	IN 2005CN02241	A	20070831	IN 2005-CN2241	20050913
	NO 2005004726	A	20051208	NO 2005-4726	20051013
	US 20060247241	A1	20061102	US 2006-549250	20060518
PRAI	GB 2003-5929	A	20030314		
	GB 2003-19227	A	20030815		
	GB 2003-22370	A	20030924		
	WO 2004-EP2616	A	20040312		

OS MARPAT 141:296041

AB The title pyrimidine derivs. I [R0-R3 = H, alkyl, aryl, etc.; or R0 and R1, R1 and R2, and/or R2 and R3 form, together with the carbon atoms to which they are attached, 5-6 membered carbocyclic or heterocyclic ring comprising 0-3 heteroatoms selected from N, O and S; R4 = H, alkyl; R5, R6 = H, alkyl, alkoxyalkyl, halo, etc.; R7-R10 = alkyl, cycloalkyl, aryl, etc.; or R7 and R8, R8 and R9, and/or R9 and R10 form, together with the carbon atoms to which they are attached, 5-6 membered carbocyclic or heterocyclic ring comprising 0-3 heteroatoms selected from N, O and S; A = C, N], useful as FAK or/and IGF-1 receptor inhibitors in the treatment of neoplastic diseases, inflammatory and immune system disorders, were prepared and formulated. E.g., a 2-step synthesis of II from 2,4-dichloro-5-nitropyrimidine, 2-amino-N-methylbenzenesulfonamide, and 2,5-dimethoxyaniline which showed IC50 of 140 nM in FAK assay, was given.

IT The pharmaceutical composition comprising the compound I is claimed.  
 761436-62-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor inhibitors useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)  
 RN 761436-62-8 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



IT 761436-42-4P 761436-43-5P 761436-44-6P  
 761436-45-7P 761436-46-8P 761436-47-9P  
 761436-48-0P 761436-49-1P 761436-50-4P  
 761436-51-5P 761436-52-6P 761436-53-7P  
 761436-54-8P 761436-55-9P 761436-56-0P  
 761436-57-1P 761436-58-2P 761436-59-3P  
 761436-60-6P 761436-61-7P 761436-63-9P  
 761436-64-0P 761436-65-1P 761436-66-2P  
 761436-67-3P 761436-68-4P 761436-69-5P  
 761436-70-8P 761436-71-9P 761436-72-0P  
 761436-73-1P 761436-74-2P 761436-75-3P  
 761436-76-4P 761436-77-5P 761436-78-6P  
 761436-79-7P 761436-80-0P 761436-81-1P  
 761436-82-2P 761436-83-3P 761436-84-4P  
 761436-85-5P 761436-86-6P 761436-87-7P  
 761436-88-8P 761436-89-9P 761436-90-2P  
 761436-91-3P 761436-93-5P 761436-94-6P  
 761436-95-7P 761436-96-8P 761436-97-9P  
 761436-98-0P 761436-99-1P 761437-00-7P  
 761437-01-8P 761437-02-9P 761437-03-0P  
 761437-04-1P 761437-05-2P 761437-06-3P  
 761437-07-4P 761437-08-5P 761437-09-6P  
 761437-10-9P 761437-11-0P 761437-12-1P  
 761437-13-2P 761437-14-3P 761437-15-4P  
 761437-16-5P 761437-17-6P 761437-18-7P  
 761437-19-8P 761437-20-1P 761437-21-2P  
 761437-22-3P 761437-23-4P 761437-24-5P  
 761437-25-6P 761437-26-7P 761437-27-8P  
 761437-28-9P 761437-29-0P 761437-30-3P  
 761437-31-4P 761437-32-5P 761437-33-6P  
 761437-34-7P 761437-35-8P 761437-36-9P  
 761437-37-0P 761437-39-2P 761437-40-5P  
 761437-41-6P 761437-42-7P 761437-43-8P  
 761437-44-9P 761437-45-0P 761437-46-1P


761437-47-2P 761437-48-3P 761437-49-4P  
 761437-50-7P 761437-51-8P 761437-52-9P  
 761437-53-0P 761437-54-1P 761437-55-2P  
 761437-56-3P 761437-57-4P 761437-58-5P  
 761437-59-6P 761437-60-9P 761437-61-0P  
 761437-62-1P 761437-63-2P 761437-64-3P  
 761437-65-4P 761437-66-5P 761437-67-6P  
 761437-68-7P 761437-69-8P 761437-70-1P  
 761437-71-2P 761437-72-3P 761437-73-4P  
 761437-74-5P 761437-75-6P 761437-76-7P  
 761437-84-7P 761437-85-8P 761437-86-9P  
 761437-88-1P 761437-91-6P 761437-92-7P  
 761437-93-8P 761437-94-9P 761437-95-0P  
 761437-96-1P 761437-97-2P 761437-99-4P  
 761438-00-0P 761438-01-1P 761438-02-2P  
 761438-03-3P 761438-04-4P 761438-05-5P  
 761438-06-6P 761438-07-7P 761438-08-8P  
 761438-09-9P 761438-10-2P 761438-11-3P  
 761438-12-4P 761438-13-5P 761438-14-6P  
 761438-15-7P 761438-16-8P 761438-17-9P  
 761438-18-0P 761438-19-1P 761438-20-4P  
 761438-21-5P 761438-22-6P 761438-23-7P  
 761438-24-8P 761438-25-9P 761438-26-0P  
 761438-27-1P 761438-28-2P 761438-29-3P  
 761438-30-6P 761438-31-7P 761438-32-8P  
 761438-33-9P 761438-34-0P 761438-35-1P  
 761438-36-2P 761438-37-3P 761438-38-4P  
 761438-39-5P 761438-40-8P 761438-41-9P  
 761438-42-0P 761438-43-1P 761438-44-2P  
 761438-45-3P 761438-46-4P 761438-47-5P  
 761438-48-6P 761438-49-7P 761438-50-0P  
 761438-51-1P 761438-52-2P 761438-53-3P  
 761438-54-4P 761438-55-5P 761438-56-6P  
 761438-57-7P 761438-58-8P 761438-59-9P  
 761438-60-2P 761438-61-3P 761438-62-4P  
 761438-63-5P 761438-64-6P 761438-65-7P  
 761438-66-8P 761438-67-9P 761438-68-0P  
 761438-69-1P 761438-70-4P 761438-71-5P  
 761438-72-6P 761438-73-7P 761438-74-8P  
 761438-75-9P 761438-76-0P 761438-77-1P  
 761438-78-2P 761438-79-3P 761438-80-6P  
 761438-81-7P 761438-82-8P 761438-83-9P  
 761438-84-0P 761438-85-1P 761438-86-2P  
 761438-87-3P 761438-88-4P 761439-95-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor  
 inhibitors useful in the treatment of neoplastic diseases, inflammatory  
 and immune system disorders)


RN 761436-42-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(2,5-dimethoxyphenyl)amino]-5-nitro-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-43-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-44-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,2-difluoro-1,3-benzodioxol-4-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-45-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-46-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-methoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-47-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-fluoro-4-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-48-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-4-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-49-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-50-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-51-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(methylamino)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-52-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-53-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-butylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-54-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-(1H-indol-4-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761436-55-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3-dihydro-1H-inden-4-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-56-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-(1H-indazol-7-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-57-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-58-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-59-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-60-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4,5-dimethoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-61-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-methylethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-63-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-64-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-65-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-cyclohexyl-4-methyl- (CA INDEX NAME)




RN 761436-66-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-piperazinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-67-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-68-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-69-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-70-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(3'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-71-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-ethoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-72-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-ethoxy-4'-methoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-73-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-74-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-75-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-76-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-77-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-78-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-difluorophenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-79-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-chloro-4-fluorophenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-80-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-chloro-5-fluorophenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-81-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761436-82-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-cyano-1-piperidiny)]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-83-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-thiomorpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-84-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[bis(2-methoxyethyl)amino]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-85-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-  
[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
(CA INDEX NAME)




RN 761436-86-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(1,1-dioxido-4-thiomorpholinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-87-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[1-[3-(4-morpholinyl)propyl]-1H-indol-4-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-88-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-89-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-90-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(1H-imidazol-1-yl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-91-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-93-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(2-hydroxyethyl)propylamino]-2-methylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-94-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-chloro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-95-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[3-(dimethylamino)-2-methylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-96-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-97-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-diethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-98-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4,4'-dimethoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-99-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-00-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-01-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-02-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(2-hydroxyethoxy)-5-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-03-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-ethoxy-5-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-04-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-methoxy-2-(1-methylethoxy)phenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-05-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-methoxy-2-propoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-06-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(dimethylamino)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-07-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-08-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(3-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761437-09-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(2-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-10-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761437-11-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-12-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-13-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-4-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-14-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-15-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-16-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[(1-acetyl-4-piperidinyloxy]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-17-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-[(1-acetyl-4-piperidinyloxy]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-18-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(1-methyl-4-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-19-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-difluorophenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-20-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-piperidinylloxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-21-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-piperidinylloxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-22-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-23-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-24-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-25-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(2-methyl-1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-26-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-27-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,2-difluoro-1,3-benzodioxol-4-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-29-0 CAPLUS

CN Benzamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-30-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761437-31-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-32-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-33-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-34-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-35-8 CAPLUS


CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761437-36-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-hydroxy-1-piperidiny)]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-37-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(2-ethoxyethoxy)-1-piperidiny]]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-39-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(2-methoxyethoxy)-1-piperidiny]]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-40-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-41-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-42-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 761437-43-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-44-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-45-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-46-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-47-2 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-  
[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 761437-48-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-49-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-

piperidiny]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-50-7 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-51-8 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-52-9 CAPLUS

CN Benzamide, 2-[[[5-chloro-2-[[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-53-0 CAPLUS


CN Benzamide, 2-[[2-[[5-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-54-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761437-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-56-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-(1H-indol-4-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-57-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(1-methyl-1H-indol-4-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-58-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[1-methyl-7-(4-morpholinyl)-1H-indol-4-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-59-6 CAPLUS

CN Benzamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)







RN 761437-60-9 CAPLUS  
 CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-61-0 CAPLUS  
 CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-62-1 CAPLUS  
 CN Benzamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-63-2 CAPLUS  
 CN Benzamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-64-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-65-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-66-5 CAPLUS


CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

10/507,060 (amended)




RN 761437-67-6 CAPLUS  
CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761437-68-7 CAPLUS  
CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

NAME)




RN 761437-69-8 CAPLUS

CN Benzamide, 2-[[2-[[5-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-70-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-71-2 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-72-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,6-dimethyl- (CA INDEX NAME)




RN 761437-73-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-74-5 CAPLUS

CN Benzamide, 2-[[2-[[4-(1,4'-bipiperidin-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-75-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(1-methyl-1H-indol-4-yl)amino]-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-76-7 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 761437-84-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 761437-85-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761437-86-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-4,5-difluoro-N-methyl- (CA INDEX NAME)




RN 761437-88-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-5-fluoro- (CA INDEX NAME)




RN 761437-91-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)-  
(CA INDEX NAME)



RN 761437-92-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)-  
(CA INDEX NAME)






RN 761437-93-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 761437-94-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)




RN 761437-95-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 761437-96-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-5-methoxy-N-methyl- (CA INDEX NAME)




RN 761437-97-2 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-99-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 761438-00-0 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl-5-(4-morpholinyl)- (CA INDEX NAME)




RN 761438-01-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-02-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-03-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-04-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-05-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-06-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-07-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-08-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-09-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-10-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-11-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-12-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-13-5 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[1-(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)



RN 761438-14-6 CAPLUS


CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 761438-15-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 761438-16-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 761438-17-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-2-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-18-0 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N,N-diethyl- (CA INDEX NAME)






RN 761438-19-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-20-4 CAPLUS

CN Benzenesulfonamide, 2-[[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-21-5 CAPLUS

CN Benzenesulfonamide, 2-[[[5-chloro-2-[[3-fluoro-2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-22-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3-hydroxy-2,2-dimethylpropyl)amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-23-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(2-hydroxy-1,1-dimethylethyl)amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-24-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-25-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-26-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-27-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-28-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-29-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)



RN 761438-30-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)



RN 761438-31-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 761438-32-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)amino]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-33-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-34-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-35-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-36-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(difluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-37-3 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 761438-38-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-39-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-methylpiperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-40-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-41-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[1-[3-(4-methyl-1-piperazinyl)propyl]-1H-indol-4-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-42-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[1-[3-(4-morpholinyl)propyl]-1H-indol-4-yl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-43-1 CAPLUS




CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-44-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-dimethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-45-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-dimethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-46-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-47-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
(CA INDEX NAME)




RN 761438-48-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-  
(CA INDEX NAME)




RN 761438-49-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-50-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-51-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-(4-hydroxy-1-piperidinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-52-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-53-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-

morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-54-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-55-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-56-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-57-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-58-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-59-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-60-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-61-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-62-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-63-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-64-6 CAPLUS

CN	Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl)amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl-	(CA INDEX NAME)
----	--	-----------------




RN 761438-65-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-66-8 CAPLUS

CN	Benzenesulfonamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl-	(CA INDEX NAME)
----	---	-----------------




RN 761438-67-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4,5-dimethoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-68-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 761438-69-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-70-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)







RN 761438-71-5 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 761438-72-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-73-7 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-74-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-75-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-76-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-77-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-78-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-79-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-80-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-81-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-82-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-83-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-84-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 761438-85-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 761438-86-2 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(cyclobutylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 761438-87-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 761438-88-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)



RN 761439-95-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




IT 761439-96-7P 761439-98-9P 761439-99-0P  
761441-29-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor inhibitors useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)


RN 761439-96-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(1-methyl-1H-indol-4-yl)amino]-4-pyrimidinyl]amino]-N-methyl-5-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 761439-98-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 761439-99-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)



RN 761441-29-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(methylanino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)






RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 56 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:718507 CAPLUS  
 DN 141:243557  
 TI Preparation of pyrimidine derivatives as Polo-like kinases inhibitors for  
 treatment of cancers  
 IN Davis-Ward, Ronda; Mook, Robert Anthony, Jr.; Neeb, Michael J.; Salovich,  
 James M.  
 PA SmithKline Beecham Corporation, USA  
 SO PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004074244	A2	20040902	WO 2004-US4197	20040211
	WO 2004074244	A3	20041111		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP	1597251	A2	20051123	EP 2004-710264	20040211
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP	2006518386	T	20060810	JP 2006-503537	20040211
US	20070010668	A1	20070111	US 2005-545352	20050811
PRAI	US 2003-448795P	P	20030220	102(e) date Claims are NOT entitle to the foreign priority date	
	WO 2004-US4197	W	20040211		
OS	MARPAT 141:243557				
AB	Title compds. represented by the formula I [wherein R1 = H, halo, alkyl, alkenyl, alkynyl; R2 = halo, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, etc.; R3 = independently H or alkyl; R4 = independently halo, (cyclo)alkyl, (cyclo)alkenyl, NO2, etc.; R5 = independently alkyl, alkenyl, amino, etc.; Y = carbonylalkyl, amino, sulfonyl, etc.; m = 0-3; n = 0-5; and pharmaceutically acceptable salts, solvates or physiol. functional derivs. thereof] were prepared as Polo-like kinases (PLK) inhibitors. For example, reaction of 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzamide with 3,4,5-trimethoxyaniline gave II•HCl in 35% yield. I were tested for inhibition of PLK1 and methylene blue growth. Thus, I and their pharmaceutical compns. are useful for the treatment of PLK-mediated conditions and a susceptible neoplasm, such as breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma (no data).				
IT	748797-69-5P 748797-71-9P 748797-79-7P 748798-07-4P 748798-15-4P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidine derivs. as Polo-like kinases inhibitors for treatment of cancers)				
RN	748797-69-5 CAPLUS				
CN	Benzamide, 2-[[5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]-4-				


pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 748797-71-9 CAPLUS


CN Benzamide, N-(1,1-dimethylethyl)-2-[[5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 748797-79-7 CAPLUS


CN Benzamide, 2-[[2-[[4-(acetylamino)phenyl]amino]-5-nitro-4-pyrimidinyl]amino]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 748798-07-4 CAPLUS


CN Benzamide, N-cyclohexyl-2-[[5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 748798-15-4 CAPLUS

CN Benzamide, 2-[[5-acetyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



IT 748798-16-5  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of pyrimidine derivs. as Polo-like kinases inhibitors for  
 treatment of cancers)  
 RN 748798-16-5 CAPLUS  
 CN Benzamide, 2-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-  
 pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



102(e) compound

L7 ANSWER 57 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:675730 CAPLUS  
 DN 141:207218  
 TI Pyrimidine derivatives for the prevention of HIV infection  
 IN Janssen, Paul Adriaan Jan; Heeres, Jan; Lewi, Paulus Joannes; De Jonge, Marc Rene; Koymans, Lucien Maria Henricus; Daeyaert, Frederik Frans Desire; Vinkers, Hendrik Maarten  
 PA Janssen Pharmaceutica N.V., Belg.; Arts, Theodora Joanna Francisca; Janssen, Graziella Maria Constantina; Janssen, Herwig Josephus Margareta; Janssen, Jasmine Josee Werner; Janssen, Paul Peter Maria; Janssen, Maroussia Godelieve Frank; Guillemont, Jerome Emile Georges; Pasquier, Elisabeth Therese Jeanne  
 SO PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004069812	A1	20040819	WO 2004-EP1011	20040204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210081	A1	20040819	AU 2004-210081	20040204
CA 2513527	A1	20040819	CA 2004-2513527	20040204
EP 1597237	A1	20051123	EP 2004-707937	20040204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007329	A	20060110	BR 2004-7329	20040204
CN 1747937	A	20060315	CN 2004-80003460	20040204
JP 2006516591	T	20060706	JP 2006-501729	20040204
IN 2005DN02821	A	20070316	IN 2005-DN2821	20050624
US 20070021449	A1	20070125	US 2005-544735	20050805
NO 2005004143	A	20050906	NO 2005-4143	20050906
PRAI WO 2003-EP1291	A	20030207		
WO 2004-EP1011	A	20040204		

OS MARPAT 141:207218

AB This invention concerns the use of a compound I [a1:a2a3:a4, b1:b2b3:b4 = atoms to form Ph, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl rings; n = 0-5; m = 1-4; R1 = H, aryl, CHO, alkylcarbonyl, alkyl, alkyloxycarbonyl, alkylcarbonyl, etc.; R2 = OH, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, carboxyl, CN, NO2, NH2, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, SOpR6, NHSOpR6, COR6, NHCOH, CONHNH2, NHCOR6, C(:NH)R6, 5-membered heterocycle; X1 = NR5, NHNH, N:N, O, CO, alkanediyl, CH(OH), S, SOp, X2-alkanediyl, alkanediyl-X2; X2 = NR5, NHNH, N:N, O, CO, CH(OH), S, SOp; R3 = NHR13, NR13R14, CONHR13, CONR13R14, COR15, CH:NNHCOR16, substituted alkyl, (substituted) alkoxyalkyl, substituted alkenyl, alkynyl, alkyl substituted with OH and a second substituent, C(:NOR8)-alkyl, R7, X3R7; R4 = halo, OH, alkyl, cycloalkyl, alkoxy, CN, NO2, polyhaloalkyl, polyhaloalkoxy, aminocarbonyl, alkyloxycarbonyl, alkylcarbonyl, CHO, NH2; R5 = H, aryl, CHO, alkylcarbonyl, alkyl, alkoxycarbonyl, etc.; R6 = alkyl, amino,


polyhaloalkyl; R7 = mono-, bi-, or tricyclic (aromatic) carbocyclyl, heterocyclyl; R13, R14 = alkyl, alkenyl, alkynyl optionally substituted by cyano, aminocarbonyl; R15 = cyanoalkyl, aminocarbonylalkyl; R16 = R15, R7; p = 1, 2] for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, and pharmaceutical compns. comprising them. Preparation of compds. I is disclosed and described in WO 2003/016306. A 2-step synthesis of novel compound I, (E)-4-({4-[4-(2-cyanoethenyl)-2,6-dimethylphenoxy]-2-pyrimidinyl}amino)benzonitrile, starting from 4-hydroxy-3,5-dimethylbenzaldehyde and 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile, which showed pIC50 of 9.00 when tested for anti-HIV properties, was given.

IT 500288-32-4 500290-33-5 500290-35-7  
500290-37-9 500290-39-1 500290-41-5  
500290-43-7 500290-45-9 500290-47-1  
500290-49-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(pyrimidine derivs. for the prevention of HIV infection)


RN 500288-32-4 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-33-5 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N,3,5-tetramethyl- (CA INDEX NAME)



RN 500290-35-7 CAPLUS


CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-N,3,5-trimethyl- (CA INDEX NAME)



RN 500290-37-9 CAPLUS


CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N-diethyl-3,5-dimethyl- (CA INDEX NAME)






RN 500290-39-1 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-41-5 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 500290-43-7 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-45-9 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-2-propyn-1-yl- (CA INDEX NAME)




RN 500290-47-1 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-2-propen-1-yl- (CA INDEX NAME)



RN 500290-49-3 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



L7 ANSWER 58 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:486399 CAPLUS

DN 141:54353

TI Pharmaceutical compositions comprising a surfactant and a physiologically tolerable water-soluble acid respectively base, and a basic respectively acidic drug compound, containing a pyrimidine unit, for treating HIV

IN Vandecruys, Roger Petrus Gerebern

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050068	A1	20040617	WO 2002-EP13558	20021129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002350719	A1	20040623	AU 2002-350719	20021129
	CA 2505742	A1	20040617	CA 2003-2505742	20031125
	WO 2004050058	A2	20040617	WO 2003-EP50890	20031125
	WO 2004050058	A3	20040930		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003294038	A1	20040623	AU 2003-294038	20031125
	EP 1567134	A2	20050831	EP 2003-789453	20031125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016532	A	20051004	BR 2003-16532	20031125
	CN 1720027	A	20060111	CN 2003-80104619	20031125
	JP 2006514635	T	20060511	JP 2004-556332	20031125
	NZ 540846	A	20080328	NZ 2003-540846	20031125
	IN 2005DN02185	A	20070302	IN 2005-DN2185	20050524
	US 20060078609	A1	20060413	US 2005-536542	20050526
	ZA 2005004312	A	20060726	ZA 2005-4312	20050526
	MX 2005PA05709	A	20050816	MX 2005-PA5709	20050527
	NO 2005003143	A	20050627	NO 2005-3143	20050627
PRAI	WO 2002-EP13558	A	20021129		
	WO 2003-EP50890	W	20031125		
AB	The invention provides a novel pharmaceutical composition for treating HIV comprising a basic resp. acidic drug compound I, a surfactant and a physiol.				

tolerable water-soluble acid resp. base in which the acid resp. base:drug compound ratio is at least 1:1 by weight [wherein X = O, NH; Y = NH, NMe; R1 = Me, H; R2 = Me, Cl, Br, OMe, 2-furanyl, etc.; R3 = H, 2-benzofuranyl, 1-naphthalenyl, (un)substituted Ph, CH<sub>2</sub>CH<sub>2</sub>CN, CH:CHCN, etc.; R4 = H, NO<sub>2</sub>, NH<sub>2</sub>, etc.; their N-oxides, pharmaceutically acceptable addition salts, quaternary amines, or stereochem. isomeric forms]. Ten pharmaceutical compns. are given. Thus, amination of 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (preparation given) with amine II (preparation given) in the presence of K<sub>2</sub>CO<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub>/MeOH at 150° for 1 h gave the title compound III. Selected I displayed pIC<sub>50</sub> values in the range 8.0-9.5 for the inhibition of the HIV-induced cytopathic effect.


IT 500288-32-4P 500290-33-5P 500290-35-7P  
500290-37-9P 500290-39-1P 500290-41-5P  
500290-43-7P 500290-45-9P 500290-47-1P  
500290-49-3P 708255-06-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-HIV agent; preparation of pyrimidine-based anti-HIV agents and their pharmaceutical compns.)


RN 500288-32-4 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-33-5 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N,3,5-tetramethyl- (CA INDEX NAME)




RN 500290-35-7 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-37-9 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N-diethyl-3,5-dimethyl- (CA INDEX NAME)



RN 500290-39-1 CAPLUS


CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-3,5-dimethyl- (CA INDEX NAME)



RN 500290-41-5 CAPLUS


CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)






RN 500290-43-7 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-45-9 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-2-propyn-1-yl- (CA INDEX NAME)




RN 500290-47-1 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-2-propen-1-yl- (CA INDEX NAME)




RN 500290-49-3 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 708255-06-5 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N,N-bis(2-methylpropyl)- (CA INDEX NAME)




IT 500293-33-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidine-based anti-HIV agents and their pharmaceutical compns.)

RN 500293-33-4 CAPLUS

CN Benzoic acid, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-, hydrazide (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 59 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:453191 CAPLUS  
 DN 141:23546

TI Preparation of 2,4-bis(phenylamino)pyrimidine derivatives for treating  
 hyperproliferative disorders  
 IN Wood, Jill E.; Bierer, Donald; Bear, Brian; Brennan, Catherine; Chandler,  
 Brent; Chen, Gang; Chen, Yuanwei; Dixon, Julie; Fu, Wenlang; Guernon,  
 Leatte; Liu, Donglei; McClure, Andrea; Miranda, Karl; Nagarathnam,  
 Dhanapalan; Sibley, Robert; Turner, Michael; Verma, Sharad; Wang,  
 Chunguang; Yi, Lin; Zhao, Jin; Zhu, Qingming

PA Bayer Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046118	A2	20040603	WO 2003-US14294	20030506
	WO 2004046118	A3	20040812		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003299474	A1	20040615	AU 2003-299474	20030506
PRAI	US 2002-378329P	P	20020506		
	WO 2003-US14294	W	20030506		

OS MARPAT 141:23546

AB Title compds. I [p = 0-2; X = alkyl, CF<sub>3</sub>, halo; R<sub>1</sub> = H, OH, halo, etc.; R<sub>2</sub> = H, S(O)<sub>2</sub>NH<sub>2</sub>, halo, etc.; R<sub>3</sub> = H, alkyl, halo, etc.; R<sub>4</sub> = H, halo, ethynyl, etc.; R<sub>5</sub>-6 = H, halo, CF<sub>3</sub>; R<sub>7</sub> = H, halo, alkoxy; R<sub>8</sub> = H, alkyl, alkoxy, halo; R<sub>9</sub> = H, alkoxy] are prepared For instance, 4-fluoroaniline is alkylated with 5-bromo-2,4-dichloropyrimidine (THF, H<sub>2</sub>O, NaOAc); this intermediate is treated with 3-(1-methyl-1H-pyrazol-3-yl)benzeneamine (t-BuOH, HCl) to give II. Compds. of the invention inhibit cell proliferation (no data).

IT 698996-39-3P, 4-[[5-Bromo-2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide trifluoroacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2,4-bis(phenylamino)pyrimidine derivs. for treating hyperproliferative disorders)

RN 698996-39-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-2-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 698996-38-2  
CMF C20 H20 Br F N6 O3 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




L7 ANSWER 60 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:142963 CAPLUS  
 DN 140:199334  
 TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor  
 modulators for treatment of autoimmune diseases  
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim,  
 Holger; Sylvain, Catherine; Li, Hui; Bhamidipati, Somasekhar  
 PA Rigel Pharmaceuticals, USA  
 SO PCT Int. Appl., 811 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014382	A1	20040219	WO 2003-US24087	20030729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492325	A1	20040219	CA 2003-2492325	20030729
AU 2003265336	A1	20040225	AU 2003-265336	20030729
AU 2003265336	B2	20080619		
EP 1534286	A1	20050601	EP 2003-784871	20030729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013059	A	20050705	BR 2003-13059	20030729
CN 1678321	A	20051005	CN 2003-821120	20030729
JP 2006514989	T	20060518	JP 2005-506142	20030729
NZ 537752	A	20061222	NZ 2003-537752	20030729
US 20070060603	A1	20070315	US 2003-631029	20030729
US 20050038243	A1	20050217	US 2004-858343	20040601
US 7060827	B2	20060613		
US 20050209230	A1	20050922	US 2004-911684	20040803
SE 2005000203	A	20050329	SE 2005-203	20050127
NO 2005001069	A	20050228	NO 2005-1069	20050228
IN 2005KN00302	A	20060421	IN 2005-KN302	20050228
US 20060025410	A1	20060202	US 2005-149105	20050608
US 7329672	B2	20080212		
US 20060035916	A1	20060216	US 2005-148746	20050608
US 7329671	B2	20080212		
US 20060058292	A1	20060316	US 2005-149418	20050608
US 7332484	B2	20080219		
US 20060135543	A1	20060622	US 2005-299207	20051208
US 7435814	B2	20081014		
US 20070225321	A1	20070927	US 2006-539013	20061005
US 20070293520	A1	20071220	US 2006-539018	20061005
US 20070293521	A1	20071220	US 2006-539029	20061005
US 20070293522	A1	20071220	US 2006-539041	20061005
US 20070293523	A1	20071220	US 2006-539049	20061005
US 20070293524	A1	20071220	US 2006-539054	20061005


	US 20070299095	A1	20071227	US 2006-539101	20061005
	IN 2007KN02546	A	20070824	IN 2007-KN2546	20070709
	US 20080039622	A1	20080214	US 2007-782581	20070724
PRAI	US 2002-399673P	P	20020729		
	US 2003-443949P	P	20030131		
	US 2003-452339P	P	20030306		
	US 2003-631029	A	20030729		
	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US24087	W	20030729		
	US 2004-858343	A3	20040601		
	IN 2005-KN302	A3	20050228		
	US 2005-149418	A1	20050608		
OS	CASREACT 140:199334; MARPAT 140:199334				
AB	<p>The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 <math>\mu</math>M and 4.4 <math>\mu</math>M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Specific examples of autoimmune diseases that can be treated or prevented with I and their pharmaceutical compns. include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis (no data).</p>				
IT	575484-54-7P 575484-59-2P 575484-65-0P 662227-39-6P 662227-46-5P 662227-55-6P 662227-67-0P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)				
RN	575484-54-7 CAPLUS				
CN	Benzamide, 3-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)				






RN 575484-59-2 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methyamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-methyl- (CA INDEX NAME)




RN 575484-65-0 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylethylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-(1-methylethyl)- (CA INDEX NAME)




RN 662227-39-6 CAPLUS

CN Benzamide, N-(2-aminoethyl)-5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 662227-46-5 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 662227-55-6 CAPLUS


CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylamino)ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 662227-67-0 CAPLUS

CN Benzamide, N-[(2R)-2,3-dihydroxypropyl]-5-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 61 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:757684 CAPLUS  
 DN 139:292258  
 TI Pyrimidine derivatives  
 IN Baenteli, Rolf; Zenke, Gerhard; Cooke, Nigel Graham; Duthaler, Rudolf;  
 Thoma, Gebhard; Von Matt, Anette; Honda, Toshiyuki; Matsuura, Naoko;  
 Nonomura, Kazuhiko; Ohmori, Osamu; Umemura, Ichiro; Hinterding, Klaus;  
 Papageorgiou, Christos  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 SO PCT Int. Appl., 45 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

Applicant's

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078404	A1	20030925	WO 2003-EP2710	20030314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2479133	A1	20030925	CA 2003-2479133	20030314
	AU 2003227070	A1	20030929	AU 2003-227070	20030314
	AU 2003227070	B2	20070201		
	EP 1487805	A1	20041222	EP 2003-744366	20030314
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008461	A	20050118	BR 2003-8461	20030314
	JP 2005527529	T	20050915	JP 2003-576410	20030314
	CN 1697830	A	20051116	CN 2003-806101	20030314
	NZ 535109	A	20060526	NZ 2003-535109	20030314
	RU 2324684	C2	20080520	RU 2004-130488	20030314
	IN 2004CN02025	A	20060224	IN 2004-CN2025	20040910
	MX 2004PA09058	A	20050125	MX 2004-PA9058	20040915
	NO 2004004374	A	20041014	NO 2004-4374	20041014
	US 20060100227	A1	20060511	US 2005-507060	20050613
	ZA 2004006709	A	20060531	ZA 2004-6709	20060330
PRAI	GB 2002-6215	A	20020315		
	WO 2003-EP2710	W	20030314		

OS MARPAT 139:292258

AB The pyrimidine derivs. (I) are claimed, wherein X = =CR or =N, R, R1, R2, R3, R4 independently is H, OH, C1-8alkyl, C2-8alkenyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-8alkyl, hydroxyC1-8alkyl, C1-8alkoxyC1-8alkyl, hydroxyC1-8alkoxyC1-8alkyl, arylC1-8alkyl which optionally may be substituted on the ring by OH, C1-8alkoxy, carboxy, C1-8alkoxycarbonyl or R3 and R4 form together with N and C atoms to which they are attached to a 5-10 membered heterocyclic ring containing 1, 2 or 3 heteroatoms of N, O or S; R1 and R2 form together with C atoms to which they are attached aryl of 5-10 membered heteroaryl moiety containing 1-2 heteroatoms of N, O, S; R and R6 independently is H, halo, CN, C1-8alkyl, haloC1-8alkyl, C2-8alkenyl, C2-8alkynyl, C3-8cycloalkyl, C3-8cycloalkylC1-8alkyl, C5-10arylC1-8alkyl,; R7, R8 and R9 is independently H, OH, C1-8alkyl, C2-8alkenyl, haloC1-8alkyl, C1-8alkoxy, C3-8cycloalkyl, C3-8cycloalkylC1-8,

arylC1-8alkyl. disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK. I are useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

Pharmaceutical compns. containing I are claimed.


IT 1066516-59-3 1066516-60-6 1066516-62-8  
 1066516-64-0 1066516-65-1 1066516-66-2  
 1066516-67-3 1066516-69-5 1066516-73-1  
 1066516-76-4 1066516-77-5 1066516-80-0  
 1066516-87-7 1066516-88-8 1066516-89-9  
 1066516-92-4 1066516-93-5 1066516-97-9  
 1066516-98-0 1066516-99-1

RL: PRPH (Prophetic)

(Pyrimidine derivatives)


RN 1066516-59-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 1066516-60-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3-dihydro-1H-inden-5-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1066516-62-8 CAPLUS

CN Benzenesulfonamide, 2-methyl-6-[[2-[[3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-64-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-iodo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1066516-65-1 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminosulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 1066516-66-2 CAPLUS

CN Acetamide, N-[4-[[4-[[4-[[2-(2-hydroxyethoxy)ethyl]amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]phenyl]-N-methyl- (CA INDEX NAME)




RN 1066516-67-3 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1066516-69-5 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1066516-73-1 CAPLUS


CN Benzenesulfonamide, N-methyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 1066516-76-4 CAPLUS

CN Benzenesulfonamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-77-5 CAPLUS

CN Benzenesulfonamide, 4-[[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1066516-80-0 CAPLUS


CN Benzenesulfonamide, 3-[[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1066516-87-7 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(1H-benzimidazol-6-yl)amino]-5-bromo-4-

pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1066516-88-8 CAPLUS

CN Benzenesulfonamide, 2-ethyl-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-89-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 1066516-92-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-hydroxy-3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-93-5 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-97-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1066516-98-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1066516-99-1 CAPLUS

CN Benzenesulfonamide, 4-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




IT 604800-86-4P 604800-89-7P 604800-91-1P  
 604800-93-3P 604800-97-7P 604800-98-8P  
 604801-01-6P 604801-02-7P 604801-05-0P  
 604801-07-2P 604801-09-4P 604801-11-8P  
 604801-13-0P 604801-14-1P 604801-17-4P  
 604801-18-5P 604801-19-6P 604801-23-2P  
 604801-25-4P 604801-27-6P 604801-28-7P  
 604801-29-8P 604801-32-3P 604801-33-4P  
 604801-34-5P 604801-39-0P 604801-40-3P  
 604801-41-4P 604801-42-5P 604801-46-9P  
 604801-47-0P 604801-48-1P 604801-51-6P  
 604801-53-8P 604801-54-9P 604801-57-2P  
 604801-58-3P 604801-59-4P 604801-60-7P  
 604801-63-0P 604801-65-2P 604801-67-4P  
 604801-69-6P 604801-70-9P 604801-74-3P  
 604801-75-4P 604801-76-5P 604801-80-1P  
 604801-86-7P 604801-87-8P 604801-88-9P  
 604801-89-0P 604801-90-3P 604801-91-4P  
 604801-92-5P 604801-93-6P 604801-94-7P  
 604801-95-8P 604801-96-9P 604801-97-0P  
 604802-00-8P 604802-05-3P 604802-06-4P  
 604802-07-5P 604802-08-6P 604802-09-7P  
 604802-10-0P 604802-11-1P 604802-12-2P  
 604802-13-3P 604802-14-4P 604802-15-5P  
 604802-16-6P 604802-17-7P 604802-18-8P  
 604802-19-9P 604802-20-2P 604802-21-3P  
 604802-22-4P 604802-23-5P 604802-24-6P  
 604802-25-7P 604802-26-8P 604802-27-9P  
 604802-28-0P 604802-29-1P 604802-30-4P  
 604802-32-6P 604802-40-6P 604802-41-7P  
 604802-42-8P 604802-43-9P 604802-44-0P  
 604802-45-1P 604802-46-2P 604802-47-3P  
 604802-48-4P 604802-49-5P 604802-50-8P  
 604802-51-9P 604802-52-0P 604802-53-1P  
 604802-54-2P 604802-55-3P 604802-56-4P  
 604802-57-5P 604802-58-6P 604802-59-7P  
 604802-60-0P 604802-61-1P 604802-62-2P  
 604803-21-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation as protein kinase inhibitor)


RN 604800-86-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-benzimidazol-6-ylamino)-4-pyrimidinyl]amino]-  
 (CA INDEX NAME)




RN 604800-89-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-91-1 CAPLUS

CN Benzenesulfonamide, 2-methyl-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-93-3 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-97-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[(hexahydro-1-methyl-1H-azepin-4-yl)oxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-98-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-2-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-01-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-02-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-05-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-07-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 604801-09-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-benzotriazol-6-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 604801-11-8 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 604801-13-0 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-14-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-17-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 604801-18-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-19-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(3,4-dimethoxyphenyl)amino]-4-




pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-23-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]-  
(CA INDEX NAME)

RN 604801-25-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-  
(CA INDEX NAME)


RN 604801-27-6 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-  
(CA INDEX NAME)

RN 604801-28-7 CAPLUS


CN Benzamide, 2-[[2-[(3-aminophenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

NAME)




RN 604801-29-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indol-5-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-32-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-33-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-34-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 604801-39-0 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-40-3 CAPLUS

CN Benzamide, N-hydroxy-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-41-4 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-42-5 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-46-9 CAPLUS

CN Benzenesulfonamide, N-propyl-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-47-0 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(2,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-48-1 CAPLUS

CN Benzenesulfonamide, N-[2-(2-hydroxyethoxy)ethyl]-4-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe


RN 604801-51-6 CAPLUS

CN Benzenesulfonamide, N-2-thiazolyl-4-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-53-8 CAPLUS

CN Benzenesulfonamide, N-(1-methylethenyl)-3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-54-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-57-2 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-58-3 CAPLUS

CN Benzenesulfonamide, 3-[[2-(1H-indazol-5-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-59-4 CAPLUS

CN Benzenesulfonamide, 3-[[5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-60-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-63-0 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-65-2 CAPLUS

CN Benzenesulfonamide, 3-[[2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-67-4 CAPLUS

CN Benzenesulfonamide, N-methyl-3-[[5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-69-6 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethenyl)- (CA INDEX NAME)




RN 604801-70-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methylene- (CA INDEX NAME)



RN 604801-74-3 CAPLUS


CN Benzenesulfonamide, N-butyl-3-[[2-[[3-(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 604801-75-4 CAPLUS


CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 604801-76-5 CAPLUS

CN Benzenesulfonamide, N-butyl-3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-80-1 CAPLUS

CN Benzenesulfonamide, 3-[[5-ethyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 604801-86-7 CAPLUS


CN [1,1'-Biphenyl]-3-sulfonamide, 4-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-87-8 CAPLUS


CN Benzenesulfonamide, 4-methyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-88-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-89-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-ethyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-90-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-91-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-92-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-methyl-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-93-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-benzotriazol-6-ylamino)-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-94-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-(1H-indazol-5-ylamino)-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-95-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-(1H-indazol-6-ylamino)-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-96-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-methoxy-3-[2-(1-methyl-4-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-97-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-00-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-5-methyl- (CA INDEX NAME)




RN 604802-05-3 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-06-4 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methyl-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-07-5 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-08-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)- (CA INDEX NAME)




RN 604802-09-7 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)





RN 604802-10-0 CAPLUS


CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-3-methyl- (CA INDEX NAME)




RN 604802-11-1 CAPLUS  
 CN Benzenesulfonamide, 2-methoxy-3-methyl-6-[[2-[[3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-12-2 CAPLUS  
 CN Benzenesulfonamide, 2-(1-methylethoxy)-6-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-13-3 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-14-4 CAPLUS

CN Benzenesulfonamide, 6-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-2,3-dimethyl- (CA INDEX NAME)



RN 604802-15-5 CAPLUS


CN Benzenesulfonamide, 5-methoxy-2-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-16-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)






RN 604802-17-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-methyl-2-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-18-8 CAPLUS

CN Benzenesulfonamide, 5-methoxy-2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-19-9 CAPLUS

CN Benzenesulfonamide, 5-methoxy-2-[[2-[[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-20-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-21-3 CAPLUS

CN Benzenesulfonamide, 5-ethoxy-2-[[2-[[4-methyl-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-22-4 CAPLUS

CN Benzenesulfonamide, 2,3-dimethoxy-6-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-23-5 CAPLUS

CN Benzenesulfonamide, 2-chloro-6-[[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-24-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-cyclopentyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-25-7 CAPLUS

CN 1-Naphthalenesulfonamide, 2-[[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-26-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-27-9 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-28-0 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-[4-(phenylmethyl)-1-piperazinyl]ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-29-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-cyclopentylethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-5-methyl- (CA INDEX NAME)




RN 604802-30-4 CAPLUS

CN Benzenesulfonamide, 5-bromo-2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-32-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]-5-methyl- (CA INDEX NAME)




RN 604802-40-6 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-5-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-41-7 CAPLUS

CN Benzenesulfonamide, N-methyl-2-[[5-(trifluoromethyl)-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-42-8 CAPLUS

CN Benzenesulfonamide, 2-methoxy-3-methyl-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-43-9 CAPLUS

CN Benzenesulfonamide, 2-(1-piperidinyl)-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-44-0 CAPLUS

CN Benzenesulfonamide, 2-(4-morpholinyl)-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-45-1 CAPLUS

CN Benzenesulfonamide, N,2-dimethyl-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-46-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-47-3 CAPLUS


CN Benzenesulfonamide, 2-methoxy-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-48-4 CAPLUS


CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 604802-49-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)- (CA INDEX NAME)




RN 604802-50-8 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)- (CA INDEX NAME)




RN 604802-51-9 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[[4-methoxy-3-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-6-(1-methylethoxy)- (CA INDEX NAME)




RN 604802-52-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[3-(1-piperidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-53-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-54-2 CAPLUS

CN Benzenesulfonamide, 2-(2-methoxyethoxy)-6-[[2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-55-3 CAPLUS

CN Benzenesulfonamide, 2-(4-methyl-1-piperazinyl)-6-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-56-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)




RN 604802-57-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-methoxy-3-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-6-methoxy- (CA INDEX NAME)




RN 604802-58-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-59-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-6-methyl- (CA INDEX NAME)




RN 604802-60-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-61-1 CAPLUS

CN Benzenesulfonamide, 2-methyl-6-[[2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-62-2 CAPLUS

CN Benzenesulfonamide, 2-methoxy-6-[[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604803-21-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(dimethylamino)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-6-fluoro- (CA INDEX NAME)




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 62 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:610204 CAPLUS  
 DN 139:164801  
 TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor  
 modulators for treatment of allergic diseases, inflammatory conditions,  
 and tissue destruction  
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Molineaux, Susan;  
 Holland, Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar;  
 Sylvain, Catherine; Li, Weigun; Rossi, Alexander B.  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 648 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063794	A2	20030807	WO 2003-US3022	20030131
	WO 2003063794	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2474277	A1	20030807	CA 2003-2474277	20030131
	US 20040029902	A1	20040212	US 2003-355543	20030131
	EP 1471915	A2	20041103	EP 2003-707654	20030131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005516046	T	20050602	JP 2003-563490	20030131
	CN 1625400	A	20050608	CN 2003-803180	20030131
	BR 2003007355	A	20060411	BR 2003-7355	20030131
	NZ 534361	A	20080430	NZ 2003-534361	20030131
	AU 2003208931	B2	20080904	AU 2003-208931	20030131
	US 20050038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	MX 2004PA07386	A	20060427	MX 2004-PA7386	20040730
	US 20050209230	A1	20050922	US 2004-911684	20040803
	IN 2004KN01139	A	20060512	IN 2004-KN1139	20040809
	NO 2004003632	A	20041026	NO 2004-3632	20040831
	US 20060025410	A1	20060202	US 2005-149105	20050608
	US 7329672	B2	20080212		
	US 20060035916	A1	20060216	US 2005-148746	20050608
	US 7329671	B2	20080212		
	US 20060058292	A1	20060316	US 2005-149418	20050608
	US 7332484	B2	20080219		
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	US 20070225321	A1	20070927	US 2006-539013	20061005
	US 20070293520	A1	20071220	US 2006-539018	20061005
	US 20070293521	A1	20071220	US 2006-539029	20061005
	US 20070293522	A1	20071220	US 2006-539041	20061005


	US 20070293523	A1	20071220	US 2006-539049	20061005
	US 20070293524	A1	20071220	US 2006-539054	20061005
	US 20080039622	A1	20080214	US 2007-782581	20070724
PRAI	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-399673P	P	20020729		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US3022	W	20030131		
	US 2004-858343	A3	20040601		
	US 2005-149418	A1	20050608		
OS	MARPAT 139:164801				
AB	<p>Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 <math>\mu</math>M and 4.4 <math>\mu</math>M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. The treatment and prevention of allergic diseases, low grade scarring, diseases associated with tissue destruction, diseases associated with tissue inflammation, inflammation, and scarring are targeted uses (no data).</p>				
IT	<p>575484-54-7P 575484-59-2P 575484-65-0P          RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)          (IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)</p>				
RN	575484-54-7 CAPLUS				
CN	Benzamide, 3-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)				






RN 575484-59-2 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylanino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-methyl- (CA INDEX NAME)



RN 575484-65-0 CAPLUS

CN Benzamide, 5-[[5-fluoro-2-[[3-[2-(methylethoxy)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]-2-methoxy-N-(1-methylethyl)- (CA INDEX NAME)



L7 ANSWER 63 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:356429 CAPLUS  
 DN 138:368902  
 TI Preparation of aminobenzamide derivatives as glycogen synthase kinase  
 3 $\beta$  inhibitors  
 IN Freyne, Eddy Jean Edgard; Buijnsters, Peter Jacobus Johannes Antonius;  
 Willems, Marc; Embrechts, Werner Constant Johan; Janssen, Paul Adriaan  
 Jan; Lewi, Paulus Joannes; Heeres, Jan; De Jonge, Marc Rene; Koymans,  
 Lucien Maria Henricus; Daeyaert, Frederik Frans Desire; Kukla, Michael  
 Joseph; Geerts, Hugo Alfons Gabriel; Nuydens, Rony Maria; Mercken, Marc  
 Hubert; Ludovici, Donald William  
 PA Janssen Pharmaceutica N.V., Belg.  
 SO PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003037877	A1	20030508	WO 2002-EP12079	20021029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463823	A1	20030508	CA 2002-2463823	20021029
	AU 2002363177	A1	20030512	AU 2002-363177	20021029
	AU 2002363177	B2	20080918		
	EP 1442024	A1	20040804	EP 2002-802307	20021029
	EP 1442024	B1	20080319		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013790	A	20041207	BR 2002-13790	20021029
	HU 2004002245	A2	20050228	HU 2004-2245	20021029
	JP 2005507420	T	20050317	JP 2003-540159	20021029
	CN 1703405	A	20051130	CN 2002-821916	20021029
	NZ 531854	A	20060331	NZ 2002-531854	20021029
	AT 389638	T	20080415	AT 2002-802307	20021029
	ES 2303565	T3	20080816	ES 2002-802307	20021029
	MX 2004PA04176	A	20040906	MX 2004-PA4176	20040430
	NO 2004002253	A	20040601	NO 2004-2253	20040601
	US 20060063789	A1	20060323	US 2005-493446	20050309
PRAI	EP 2001-204192	A	20011101		
	WO 2002-EP12079	W	20021029		

OS MARPAT 138:368902

AB Aminobenzamide derivs. (I), N-oxides, pharmaceutically acceptable addition salts, quaternary amines, and stereochem. isomeric forms thereof [wherein ring A = pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl; R1 = H, aryl, CHO, C1-6 alkylcarbonyl, optionally substituted C1-6 alkyl, C1-6 alkyloxycarbonyl, optionally substituted C1-6 alkyloxy-C1-6 alkylcarbonyl; X = a direct bond or a linker atom or group; Z = O, S; R2 = H, each (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, or carbocycle

or heterocycle group; R3 = H, HO, halo, each optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, C1-6 alkyloxy, C1-6 alkylthio; C1-6 alkyloxycarbonyl, C1-6 alkylcarbonyloxy, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalo-C1-6 alkyl, polyhalo-C1-6 alkyloxy, polyhalo-C1-6 alkylthio, R21, R21-C1-6 alkyl, R21O, R21S, R21CO, R21S(O)n, NHCHO, CONHNH2, etc.; R4a, R4b = H, R8, Y1-NR9-Y2-NR10R11, Y1-NR9-Y1-R8, Y1-NR9R10; wherein n = 1,2; R21 = (un)substituted monocyclic, bicyclic or tricyclic (partially) saturated carbocycle or heterocycle, monocyclic, bicyclic or tricyclic aromatic carbocycle or heterocycle; Y1, Y2 = a direct bond, a linker group; R8 = C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R9, R10, R11 = H, R8, etc.; p = 1-3] are prepared These compds. are useful for the prevention or the treatment of diseases mediated through GSK3 including bipolar disorder (in particular manic depression), diabetes, Alzheimer's disease, leukopenia, FTDP-17 (fronto-temporal dementia associated with Parkinson's disease), cortico-basal degeneration, progressive supranuclear palsy, multiple system atrophy, Pick's disease, Niemann Pick's disease type C, Dementia Pugilistica, dementia with tangles only, dementia with tangles and calcification, Down syndrome, myotonic dystrophy, Parkinsonism-dementia complex of Guam, AIDS related dementia, Postencephalic Parkinsonism, prion diseases with tangles, subacute sclerosing panencephalitis, frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotizing panencephalitis (SSPE) (late complication of viral infections in the central nervous system), inflammatory diseases, cancer, dermatol. disorders, neuronal damage, schizophrenia, and pain. Thus, a solution of 2-chloro-5-nitro-N-(phenylmethyl)-4-pyrimidinamine (0.012 mol), 3-aminobenzamide (0.012 mol) and Et3N (0.012 mol) in DMF (50 mL) was stirred for 2 h at 60° to give 77% 3-[[4-benzylamino-5-nitropyrimidin-2-yl]amino]benzamide (II). II and 3-[(4-benzyloxypyrimidin-2-yl)amino]benzamide showed pIC50(M) of 6.74 and 5.85, resp., against GSK3β.


IT 840537-61-3 1055175-99-9

RL: PRPH (Prophetic)


(Preparation of aminobenzamide derivatives as glycogen synthase kinase 3β inhibitors)

RN 840537-61-3 CAPLUS


CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-5-nitro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1055175-99-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



IT	521304-18-7P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of aminobenzamide derivs. as glycogen synthase kinase 3 $\beta$ (GSK3 $\beta$ ) inhibitors for preventing or treating GSK3 $\beta$ -mediated diseases)
RN	521304-18-7 CAPLUS
CN	Benzamide, 3-[[2-[[3-(1-methyl-1H-imidazol-2-yl)phenyl]amino]-5-nitro-4-pyrimidinyl]amino]- (CA INDEX NAME)



IT	521304-20-1P
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
	(preparation of aminobenzamide derivs. as glycogen synthase kinase 3β (GSK3β) inhibitors for preventing or treating GSK3β-mediated diseases)
RN	521304-20-1 CAPLUS
CN	Benzamide, 3-[[5-amino-2-[[3-(1-methyl-1H-imidazol-2-yl)phenyl]amino]-4- pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 64 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:154426 CAPLUS  
 DN 138:205077  
 TI Preparation of pyrimidines as HIV inhibitors.  
 IN Guillemont, Jerome Emile Georges; Palandjian, Patrice; De Jonge, Marc  
 Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Daeyaert,  
 Frederik Frans Desire; Heeres, Jan; Van Aken, Koen Jeanne Alfons; Lewi,  
 Paulus Joannes; Janssen, Paul Adriaan Jan  
 PA Janssen Pharmaceutica N.V., Belg.  
 SO PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003016306	A1	20030227	WO 2002-EP8953	20020809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2452217	A1	20030227	CA 2002-2452217	20020809
	AU 2002329238	A1	20030303	AU 2002-329238	20020809
	AU 2002329238	B2	20080124		
	EP 1419152	A1	20040519	EP 2002-764839	20020809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002011909	A	20040824	BR 2002-11909	20020809
	CN 1541215	A	20041027	CN 2002-815920	20020809
	HU 2004001346	A2	20041228	HU 2004-1346	20020809
	JP 2005507380	T	20050317	JP 2003-521229	20020809
	NZ 530951	A	20051028	NZ 2002-530951	20020809
	AP 1610	A	20060630	AP 2004-2993	20020809
	TW 272945	B	20070211	TW 2002-91118061	20020812
	KR 817453	B1	20080327	KR 2004-700372	20040109
	US 20040198739	A1	20041007	US 2004-485636	20040203
	US 7125879	B2	20061024		
	IN 2004DN00265	A	20050401	IN 2004-DN265	20040206
	NO 2004000633	A	20040312	NO 2004-633	20040212
	ZA 2004001159	A	20050512	ZA 2004-1159	20040212
	MX 2004PA01401	A	20040527	MX 2004-PA1401	20040213
	US 20060111379	A1	20060525	US 2005-219163	20050902
	US 20060252764	A1	20061109	US 2006-474855	20060626
	KR 2007101409	A	20071016	KR 2007-722611	20071002
	IN 2008DN00715	A	20080711	IN 2008-DN715	20080125
PRAI	EP 2001-203090	A	20010813		
	EP 2002-77748	A	20020610		
	WO 2002-EP8953	W	20020809		
	EP 2003-103275	A	20030903		
	EP 2003-103319	A	20030908		
	EP 2003-103335	A	20030910		

EP 2003-103668	A	20031002
KR 2004-700372	A3	20040109
US 2004-485636	A2	20040203
IN 2004-DN265	A3	20040206
MY 2004-3578	A	20040902
WO 2004-EP52028	A	20040903
EP 2005-101467	A	20050225

OS MARPAT 138:205077

AB Title compds. [I; a1:a2a3:a4, b1:b2b3:b4 = atoms to form Ph, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl rings; n = 0-5; m = 1-4; R1 = H, aryl, CHO, alkylcarbonyl, alkyl, alkyloxycarbonyl, substituted alkyl, alkylcarbonyl; R2 = OH, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkoxy carbonyl, carboxyl, cyano, NO<sub>2</sub>, amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, SOpR6, NHSOpR6, COR6, NHCOH, CONHNH<sub>2</sub>, NHCOR6, C(:NH)R6, 5-membered heterocycle; X1 = NR5, NNNH, N:N, O, CO, alkanediyl, CH(OH), S, SOp, X2-alkanediyl, alkanediyl-X2; X2 = NR5, NNNH, N:N, O, CO, CH(OH), S, SOp; R3 = NHR13, NR13R14, CONHR13, CONR13R14, COR15, CH:NNHCOR16, substituted alkyl, (substituted) alkoxyalkyl, substituted alkenyl, alkynyl, alkyl substituted with OH and a second substituent, C(:NOR8)-alkyl, R7, X3R7; R4 = halo, OH, alkyl, cycloalkyl, alkoxy, cyano, nitro, polyhaloalkyl, polyhaloalkoxy, aminocarbonyl, alkyloxycarbonyl, alkylcarbonyl, CHO, amino; R5 = H, aryl, CHO, alkylcarbonyl, alkyl, alkoxy carbonyl, etc.; R6 = alkyl, amino, polyhaloalkyl; R7 = mono-, bi-, or tricyclic (aromatic) carbocyclyl, heterocyclyl; R13, R14 = alkyl, alkenyl, alkynyl optionally substituted by cyano, aminocarbonyl; R15 = cyanoalkyl, aminocarbonylalkyl; R16 = R15, R7; p = 1, 2], were prepared. Thus, 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (preparation given) and 4-(2-cyanoethenyl)-2,6-dimethylaniline were stirred together at 150° for 1 h to give 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile. The latter inhibited HIV-induced cytopathic effect in MT-4 cells with pIC<sub>50</sub> = 9.4.

IT 500288-32-4P 500290-33-5P 500290-35-7P  
500290-37-9P 500290-39-1P 500290-41-5P  
500290-43-7P 500290-45-9P 500290-47-1P  
500290-49-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidines as HIV inhibitors)

RN 500288-32-4 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)






Two differences:  
 (1) R7, R8 or R9 can not be CN  
 (2) one of the ortho positions is unsubstituted on the phenyl ring


RN 500290-33-5 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N,3,5-tetramethyl- (CA INDEX NAME)




RN 500290-35-7 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-37-9 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,N-diethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-39-1 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-ethyl-3,5-dimethyl- (CA INDEX NAME)




RN 500290-41-5 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 500290-43-7 CAPLUS

CN Benzamide, N-(cyanomethyl)-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N,3,5-trimethyl- (CA INDEX NAME)




RN 500290-45-9 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-2-propyn-1-yl- (CA INDEX NAME)




RN 500290-47-1 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-2-propen-1-yl- (CA INDEX NAME)



RN 500290-49-3 CAPLUS

CN Benzamide, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)




IT 500293-33-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidines as HIV inhibitors)

RN 500293-33-4 CAPLUS

CN Benzoic acid, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-, hydrazide (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 65 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2001:661402 CAPLUS  
 DN 135:227009  
 TI Preparation of pyrimidin-2-amines as cyclin-dependent serine/threonine  
 kinase (CDK) inhibitors  
 IN Pease Elizabeth Janet; Breault, Gloria Anne; Morris, Jeffrey James  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2 102(b)  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064654	A1	20010907	WO 2001-GB782	20010226
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2399196	A1	20010907	CA 2001-2399196	20010226
	EP 1272477	A1	20030108	EP 2001-905990	20010226
	EP 1272477	B1	20070509		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008841	A	20030506	BR 2001-8841	20010226
	JP 2003525277	T	20030826	JP 2001-563496	20010226
	AU 765151	B2	20030911	AU 2001-33953	20010226
	NZ 520394	A	20040430	NZ 2001-520394	20010226
	AT 361916	T	20070615	AT 2001-905990	20010226
	ES 2284617	T3	20071116	ES 2001-905990	20010226
	ZA 2002006191	A	20031103	ZA 2002-6191	20020802
	MX 2002PA08370	A	20021213	MX 2002-PA8370	20020827
	US 20030149064	A1	20030807	US 2002-220139	20020828
	US 7153964	B2	20061226		
	NO 2002004154	A	20021028	NO 2002-4154	20020830
	NO 325241	B1	20080303		
	KR 790414	B1	20080102	KR 2002-711407	20020830
PRAI	GB 2000-4888	A	20000301		
	WO 2001-GB782	W	20010226		

OS MARPAT 135:227009


AB The title compds. [I; Q1, Q2 = (un)substituted aryl, carbon linked heteroaryl; one of Q1 and Q2 or both is substituted on a ring carbon by sulfamoyl, N-alkylsulfamoyl, alkylsulfonyl, etc.; G = O, S, NR<sub>2</sub>; R<sub>1</sub> = H, halo, OH, etc.; R<sub>2</sub> = H, alkyl, alkenyl, etc.], useful for their anticancer activity, were prepared and formulated. Thus, reacting 2,5-dichloro-4-(2-cyanoanilino)pyrimidine with sulfanilamide in BuOH afforded II which showed IC<sub>50</sub> of 0.347  $\mu$ M when tested in vitro assay for the CDK2 inhibitory activity.

IT 359010-49-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrimidin-2-amines as cyclin-dependent serine/threonine

kinase (CDK) inhibitors)

RN 359010-49-4 CAPLUS

CN Benzenesulfonamide, 4,4'-[(5-bromo-2,4-pyrimidinediyl)diimino]bis- (9CI)  
(CA INDEX NAME)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 66 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2000:457043 CAPLUS  
 DN 133:89537  
 TI Preparation of 2,4-pyrimidinediamine derivatives as anticancer agents  
 IN Bradbury, Robert Hugh; Breault, Gloria Anne; Jewsbury, Philip John; Pease, Janet Elizabeth  
 PA Astrazeneca UK Limited, UK  
 SO PCT Int. Appl., 137 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039101	A1	20000706	WO 1999-GB4325	19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2352896	A1	20000706	CA 1999-2352896	19991220
EP 1140860	A1	20011010	EP 1999-962375	19991220
EP 1140860	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916590	A	20011023	BR 1999-16590	19991220
JP 2002533446	T	20021008	JP 2000-591012	19991220
AU 763091	B2	20030710	AU 2000-18743	19991220
NZ 512118	A	20030829	NZ 1999-512118	19991220
AT 277020	T	20041015	AT 1999-962375	19991220
PT 1140860	T	20050131	PT 1999-962375	19991220
ES 2228145	T3	20050401	ES 1999-962375	19991220
CN 1285580	C	20061122	CN 1999-816278	19991220
ZA 2001004413	A	20020829	ZA 2001-4413	20010529
NO 2001003038	A	20010822	NO 2001-3038	20010619
NO 319815	B1	20050919		
MX 2001PA06575	A	20011203	MX 2001-PA6575	20010625
US 6593326	B1	20030715	US 2001-868602	20010823
PRAI GB 1998-28511	A	19981224		
WO 1999-GB4325	W	19991220		

OS MARPAT 133:89537

AB The present invention relates to the title compds. (I) [wherein R1 = H, (un)substituted alkyl, alkenyl, or alkynyl, benzyl, 2-phenylethyl, phthalimidoalkyl, or cycloalkylalkyl; Rx = halo, OH, NO2, NH2, CN, SH, CO2H, SO2NH2, NHCHO, ureido, etc.; Q1 and Q2 = independently (un)substituted aryl, 5- or 6-membered monocycle, or 9- or 10-membered bicyclic heterocycle], processes for their manufacture, and pharmaceutical compns. containing them. For example, addition of 4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline•HCl in MeOH to 5-bromo-2-chloro-4-(indan-5-ylamino)pyrimidine in BuOH (preps. given) and heating to 100°C for 18 h gave II (42%). I inhibited the effects of cyclin-dependent serine/threonine kinases (CDKs), showing selectivity for CDK2 (no data), CDK4 (IC50 ranging from 0.02 µM to 0.07 µM), and CDK6 (no data). In a tyrosine kinase activity assay using Sf21 cells

transfected with plaque-pure FAK recombinant virus, I also inhibited focal adhesion kinase 3 (FAK3) with IC50 ranging from 0.032  $\mu$ M to 0.07  $\mu$ M. Typical IC50 values for I when tested for inhibition of cell growth in an Sulforhodamine B (SRB) assay were in the range of 1 mM to 1 nM. Thus, I possess anti-cancer properties, including anti-cell-migration, antiproliferation and/or apoptotic properties. Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumors and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases, and ocular diseases with retinal vessel proliferation.


IT 280579-49-9P 280579-54-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamine anticancer agents by coupling halopyrimidines with anilines and optional derivatization)

RN 280579-49-9 CAPLUS


CN Benzamide, 4-[[5-bromo-2-[[4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:2)  
(CA INDEX NAME)



● 2 HCl

RN 280579-54-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-bromo-2-[[4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:1)  
(CA INDEX NAME)



● HCl

RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 67 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1989:116656 CAPLUS

DN 110:116656

OREF 110:19241a,19244a

TI Pyrimidine compounds for dyeing and printing fiber materials

IN Morimitsu, Toshihiko; Omura, Takashi

PA Sumitomo Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 63207860	A	19880829	JP 1987-42224	19870224
	JP 08026237	B	19960313		
PRAI	JP 1987-42224		19870224		

OS MARPAT 110:116656

AB The title reactive dyes I [D = dye residue; n = 0.1; A = H, Cl, Br, Me, NO<sub>2</sub>, CN, carboxy, sulfo; R<sub>1</sub>-R<sub>3</sub> = H, (un)substituted alkyl; B<sub>1</sub>, B<sub>2</sub> = (un)substituted phenylene, naphthylene; Y<sub>1</sub>, Y<sub>2</sub> = CH<sub>2</sub>CH<sub>2</sub>L, vinyl; L = alkali-removable group], useful for dyeing and printing cotton, are prepared. 2,4,6-Trifluoro-5-chloropyrimidine was condensed with 1-amino-8-hydroxy-7-(o-sulfophenylazo)-3,6-naphthalenedisulfonic acid, p-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OSO<sub>3</sub>H, and m-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OSO<sub>3</sub>H, and salted to give II (Na salt),  $\lambda_{\text{max}}$  540 nm (fabric color not specified).

IT 118521-58-7P 118521-59-8P


RL: IMF (Industrial manufacture); RCT (Reactant); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(manufacture of, as reactive dye for cotton)

RN 118521-58-7 CAPLUS

CN 2,7-Naphthalenedisulfonic acid, 5-[[4-[[2,6-bis[[3-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]amino]-4-pyrimidinyl]amino]benzoyl]amino]-3-[2-(2,5-disulfophenyl)diazenyl]-4-hydroxy- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OSO<sub>3</sub>H

RN 118521-59-8 CAPLUS

CN 2,7-Naphthalenedisulfonic acid, 5-[[4-[[5-chloro-2,6-bis[[3-[[2-(sulfoxy)ethyl]sulfonyl]phenyl]amino]-4-pyrimidinyl]amino]benzoyl]amino]-3-[2-(2,5-disulfophenyl)diazenyl]-4-hydroxy- (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

 $-\text{OSO}_3\text{H}$


L7 ANSWER 68 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1988:570352 CAPLUS  
 DN 109:170352  
 OREF 109:28255a,28258a  
 TI 2,4-bis(substituted) 5-nitropyrimidines of expected diuretic action  
 AU El-Kerdawy, M. M.; Zayed, A. A.; Abou Hamid, M. M.  
 CS Natl. Org. Drug Control Res., Cairo, Egypt  
 SO Egyptian Journal of Chemistry (1987), Volume Date 1986, 29(2), 247-51  
 CODEN: EGJCA3; ISSN: 0367-0422  
 DT Journal  
 LA English  
 AB 2,4-Dichloro-5-nitropyrimidine was treated with amines to give  
 pyrimidinediamines I [R1 = H2NSO2C6H4, substituted sulfamoylphenyl,  
 HO(EtO2C)C6H3, H2NC6H4, HOC6H4, Cl(HO)C6H3, CH2CH2NH2, furfuryl,  
 antipyrinyl, substituted pyrimidinyl]. Also prepared, from I (R1 = NH2),  
 were I (R1 = NHCO2Et) and I (R1 = N:CHC6H4NO2-4).  
 IT 116859-92-8P 116859-93-9P 116859-94-0P  
 116859-95-1P 116859-96-2P 116859-97-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 116859-92-8 CAPLUS  
 CN Benzenesulfonamide, 4,4'-[(5-nitro-2,4-pyrimidinediyl)diimino]bis- (9CI)  
 (CA INDEX NAME)



RN 116859-93-9 CAPLUS  
 CN Benzenesulfonamide, 4,4'-[(5-nitro-2,4-pyrimidinediyl)diimino]bis[N-(  
 aminoiminomethyl)- (9CI) (CA INDEX NAME)




RN 116859-94-0 CAPLUS  
 CN Benzenesulfonamide, 4,4'-[(5-nitro-2,4-pyrimidinediyl)diimino]bis[N-2-  
 pyrimidinyl- (9CI) (CA INDEX NAME)



RN 116859-95-1 CAPLUS

CN Benzenesulfonamide, 4,4'-[(5-nitro-2,4-pyrimidinediyl)diimino]bis[N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Me

RN 116859-96-2 CAPLUS

CN Benzenesulfonamide, 4,4'-[(5-nitro-2,4-pyrimidinediyl)diimino]bis[N-(4,6-dimethyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Me

RN 116859-97-3 CAPLUS


CN Acetamide, N,N'-[(5-nitro-2,4-pyrimidinediyl)bis(imino-4,1-phenylenesulfonyl)]bis- (9CI) (CA INDEX NAME)





10/507,060 (amended)

L7 ANSWER 69 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 1981:497712 CAPLUS  
DN 95:97712  
OREF 95:16419a,16422a  
TI 2,4-Bis(arylamino)-6-methylpyrimidines as antimicrobial agents  
AU Ghosh, Dolly  
CS Dep. Chem., Bose Inst., Calcutta, 700 009, India  
SO Journal of the Indian Chemical Society (1981), 58(5), 512-13  
CODEN: JICSAH; ISSN: 0019-4522  
DT Journal  
LA English  
AB Pyrimidines I (R = aryl, R1 = Me, H; R2 = H, Me) were synthesized. All were tested against some gram-pos. and gram-neg. bacteria and Candida albicans. 2,4-Bis(p-chloroanilino)- and 2,4-bis(p-bromoanilino)pyrimidine derivs. possess significant activity.  
IT 78830-66-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and bactericidal and fungicidal activities of)  
RN 78830-66-7 CAPLUS  
CN Benzenesulfonamide, 4,4'-[(6-methyl-2,4-pyrimidinediyl)diimino]bis- (9CI)  
(CA INDEX NAME)



L7 ANSWER 70 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1969:96808 CAPLUS  
 DN 70:96808  
 OREF 70:18097a,18100a  
 TI Sulfanilamides  
 IN Short, James H.  
 PA Abbott Laboratories  
 SO U.S., 2 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3432493	A	19690311	US 1966-560799	19660627
PRAI	US 1966-560799	A	19660627		

AB p-RNHC6H4SO2NH2 (I) and their HCl salts, useful for increasing the flow of blood in warm-blooded animals, are prepared Thus, 0.05 mole sulfanilamide and 0.05 mole 2-amino-4-chloro-6-methylpyrimidine in 100 ml. H2O containing 3 ml. concentrated HCl was stirred 2 hrs. on a steam bath, filtered hot, and chilled to precipitate 4-(2-amino-6-methylpyrimidin-4-yl)sulfanilamide-HCl, m. 329-30.5° (H2O). Similarly prepared were the following I (R and m.p. given): 6-aminopyrimidin-4-yl, -(HCl salt m. 293-5°); 2-anilino-6-methylpyrimidin-4-yl, -(HCl salt m. 284-6°); 2-(4-amino-6-hydroxypyrimidin-2-yl, 203-6.5°); 2,6-dimethoxypyrimidin-4-yl, -(HCl salt m. 189-90°); 2-amino-6-(p-sulfamoylanilino)pyrimidin-4-yl, - (HCl salt m. 266-7°); and 4-amino-s-triazin-2-yl, 280-2°.

IT 21822-50-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 21822-50-4 CAPLUS

CN Benzenesulfonamide, 4-[[6-methyl-2-(phenylamino)-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)





● HCl

L7 ANSWER 71 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1966:414134 CAPLUS  
 DN 65:14134  
 OREF 65:2647c-e  
 TI 2,4-Bis(arylamino)pyrimidines as antimicrobial agents  
 AU Ghosh, Dolly  
 CS Univ. Coll. Sci., Calcutta  
 SO Journal of Medicinal Chemistry (1966), 9(3), 423-4  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 AB 2,4-Bis(arylamino)pyrimidines (I) were synthesized by the acid-catalyzed condensation of 2,4-dichloropyrimidine with appropriate aromatic amines by a previously described method (Banks, CA 38, 49525) and were tested for their antimicrobial activity against *Streptococcus faecalis*, *Escherichia coli* B, and *Candida albicans*. The compds. with Ar = p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, p-ClC<sub>6</sub>H<sub>4</sub>, m-ClC<sub>6</sub>H<sub>4</sub>, o-ClC<sub>6</sub>H<sub>4</sub>, p-MeOC<sub>6</sub>H<sub>4</sub>, pMeC<sub>6</sub>H<sub>4</sub>, and p-H<sub>2</sub>NSO<sub>2</sub>C<sub>6</sub>H<sub>4</sub> showed antimicrobial activities comparable to or greater than those of 6-azauracil and neomycin. The compound with Ar = p-AcC<sub>6</sub>H<sub>4</sub> at a saturating concentration produced no growth inhibition of the gram-neg. and gram-pos. bacteria, while it was active against the yeast. The compound with Ar = p-HOC<sub>6</sub>H<sub>4</sub> was much less active.  
 IT 5301-27-9  
 (Derived from data in the 7th Collective Formula Index (1962-1966))  
 RN 5301-27-9 CAPLUS  
 CN Benzenesulfonamide, 4,4'-(2,4-pyrimidinediyl-diimino)bis-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


IT 98145-50-7, Sulfanilamide, N<sub>4</sub>,N<sub>4</sub>'-2,4-pyrimidinediylbis-, hydrochloride  
 (as bactericide and fungicide)  
 RN 98145-50-7 CAPLUS  
 CN Sulfanilamide, N<sub>4</sub>,N<sub>4</sub>'-2,4-pyrimidinediylbis-, hydrochloride (7CI) (CA INDEX NAME)



L7 ANSWER 72 OF 72 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1942:2727 CAPLUS  
 DN 36:2727  
 OREF 36:425i,426a  
 TI Pyrimidines. CLXXV. (p-Sulfamylphenylamino)pyrimidines  
 AU de Suto-Nagy, Gyula; Johnson, Treat B.  
 SO Journal of the American Chemical Society (1941), 63, 3234-5  
 CODEN: JACSAT; ISSN: 0002-7863  
 DT Journal  
 LA Unavailable  
 AB cf. C. A. 35, 7375.4. The following pyrimidines were prepared from the  
 known pyrimidine halides and p-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NH<sub>2</sub> in EtOH:  
 2,6-bis(p-sulfamylphenylamino), m. 280-2°; 4-Me homolog, m.  
 218-20°; 2-amino-6-(p-sulfamylphenylamino), m. 239-40°;  
 6-amino-2-(p-sulfamylphenylamino), m. 237-9°.  
 IT 78830-66-7P, Pyrimidine, 4-methyl-2,6-bis(p-sulfamylanilino)-  
 697727-91-6P, Pyrimidine, 2,4-bis(p-sulfamylanilino)-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 78830-66-7 CAPLUS  
 CN Benzenesulfonamide, 4,4'-[(6-methyl-2,4-pyrimidinediyl)diimino]bis- (9CI)  
 (CA INDEX NAME)



RN 697727-91-6 CAPLUS  
 CN Benzenesulfonamide, 4,4'-(2,4-pyrimidinediyl)diimino)bis- (9CI) (CA INDEX NAME)



10/507,060 (amended)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

395.76

583.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-57.60

-57.60

STN INTERNATIONAL LOGOFF AT 10:44:51 ON 12 DEC 2008